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Abstract
The actions of LHRH, CRH and NPY on the activity of the reproductive
axis and, in particular, the LHRH pulse generator were investigated in
vivo. A model was developed to allow direct administration of neuro¬
peptides, antagonists and antibodies into the third cerebral ventricle of
conscious, free-moving and unstressed sheep, giving access to hypo¬
thalamic periventricular structures involved in the control of the anterior
pituitary gland. Plasma levels of LH were used as a measure of LHRH
pulsatility. Three major questions were addressed:
1
(1) Does hypothalamic LHRH autoregulate its own release? Injection
of LHRH (2.1-21 pmol) into the third ventricle caused a specific, dose-
related and receptor-mediated inhibition of LH secretion. It is therefore
suggested that the intrinsic communication between LHRH neurones may
be inhibitory and may provide a mechanism to affect the timing of the
pulsatile release of LHRH. However, as central injection of LHRH also
caused a rapid 4-5-fold rise in plasma Cortisol levels, prior to and
correlated with the reduction in LH secretion, this inhibitory commun¬
ication may be indirect.
(2) Does CRH act as a central neurotransmitter to mediate the
inhibitory effects of stress on LHRH release? In contrast to other species,
central injection of CRH (0.12-1.2 nmol) caused a dose-related stimulation
of LH secretion, due to a significant increase in LH pulse frequency. CRH
also caused a marked and dose-related stimulation of prolactin and
Cortisol secretion, two hormones known to be released under conditions
of stress. Endogenous opioid peptides were shown to mediate the central
effect of CRH on the release of prolactin, but not on LH or Cortisol. The
effect on LH may reflect a species difference, or alternatively may be
similar to the increase in LH secretion reported in rats and monkeys
subjected to short-term handling or restraint stress. These data provide
evidence that CRH acts as a central neurotransmitter; i.e., distinct from its
action as a secretagogue for ACTH.
(3) Does central NPY interact with LHRH and/or CRH to modulate the
reproductive axis? In contrast to the rat, central injection of NPY (0.15-
1.5 nmol) had no effect on LH levels in ovariectomized ewes with or
vii
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without oestradiol implants; nor was LH secretion altered by central NPY
in intact animals. However, central administration of NPY (1.5 nmol)
during both the follicular and luteal phases, and in the oestradiol-
implanted ovariectomized ewe, caused a large and significant increase in
plasma Cortisol. Passive systemic immunization with high-titre anti¬
bodies raised against NPY had no effect on LH secretion during either the
oestradiol-induced LH surge in anoestrous ewes or the pre-ovulatory LH
surge in intact ewes. Central administration of anti-NPY antibodies,
however, resulted in a delay in the onset of the pre-ovulatory LH surge.
These results demonstrate that NPY could play a part in the modulation of
the timing of the LH surge at the level of the hypothalamus and also that
NPY is involved in the multi-factorial regulation of ACTH release.
Thus complex and hierarchical intra-hypothalamic interactions exist
between neuropeptides involved in the control of the anterior pituitary
gland of the ewe: (1) LHRH regulates the pattern of its own release via a
hypothalamic mechanism; (2) CRH acts as a central transmitter integrating
neuroendocrine responses to stress; (3) NPY modulates the timing of the
pre-ovulatory LH surge and the activity of the hypothalamo-pituitary-
adrenal axis.
[-42 000 words in main text]
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1. Introduction
Reproduction in female mammals is regulated by complex interactions
between neuropeptides, glycoprotein hormones and steroids secreted from
the hypothalamus, the anterior pituitary gland and the ovary, respectively.
Luteinizing hormone-releasing hormone (LHRH) is released from the
hypothalamus into the pituitary portal circulation, where it passes to the
anterior pituitary gland and triggers the release of luteinizing hormone
(LH) and follicle-stimulating hormone (FSH). These, in turn, control the
functions of the ovary. Steroids released from the ovary feed back on the
pituitary and hypothalamus to modulate the secretion of LHRH and the
gonadotrophins. Superimposed upon this primary control are important
external influences such as photoperiod, stress, olfactory and social cues.
Since its isolation, characterization and subsequent synthesis by the
research groups of Andrew Schally and Roger Guillemin almost 20 years
ago (Matsuo, Arimura, Nair & Schally, 1971a; Burgus, Butcher, Amoss et
al. 1972), the hypothalamic decapeptide LHRH has been shown to be the
single most important neuropeptide in reproduction, governing—directly
or indirectly—almost every reproductive process. However, it is also clear
that many other neuropeptides have the ability to regulate or modulate
the secretion of LHRH and therefore the secretion of LH.
In the last 10-15 years there has been a surge of knowledge in the
neuropeptide field. Immunocytochemical studies have established that
many biologically-active peptides exist widely throughout the central
nervous system. Many of these peptides had already been isolated from
other tissues, particularly the gut. Examples include cholecystokinin
(CCK), substance P and vasoactive intestinal polypeptide (VIP). In other
cases, hypothalamic peptides known to serve as releasing or inhibiting
factors for pituitary hormones (e.g. somatostatin and LHRH) were found
to have an independent existence elsewhere in the CNS. This widespread
distribution of peptides within the brain suggests that these substances
may function under physiological conditions as neurotransmitters or
neuromodulators.
The 'classical' role of the hypothalamic releasing factors in the control
of pituitary hormone secretion has been recognized for many years, but it
1
Chapter 1 Introduction 2
has only recently become clear that neuropeptides can have many other
actions both within the hypothalamus and elsewhere in the brain. For
example, LHRH in the limbic system has a role in behavioural and mood
changes; vasopressin acts as a neurotransmitter involved in the thermo¬
regulatory responses to fever and also seems to be involved in memory
processes; and CCK-8, as well as its well-documented role in the inhibition
of feeding, has recently been suggested to have a role as a transmitter
involved in mediating anxiety.
Neuropeptides differ from the classical neurotransmitters in that they
are synthesized as large protein precursors in the perikarya of neurones,
undergo post-translational processing by proteolytic cleavage, glycosylation
and/or acylation and are transported to the nerve terminals packaged in
vesicles. After release, peptides must be degraded back to their constituent
amino acids as Cellular uptake of intact peptides for recycling apparently
does not occur. This is reflected in the longer-acting, modulatory effects of
many neuropeptides. In contrast, the 'classical' neurotransmitters are
largely synthesized in nerve terminals from appropriate precursors and
can be taken up into presynaptic terminals by specific uptake systems (e.g.
noradrenaline) or broken down by enzyme action (e.g. acetylcholine), thus
permitting rapid recycling of active chemicals. The secretion and synthesis
of neuropeptides is therefore metabolically expensive when compared
with the 'classical' neurotransmitters. However, this is offset by a much
higher potency and specificity, which allows for effective actions from the
release of much smaller quantities of neuropeptide and for action at
remote sites via transport in extracellular fluid, cerebrospinal fluid (CSF)
and plasma.
In this thesis, experiments are described to investigate aspects of the
physiology of hypothalamo-pituitary interactions in vivo, with reference
to the effects of the hypothalamic neuropeptides LHRH, corticotrophin-
releasing hormone (CRH) and neuropeptide Y (NPY) on the activity of the
reproductive axis and, in particular, the LHRH pulse generator. A model
was developed, using sheep, that allowed the administration of neuro¬
peptides, antagonists and antibodies directly into the third cerebral
ventricle. The third ventricle is a midline structure, filled with CSF. It
bathes the hypothalamus on either side and below, therefore allowing
access by diffusion to periventricular structures involved in the control of
the anterior pituitary such as the paraventricular nucleus of the
hypothalamus (PVN), the mediobasal hypothalamus (MBH), the preoptic
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area (POA), the anterior hypothalamic area (AHA), and the arcuate (or
infundibular) nucleus. Plasma levels of LH were used to assess the
secretion of LHRH. Also of interest were the effects of LHRH, CRH and
NPY on the secretion of FSH, prolactin and adrenocorticotrophic hormone
(corticotrophin; ACTH) from the anterior pituitary gland. However, as
ACTH-immunoreactivity is affected adversely by freeze-thaw cycles,
plasma Cortisol levels were determined as a measure of pituitary ACTH
secretion. The main advantages of this model are that it allows exper¬
iments in conscious, free-moving and unstressed animals, whilst serial
samples can be taken to allow the monitoring of pulsatile hormone
secretion over long periods of time as the sheep has a large blood volume
and a particularly well-characterized pattern of LH release. Details of the
animals, surgical procedures, assays and other general methods are given
in Chapter 3. 1
Three major areas were addressed in the experiments reported in this
thesis. The first centred on the concept of LHRH autoregulation, or 'ultra¬
short'-loop feedback and potential mechanisms whereby this might be
achieved (Chapters 4-6). The second theme involved the role of CRH as a
neurotransmitter mediating the inhibitory effects of stress on the secretion
and/or release of LHRH (Chapter 7). The third area of investigation was
the interactive role of the recently-discovered hypothalamic peptide NPY
in the modulation of the reproductive and hypothalamo-pituitary-adrenal
axes (Chapters 8 and 9).
Each chapter has a specific introductory section relevant to the
questions addressed by those experiments, and aims to review the work of
others in that particular field. Thus, the overview provided in Chapter 2
does not set out to review the whole literature pertinent to all the material
in the thesis: it aims solely to provide a foundation for the understanding
and appreciation of the studies reported in the rest of the thesis. Chapter 2,
therefore, contains background information on the neuroendocrine
physiology of LHRH; aspects of the hypothalamic control of the stress axis
are addressed briefly; and a detailed review of selected aspects of the
biology of neuropeptide Y is given. Each experimental chapter concludes
with a discussion of the results in the context of those of other
investigators. Limitations of the approaches used in the thesis, questions
that remain, and areas ripe for further investigation are discussed in
Chapter 10, with suggestions as to how these might be addressed.
2. Background
2.1. LHRH and the control of reproduction in the ewe
The reproductive cycle of the ewe is seasonal, comprising periods of
reproductive cyclicity (the breeding season) and reproductive quiescence
(anoestrus) each lasting approximately 6 months, depending on the breed
(for reviews see Karsch, 1980; Lincoln & Short, 1980). The breeding season
is confined to autumn and winter, which ensures that the lambs are born
in the favourably environment of spring. It consists of successive 16-17
day oestrous cycles, unless fertilization and pregnancy supervene. Each
cycle starts with a period of sexual receptivity (oestrus) followed by
ovulation, and is characterized by distinctive variations in the
concentrations of reproductive hormones in the plasma.
As will become clear, the primary control of reproduction depends
upon the secretion of LHRH—and possibly upon the secretion of a still-
putative FSH-releasing factor (FSH-RF)—from the hypothalamus. Under
the influence of LHRH, LH (and FSH) is secreted from the anterior
pituitary gland. The pattern of LH release comprises a tonic secretion of
LH which is interrupted once every cycle by a massive discharge of LH
after oestrus (called the pre-ovulatory LH surge), which allows the animal
to ovulate. This surge is governed by changes in the characteristics of the
feedback mechanisms of ovarian steroids. The tonic mode of LH secretion
is necessary for normal development of the ovaries and for the secretion
of both oestradiol from large ovarian follicles and progesterone from the
corpus luteum (the temporary endocrine gland formed from the remnants
of a follicle after it has ovulated). Tonic LH secretion, in turn, is regulated
by the feedback effects of these ovarian steroids. The longest portion of the
sheep oestrous cycle (-80%) is the luteal phase, during which the corpus
luteum develops and secretes large quantities of progesterone. In the
remainder of the cycle, the 2-3 day follicular phase, the corpus luteum
regresses, resulting in a precipitous drop in circulating progesterone, while
the follicle(s) destined to ovulate next enlarge and secrete an increasing
quantity of oestradiol. This phase culminates in the pre-ovulatory surge
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of LH and the consequent ovulation of the follicle.
2.1.1. Demonstration of pulsatile LH secretion
Prior to the development and application of sensitive radioimmunoassay
(RIA) techniques, the large increase in LH at the time of the surge was the
only detectable change throughout the sheep oestrous cycle. Even this
could only be detected using cumbersome bioassay techniques such as the
ovarian ascorbic acid depletion method (e.g., see Dierschke & Clegg, 1968).
With the development of more sensitive bioassays and the advent of RIA
in the late 1950s (Yalow & Berson, 1959), however, it had become possible
to measure concentrations of selected hormones in relatively small
amounts of blood. This meant that the dynamics of hormone secretion
could be monitored in consecutive samples. It soon became apparent that
the release of hormones such as GH (Hunter & Rigal, 1966), ACTH (Berson
& Yalow, 1968), and Cortisol (Weitzman, Schaumburg & Fishbein, 1966;
Hellman, Nakada, Curti et al. 1970) into the systemic circulation was in the
form of intermittent boluses, and not continuously as had been assumed
previously. With further assay refinement, and improvements in
sensitivity and precision, it then became clear that LH and FSH were also
secreted episodically (monkey: Dierschke, Bhattacharya, Atkinson &
Knobil, 1970; bull: Katongole, Naftolin & Short, 1971; human: Midgley &
Jaffe, 1971; sheep: Butler, Malven, Willett & Bolt, 1972). Since then, LH
pulses have been observed in the sheep and other animals in every
reproductive state investigated.
2.1.2. Feedback effects of ovarian steroids on LH secretion
The frequency—and to a lesser extent the amplitude—of LH secretory
episodes varies considerably between different reproductive states
(Lincoln, Fraser, Lincoln et al. 1985). In the luteal phase and during
seasonal anoestrus, LH pulses occur once every 3-12 h (Baird, Swanston &
Scaramuzzi, 1976; Hauger, Karsch & Foster, 1977; Scaramuzzi & Baird,
1977; Yuthasastrakosol, Palmer & Howland, 1977). LH pulse frequency
increases through the follicular phase to reach a rate of one per hour or
more prior to the pre-ovulatory LH surge (Hauger et al. 1977, Baird, 1978).
This variation has been shown to be due, in part, to the feedback effects
of the ovarian steroids, oestradiol and progesterone, and the interactions
between them. It became clear that tonic LH secretion was governed by the
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negative feedback effects of gonadal steroids when removal of the gonads
in sheep (Niswender, Roche, Foster & Midgley, 1968) and rats (Gay &
Midgley, 1969) resulted in a massive increase in circulating LH levels.
This overall increase in LH release was later shown to be largely
due to an increased number of pulses (Butler et al. 1972; Diekman &
Malven, 1973).
Early work provided circumstantial evidence that progesterone is an
important negative feedback steroid. As it was known to be secreted from
the corpus luteum at high levels for at least 10 days during the luteal
phase of the cycle (Edgar & Ronaldson, 1958; Stabenfeldt, Holt & Ewing,
1969; Moore, Barrett, Brown et al. 1969), it seemed likely that it was
important in the control of LH secretion. In addition, Hauger et al. (1977)
demonstrated an inverse correlation between circulating LH and
progesterone levels throughout the sheep oestrous cycle, particularly
during the follicular phase between the drop from luteal levels of
progesterone and the onset of the pre-ovulatory LH surge.
Although it had been shown that single injections of progesterone
reduce the frequency of LH pulses in OVX rhesus monkeys (Yamaji,
Dierschke, Bhattacharya & Knobil, 1972), the physiological significance of
this was not initially appreciated as a pharmacological level of
progesterone was required for the effect. Moreover, mean LH levels were
unchanged as decreases in frequency were offset by increases in pulse
amplitude. However, it was soon demonstrated that a physiological level
of circulating progesterone could lower LH levels in the OVX monkey,
provided the treatment was sustained by means of a constant release
implant and that oestradiol was also present in low concentrations
(Karsch, Weick, Hotchkiss et al. 1973). This was confirmed later in the
sheep. Ovariectomy during the luteal phase caused a prompt increase in
LH pulse frequency. Insertion of constant release implants to maintain a
mid-luteal phase level of progesterone abolished this post-castration
increase in LH pulse frequency (Karsch, Legan, Hauger & Foster, 1977;
Goodman & Karsch, 1980). When maintained at a concentration below
the luteal phase maximum (e.g., at an early luteal phase level),
progesterone alone was shown to be unable to reduce the post-castration
rise in LH pulse frequency. However, this low level of progesterone was
effective in the presence of a basal concentration of oestradiol (Goodman,
Bittman, Foster & Karsch, 1981; Martin, Scaramuzzi & Henstridge, 1983).
Following luteolysis, the levels of progesterone fall in the follicular
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phase, leaving oestradiol as the only putative negative feedback hormone,
a role which it cannot fulfil during the breeding season (Legan, Karsch &
Foster, 1977; Karsch, Legan, Ryan & Foster, 1978). The earliest description
of the negative feedback effect of a physiological concentration of
oestradiol on the LH pulse-generating mechanism was made in the OVX
rhesus monkey (Yamaji, Dierschke, Bhattacharya & Knobil, 1972).
Infusion of early- to mid-follicular phase levels of the steroid led to a
profound suppression of the hourly discharge of LH pulses. It was
subsequently shown that this inhibition of LH secretion could be
maintained for months, provided the oestradiol level remained high
(Karsch, Dierschke, Weick et al. 1973; Karsch, Weick, Hotchkiss et al. 1973).
The negative feedback effects of oestradiol on LH secretion were also
explored in early studies in the ewe. However, the response pattern in the
sheep is more complicated than in the monkey as there are marked
seasonal differences in response to oestradiol (Legan, Karsch & Foster,
1977; Goodman, Legan, Ryan et al. 1981; Webster & Haresign, 1983;
Robinson, Radford & Karsch, 1985). During anoestrus, oestradiol at
physiological levels is a potent inhibitor of LH pulse frequency. During
the breeding season, however, oestradiol serves primarily to reduce LH
pulse amplitude. Physiological levels of the steroid were found to be
unable to lower LH pulse frequency in OVX animals at this time
(Goodman & Karsch, 1980; Martin, Scaramuzzi & Henstridge, 1983), and in
fact enhanced LH pulse frequency in the follicular phase of the oestrous
cycle (Karsch, Foster, Bittman & Goodman, 1983). Thus, after luteolysis,
oestradiol alone is unable to inhibit the secretion of LH and so plasma LH
rises and stimulates oestradiol production by the ovary (Baird, 1978), thus
eventually triggering the LH surge and ovulation (Baird & Scaramuzzi,
1976; Karsch, Foster, Legan et al. 1979).
It is well established that rising oestrogen levels during the follicular
phase, operating via a positive feedback system, are responsible for the LH
surge. This was shown by the induction of an LH surge when an
oestradiol injection was given to anoestrous ewes (e.g., Goding, Catt,
Brown et al. 1969; Bolt, Kelley & Hawk, 1971) and to OVX ewes
(Scaramuzzi, Tillson, Thorneycroft & Caldwell, 1971). In addition,
immunization against circulating oestradiol in normally cycling ewes
prevented ovulation (Rawlings, Kennedy & Henricks, 1978; 1979). When
endogenous progesterone levels are high, as during the luteal phase,
oestradiol is unable to elicit an LH surge (Bolt et al. 1971) and in OVX ewes,
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exogenous progesterone prevents the normal positive feedback effect of
oestrogen (Scaramuzzi et al. 1971).
The characteristics of pulsatile LH release during the surge, though
difficult to elucidate as frequent sampling is required, have been
investigated in several species. Studies in the rat (Gallo, 1981), cow (Rahe,
Owens, Fleeger et al. 1980), sheep (Karsch, Foster, Bittman & Goodman,
1983) and human (Djahanbakhch, Warner, McNeilly & Baird, 1984)
indicate that the LH surge is composed of large pulses of high frequency
(up to one pulse per 15-20 min). The pulsatile nature of the pre-ovulatory
surge of LH has been investigated in detail, both experimentally and from
a theoretical standpoint, in a recent study in the ewe by Martin, Thomas,
Terqui & Warner (1987). Their experimental observations showed the
surge to be composed of an increase in both LH pulse frequency and
amplitude, and that the high frequency of LH pulses was established some
time before the onset of the surge proper. Applying a simple
mathematical model of pulsatile secretion, the authors concluded their
results could only be explained by pulse frequencies and amplitudes well
above those normally observed in other physiological situations, and that
an increase in pulse frequency was essential for initiation of the surge.
2.1.3. Recognition of the importance of the hypothalamus and the
pituitary portal vasculature
There was considerable evidence from early studies, despite the technical
limitations of the bioassays available, that the secretion of hormones from
the anterior pituitary gland was under the control of releasing factors from
the hypothalamus/median eminence.
The role of the nervous system in the regulation of gonadotrophin
secretion had been appreciated by Marshall (1936; 1942) as early as 50 years
ago and subsequently much research effort was directed towards the
question of hypothalamic control of adenohypophysial activity. For
instance, hypothalamic stimulation resulted in an increased discharge of
LH and ACTH (Harris, 1937; 1948; Haterius & Derbyshire, 1937; Markee,
Sawyer & Hollinshead, 1946; de Groot & Harris, 1950). Although many
studies addressed the concept of a secretomotor innervation of the
anterior pituitary gland, it soon became clear that such an innervation did
not exist. With increased appreciation of the significance of the hypo¬
physial portal system—first described by Popa & Fielding (1930; 1933)—
attention was directed towards the possibility of a humoral control
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mechanism, as originally suggested tentatively by Harris (1937).
A specific action of the pituitary portal blood supply on the activity of
the anterior pituitary gland was soon demonstrated by experiments
involving pituitary stalk section (e.g. Harris, 1950) and comparison of the
function of pituitary grafts under the median eminence with grafts at
other sites (Harris & Jacobsohn, 1952; Nikitovitch-Winer & Everitt, 1958;
Smith, 1961). These studies showed that anterior pituitary tissue functions
apparently normally when vascularized by the hypophysial portal vessels,
but not when supplied only by systemic vessels. They provided further
evidence in support of the neuroendocrine hypothesis proposed by Green
& Harris (1947), whereby the reproductive functions of the anterior
pituitary gland are controlled by hypothalamic releasing factors secreted
into the pituitary portal blood.
I
2.1.4. Demonstration of a hypothalamic LH-releasing factor (LRF)
Following on from the above experiments, studies into the existence of a
releasing factor for luteinizing hormone were commenced. Crude extracts
of median eminence (but not other parts of brain) were shown to cause
ovulation in the oestrous rabbit when infused directly into the anterior
pituitary gland (Campbell, Feuer & Harris, 1964). In addition, extracts of
sheep hypothalamic tissue induced ovulation in rats rendered acyclic by
hypothalamic lesions (Schiavi, Jutisz, Sakiz & Guillemin, 1963). McCann
and co-workers investigated the effects of i.v. treatment with extracts of
stalk/median eminence tissue on LH secretion, as measured by bioassay,
in ovariectomized, normal and hypothalamic-lesioned rats and found
plasma LH levels to increase rapidly (McCann & Taleisnik, 1961; McCann,
1962; Ramirez & McCann, 1963). These experiments supported the
existence of an LRF in the hypothalamus and median eminence.
An LRF of < 5 000 kDa was subsequently demonstrated in the hypo¬
thalamus (Ramirez & Sawyer, 1965) and in pituitary stalk blood through¬
out the cycle (Fink & Harris, 1970). These studies showed an unexpected
decrease in secretion at oestrus, with no rise at pro-oestrus, as the
neuroendocrine hypothesis predicted. However, the procedures required
for sampling of pituitary portal blood required extensive surgery, and
there was concern that, as the deep anaesthesia necessary compromised
the pre-ovulatory LH surge and blocked ovulation, the hypothalamic
secretion of LRF was also inhibited. It was only with the development and
application of novel anaesthetics and the use of RIA, that a massive rise in
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portal LRF [called LHRH by now] was demonstrated for the first time
during the LH surge (Sarkar, Chiappa, Fink & Sherwood, 1976).
2.1.5. Isolation of luteinizing hormone-releasing hormone (LHRH)
These early experiments demonstrated that a low-molecular weight factor
was secreted from the hypothalamus into the hypophysial portal blood
and acted on the anterior pituitary gland to cause release of LH, and that
the concentration of this factor in portal blood increased dramatically at
the time of the LH surge.
The factor was subsequently isolated from porcine hypothalamus by
Schally, Arimura, Baba et al. (1971) and by Amoss, Burgus, Blackwell et al.
(1971) from ovine hypothalamus. Both these groups concluded that 'LRF'
was a nonapeptide containing, on the basis of acid hydrolysis, 1 His, 1 Arg,
1 Ser, 1 Glu, 1 Pro, 2 Gly, 1 Leu, 1 Tyr. However, it was then reported
(Matsuo, Baba, Nair et al. 1971b) that the porcine LRF also contained a
residue of tryptophan (Trp) in addition to the other amino acids already
observed. The primary structure of LRF from both species was established
as pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 with the N-terminal
glutamate residue in its cyclized pyroglutamate (pGlu) form and an
amidated C-terminal (Matsuo et al. 1971b; Burgus, Butcher, Amoss et al.
1972). Synthesis of such a decapeptide gave the same result as the isolated
molecule on sequencing, and analysis of the biological properties of the
synthetic peptide showed identical bioactivity with the native form, thus
confirming the proposed structure (Matsuo, Arimura, Nair & Schally,
1971a; Burgus et al. 1972).
Since its isolation and synthesis, LRF has been termed luteinizing
hormone-releasing hormone, or LHRH. As it also has the ability to
stimulate FSH secretion, it is often referred to as gonadotrophin-releasing
hormone (GnRH).
Only one LHRH sequence has been identified in all mammals studied
to date. Moreover, salmon LHRH has only two substitutions and chicken
LHRH-I differs from mammalian LHRH by only one amino acid: in
addition, amphibian LHRH is identical to the mammalian form (see
Sherwood, 1986). The high degree of homology between known LHRH
structures throughout evolution suggests an important role for this
peptide in the regulation of reproductive function. A second LHRH
(chicken-II) has also been identified within the chicken brain, which has
three amino acid substitutions. Interestingly, chicken-II is considerably
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more potent than chicken-I LHRH in releasing both LH and FSH from
cultured chicken or rat pituitary cells (see Sherwood, 1986). This supports
the possibility that LH and FSH may have separate releasing hormones in
avian species.
2.1.6. Evidence for an FSH-releasing factor
As LHRH releases FSH, though to a lesser extent than it does LH (Schally,
Redding, Matsuo & Arimura, 1972), and as Schally and co-workers were
unable to separate FSH- from LH-releasing activity (Schally, Arimura,
Redding et al. 1976), these authors concluded that there was only one
releasing hormone which controls the release of both gonadotrophins; i.e.
the decapeptide LHRH.
This concept, originally put forward by Schally, Arimura, Kastin et al.
(1971), has attracted much support. However, there is considerable
evidence—mostly from McCann's group—that there must be an FSH-RF
which is yet to be isolated. For instance, crude extracts of the OVLT
contain much more FSH-releasing activity than can be accounted for by
the LHRH content, and the slope of the dose-response curve in the
bioassay for FSH release is much steeper than that obtained with LHRH
(Samson, Snyder, Fawcett & McCann, 1980). Similarly, extracts of the
posterior median eminence contain more FSH-releasing activity than can
be accounted for by the content of LHRH (Mizunuma, Samson, Lumpkin
& McCann, 1983). In a recent study, Lumpkin, Moltz, Yu et al. (1987)
subjected extracts of sheep pituitary stalk/median eminence tissue to gel
filtration and demonstrated FSH-releasing activity in fractions of higher
molecular weight than that corresponding to LHRH. These fractions
contained no LH-releasing activity measured either by bioassay or by RIA
for LHRH. Proof of the existence of a specific FSH-RF, however, must
await its definitive isolation and characterization.
Passive immunization against LHRH selectively inhibits LH secretion
in the follicular phase ewe, whereas FSH secretion gradually rose in
antiserum-treated animals (Fraser & McNeilly, 1983). It could be argued
that this supports the hypothesis of a separate FSH-RF. However, as the
reduction in LH secretion is likely to reduce ovarian function, the changes
in FSH secretion may be attributable to the removal of negative feedback
influences of ovarian origin on FSH secretion, such as oestradiol or
inhibin. Inhibin, for instance, has been shown to act at a hypothalamic
site to suppress FSH release selectively (Lumpkin, Negro-Vilar,
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Franchimont & McCann, 1981). In this study, bioactive inhibin was highly
purified from rete testis fluid of rams. Injection of the inhibin preparation
into the third ventricle of castrate male rats suppressed FSH secretion
without affecting plasma LFI levels, whereas i.v. administration of
purified inhibin was without effect on either gonadotrophin. The
response of the pituitary gland to exogenous LHRH was unaffected. This
study in itself provides circumstantial evidence for a differential control of
FSH and LH release.
Further evidence for an FSH-RF was provided by a recent push-pull
perfusion study in the rat. Levine & Duffy (1988) demonstrated that while
pulses of LH showed high concordance with LHRH pulses, FSH pulses
were not associated with LHRH release in an obvious and consistent
manner, less than 45% being temporally associated with LHRH pulses.
These authors suggested that either the LHRH/FSH relationships were not
easily discernible in these animals, or that an FSH-RF distinct from LHRH
may regulate FSH secretion.
Evidence from electrical stimulation studies and lesions supports the
concept that specific areas of the rat dorsal AHA are involved in the
selective secretion of FSH by the anterior pituitary, whereas the LH-
controlling region is thought to be in the POA of the rat (e.g., Chappel &
Barraclough, 1976; see also Kalra & Kalra, 1983). Indeed, Kimura &
Kawakami (1978) have shown that separate neural pathways control the
secretion of LH and FSH in the rat. Whether this of itself provides
evidence for a separate FSH-RF is debatable, and the results can be
explained by several hypotheses. For instance, it may be that LHRH only
stimulates FSH synthesis and that FSH secretion is essentially passive, or
alternatively it may be the temporal pattern of LHRH secretion that is
important.
There is evidence from a recent molecular biological study that the
frequency of LHRH stimulation may indeed be of importance in the
differential regulation of LH and FSH secretion (Dalkin, Haisenleder,
Ortolano et al. 1989). A previous study (Leung, Kaynard, Negrini et al.
1987) had suggested that ovine LHP mRNA was increased considerably
more than FSHp mRNA by higher LHRH pulse frequencies. This was
investigated further by Dalkin et al. (1989), who demonstrated that fast
frequency LHRH stimuli (pulses every 8 min) increased a and LHp
mRNA—but not FSHp mRNA—whereas only FSHP mRNA was
increased by slow frequency LHRH pulses (every 480 min). This therefore
Chapter 2 Background 13
provides a mechanism whereby a single LHRH peptide could selectively
control both LH and FSH secretion. Whether it is sufficient to account for
the complete differential control of LH and FSH secretion is not known.
2.1.7. Control of LH secretion by LHRH
Clearly, the secretion of LH is pulsatile. But how are these pulses
initiated? Several mechanisms have been postulated and subsequently
discounted.
It appears that the anterior pitutiary gland has an inherent capacity to
secrete at least some of its hormones in a pulsatile fashion. For instance,
Shin & Reifel (1981) reported an episodic secretion of prolactin in
hypophysectomized male rats in which the anterior pituitary was grafted
under the kidney capsule. Pulsatile GH and prolactin release has also been
shown from perfused monkey hemipituitaries in vitro (Stewart, Clifton,
Koerker et al. 1985). However, as the pulsatile secretion patterns were
much more rapid than those observed in vivo, it seems unlikely that the
pulsatile release of LH is a result of pituitary oscillations.
A change in pituitary sensitivity also seems unlikely as electrical
stimulation of the median eminence at the time of a downward slope of
an LH pulse initiated further LH secretion (Malven, 1975). A short-loop
negative feedback is also unlikely as continuous infusions of LH failed to
inhibit endogenous LH secretion in ovariectomized ewes (Coppings &
Malven, 1975).
As described above, it was clear from early studies that; (a) LH secretion
is pulsatile and (b) a releasing factor for LH (i.e. LHRH) is secreted into the
pituitary portal plasma. Are these two phenomena connected? i.e., are
the pulses of LH caused by concomitant pulsatile release of LHRH? This
has been investigated in some detail and evidence from a number of
different experimental approaches indicates that every LH pulse is
precipitated by a corresponding LHRH pulse. Some of these studies are
outlined as follows:
Immunoneutralization of endogenous LHRH, by the injection of
specific anti-LHRH antibodies, eliminates the pulsatile secretion of LH
(ewe: Clarke, Fraser & McNeilly, 1978; McNeilly, Fraser & Baird, 1984; ram:
Lincoln & Fraser, 1979; rat: Kawakami & Higuchi, 1979; Snabels & Kelch,
1979; Ellis, Desjardins & Fraser, 1983). In addition, in the female,
neutralization with anti-LHRH antibodies inhibits the pre-ovulatory LH
surge and the steroid-induced surge of LH (Koch, Chobsieng, Zor et al.
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1973; Arimura, Debeljuk & Schally, 1974; Blake & Kelch, 1981; Fraser &
McNeilly, 1982; 1983). An LH pulse, identical to that observed before
immunization, can be induced by the bolus injection of an LHRH agonist
that does not cross-react with the anti-LHRH-antibodies in the circulation
(Caraty, Martin & Montgomery, 1984).
Some of the best evidence came when pulses of LHRH were measured
in the hypophysial portal blood of ovariectomized rhesus monkeys
(Carmel, Araki & Ferin, 1976; Neill, Patton, Dailey et al. 1977) and rats
(Soper & Weick, 1980). These studies had some limitations, as it was not
possible to measure LH simultaneously. Since then, however, LHRH has
been shown to exhibit tonic pulsatile release, concomitant with plasma LH
secretion, into the portal blood of sheep (Clarke & Cummins, 1982) and
has been measured coincident with peripheral LH pulses in third
ventricular cerebrospinal fluid (CSF) of the rhesus monkey (Van Vugt,
Diefenbach, Alston & Ferin, 1985) and push-pull perfusates of the median
eminence of sheep (Levine, Pau, Ramirez & Jackson, 1982) and rats
(Levine & Ramirez, 1980).
Measurement of portal blood in sheep involves transection of part of
the pituitary portal vasculature in the conscious sheep, previously
operated upon to give access using a trans-nasal/trans-sphenoidal route.
This has permitted samples of blood to be collected over 10- to 15-min
periods for up to 12 h or more. Using this technique, an excellent
correlation has been observed between LHRH and LH pulses in OVX ewes
and at the time of the oestradiol-induced LH surge (Clarke & Cummins,
1982; 1985). This group has applied the portal sampling approach to the
analysis of the mechanism of the pre-ovulatory LHRH and LH surges, and
those induced by oestradiol benzoate, and also to the investigation of the
changes in LHRH secretion that occur throughout the cycle (Clarke,
Thomas, Yao & Cummins, 1987). In this study, the levels of LHRH in
hypophysial portal blood were observed to surge at the same time as the
surge of LH in some ewes but, in other sheep, the LPIRH levels did not
change, or only increased slightly. These findings could be taken to
suggest that the variation in response could be because, as in the monkey,
a heightened secretion of LHRH may not be a necessary surge-inducing
stimulus in the ewe. However, there is considerable evidence in the ewe
that an increased secretion of LHRH and, in particular, an increase in
LHRH pulse frequency is required for a normal LH surge.
In the monkey, measurements of LHRH in either pituitary stalk
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plasma (Neill, Pattern, Dailey et al. 1977) or push-pull perfusates of the
MBH (Levine, Norman, Gliessman et al. 1985; Pau, Gliessman, Hess &
Spies, 1988) led to the tentative conclusion that LHRH secretion increased
during the oestradiol-induced LH surge. However, as administration of
unvarying hourly pulses of LHRH to monkeys with arcuate nucleus
lesions was shown to restore the ovulatory LH surge and menstrual
cyclicity (Knobil, Plant, Wildt et al. 1980), and as a wealth of evidence, both
in vivo and in vitro, demonstrated that the response of the pituitary gland
to LHRH was enormously increased by oestrogen (e.g. Reeves, Arimura &
Schally, 1971; Drouin, Lagace & Labrie, 1976), this led to the view that the
LH surge depended exclusively on the pituitary gland, and that the
hypothalamus provided no more than a 'permissive' signal (e.g. Knobil,
1980). However, it is likely that the hypothalamic lesions did not
eliminate the entire endogenous LHRH signal, as two recent anatomical
studies in the ewe have concluded. Both Lehman, Robinson, Karsch &
Silverman (1986) and Caldani, Batailler, Thiery & Dubois (1988) have
suggested that inputs to the anterobasal OVLT and from the MBH to the
ME may remain intact, and some LHRH fibres reaching the ME by the
lateral and periventricular pathways may escape lesioning by the knife
cuts used in some studies. Moreover, constant LHRH pulse therapy is
ineffective when an impervious Teflon barrier is inserted across the
pituitary stalk (Norman, Gliessman, Lindstrom et al. 1982).
The importance of a change in LHRH pulse frequency in the initiation
of the LH surge in the ewe is much less ambiguous. The situation in the
sheep appears to be quite different from the received view of the LHRH
mechanism operating in the monkey which, according to Knobil and
others (e.g. Knobil, 1980), should only be regarded as being 'permissive'.
Studies using two different models and designed to determine the
pattern of LHRH secretion required to induce the LH surge in the ewe
have clearly indicated that a large 'deterministic' increase in LHRH
secretion must occur, and that the primary requirement is for an increase
in LHRH pulse frequency. For instance, using a model in which the
hypothalamic inputs to the hypophysial portal vessels in the OVX ewe
were removed by a surgical hypothalamo-pituitary disconnection (HPD)
procedure (Clarke, Cummins & de Kretser, 1983), oestradiol caused only a
modest rise in plasma LH levels when hourly pulses of LHRH were given
(Clarke & Cummins, 1984). Using another model in which the
sndogenous secretion of LHRH was suppressed by treatment with
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progesterone in the anoestrous ewe, hourly pulses of LHRH were
insufficient to restore the positive feedback response of oestradiol, while
in progesterone-blocked OVX ewes, half-hourly LHRH pulses plus
oestradiol produced an LH surge that was 50% of the peak value obtained
in OVX ewes without a progesterone block (Kaynard & Karsch, 1988).
Further investigations by the groups of Karsch and Clarke have
demonstrated that an abrupt increase in the LHRH input is required to
initiate the LH surge (Kaynard, Malpaux, Robinson et al. 1988; Clarke,
Cummins, Jenkin & Phillips, 1989).
This 'deterministic' view is supported by the recent careful studies of
Caraty and co-workers. Using a refinement (Caraty & Locatelli, 1988) of the
portal sampling technique described by Clarke & Cummins (1982), Caraty,
Locatelli & Martin (1989) showed a clear, consistent and unambiguous
increase in the pulsatile secretion of LHRH in response to oestradiol in the
ovariectomized ewe. Moenter, Caraty & Karsch (1990) recently applied this
technique, refined still further, to an artificial follicular phase model in
which oestradiol and progesterone implants were used in ovariectomized
ewes in anoestrus and in the breeding season to achieve physiological
levels comparable with those of cyclic animals. The essential features of
this elegant study were that oestradiol levels were manipulated to mimic
those that circulate in the late follicular phase—rather than the more
usual pharmacological approach of a single injection—and that this was
combined in the same model with an efficient and minimally invasive
method of portal blood collection. Regardless of season, the LH surge
induced by administration of a follicular phase level of oestradiol was
invariably accompanied by a massive and robust surge of LHRH secretion
that appeared to be due to an increase in LHRH pulse frequency.
Moenter et al. (1990) also showed clearly that the duration of the LHRH
surge was extended compared to the length of the LH surge. Moreover,
the hypothalamus of the sheep contains 20-80 ng LHRH, whereas each
LHRH pulse probably contains less than 100 pg LHRH (Lincoln, 1985).
These observations indicate that the LH surge is terminated for reasons
other than a lack of LHRH. It is possible that pituitary depletion of LH, or
desensitization of the pituitary to LHRH, may contribute to its
termination. In this regard, both the pituitary LH content and the number
of pituitary LHRH receptors have been shown to decrease at the end of the
LH surge in the ewe (Crowder & Nett, 1984; Landefeld, Kepa & Karsch,
1984). As the continuous administration of LHRH to the ewe decreases
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the number of pituitary LHRH receptors (Nett, Crowder, Moss & Duello,
1981), the large surge of LHRH may down-regulate the LHRH receptors,
thus desensitizing the pituitary gland to LHRH and causing the LH surge
to end despite the elevated levels of LHRH.
Alternatively, a specific neuroendocrine factor may be released to
suppress LH secretion. A factor with such activity has been extracted from
rat hypothalamus and has been shown to inhibit LHRH-stimulated LH
release in vivo and in vitro (Hwan & Freeman, 1987). In addition, the
existence of a gonadotrophin surge inhibiting/attenuating factor of
ovarian origin that is neither a steroid nor inhibin has been inferred in
the monkey and woman—this hypothesis has recently been discussed by
Whitehead (1990). Whether such a factor is of physiological relevance in
the termination of the LH surge in the sheep is not known at present.
»
2.1.8. Biosynthesis of LHRH
Seeburg & Adelman (1984) isolated cloned genomic and cDNA sequences
coding for LHRH from human placental material. Correct translation of
the corresponding mRNA could be predicted to result in the synthesis of a
92 amino acid precursor, having a simple structure comprising three
elements. The first part forms a signal peptide, 23 amino acid residues in
length, incorporating a hydrophobic centre region. This is followed by the
mature LHRH decapeptide. Cleavage at the N-terminal site exposes the N-
terminal glutamate residue which is cyclized to pyroglutamate. The
native hormone is flanked at the C-terminus with a tripeptide -Gly-Lys-
Arg- sequence. This provides proteolytic cleavage sites and donates the
amino group for amidation of the C-terminal glycine residue. The
processing site is followed by the remaining 56 amino acids of the
precursor. After post-translational processing, the precursor gives rise to
two peptides: LHRH and the 56 amino acid flanking peptide which
Seeburg & Adelman (1984) termed GnRH-associated peptide (GAP).
The presence in rat brain of an identical prohormone for LHRH was
confirmed by immunocytochemical co-localization of LHRH and GAP in
cell bodies in the POA and septal complex, and in terminal fields in the
OVLT and ME (Phillips, Nikolics, Branton & Seeburg, 1985). In addition,
cDNA coding for the same precursor has been characterized from human
and rat hypothalamus (Adelman, Mason, Hayflick & Seeburg, 1986).
The co-secretion of LHRH and GAP into pituitary portal blood has been
demonstrated by Clarke, Cummins, Karsch et al. (1987), though as the
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secretion ratio was not 1:1, this may reflect a further processing to smaller
peptides. This co-release is of considerable interest, as GAP has been
shown to be a highly potent prolactin inhibiting factor in vitro (Nikolics,
Mason, Szdnyi et al. 1985), and passive immunization of rabbits against
GAP-related fragments resulted in highly elevated plasma prolactin levels
(Nikolics & Seeburg, 1986). The existence of a prolactin inhibiting
sequence within the LHRH precursor may explain partially the inverse
relationship between LH and prolactin secretion that occurs during
lactation, seasonal breeding and infertility.
Reproductive functions in all mammalian species investigated to date
are uniquely dependent on a single gene which encodes the LHRH-GAP
precursor (see Seeburg, Mason, Stewart & Nikolics, 1987). This group used
a mouse strain with a mutation that results in a hypogonadal (hpg)
phenotype characterized by undetectable levels of hypothalamic LHRH
and of circulating gonadotrophins (Cattanach, Iddon, Charlton et al. 1977).
As LHRH administration elevated circulating gonadotrophin levels, and
as foetal pre-optic tissue grafted into the third ventricle of hpg mice
resulted in the synthesis and secretion of LHRH with a partial restoration
of gonadtrophin secretion, an isolated LHRH deficiency was proposed to be
the cause of the hypogonadism (Krieger, Perlow, Gibson et al. 1982;
Charlton, Halpin, Iddon et al. 1983; Gibson, Krieger, Charlton et al. 1984).
Analysis of the LHRH gene in hpg mice revealed a large deletion
which removed the third and fourth exons encoding the 45 C-terminal
residues of GAP (Mason, Hayflick, Zoeller et al. 1986a). Interestingly, the
second exon encoding LHRH and the first 11 residues of GAP was left
intact, as was the first exon and the 5' DNA regions thought to control the
:issue-specific expression of the gene. Although in situ hybridization of
Hypothalami from hpg mice revealed mRNA containing the coding
sequence for LHRH in POA neurones, the mutant mRNA does not
generate any functional LHRH or GAP, as shown by immuno-
:ytochemistry (Mason et al. 1986a). The architecture and neuronal
:ircuitry of the hypothalamus appears to be intact in hpg mice, and thus a
ion-functional LHRH gene seems to be the sole cause of the phenotype.
Mason, Pitts, Nikolics et al. (1986b) restored the reproductive capacity of
:he hpg mouse by creating a transgenic construct incorporating the normal
nouse LHRH-GAP gene. This was introduced into the mutant genome
hrough a series of crosses between heterozygous hpg mice and transgenic
vild-types. The transgenic homozygous hpg offspring all showed a
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complete phenotypic reversal of the hpg mutation, with normal gonadal
development, ovulatory cycles and fertility. The presence of LHRH, GAP
and the corresponding mRNA sequences was demonstrated by immuno-
cytochemistry and in situ hybridization in the hypothalamus. These
experiments demonstrate clearly that reproductive functions in
mammalian species are critically dependent on a single LHRH-GAP gene.
In the human, this gene has been located on the short arm of
chromosome 8 (Yang-Feng, Seeburg & Francke, 1985).
2.1.9. Anatomical localization of LHRH in brain
Neurones immunoreactive for LHRH have been located scattered
throughout the mediobasal hypothalamus, in the anterior hypothalamic
and preoptic areas, and also in extrahypothalamic sites such as the septal
complex and other parts of the forebrain (Jennes & Stumpf, 1980;
Silverman, Antunes, Abrams et al. 1982; Witkin, Paden & Silverman,
1982; Hoffman, 1983; Lehman, Robinson, Karsch & Silverman, 1986;
Caldani, Batailler, Thiery & Dubois, 1988). Unlike the posterior pituitary
neurones, LHRH cells are not tightly organized within clearly defined
hypothalamic nuclei and nowhere are the neurones very numerous: there
are only about 2 500 in the entire sheep brain (Caldani et al. 1988).
There appears to be a species difference in the distribution pattern of
LHRH-ir in the brain. LHRH neurones occur in relatively high density in
the MBH of the monkey (Silverman, Antunes, Abrams et al. 1982),
whereas in the sheep (Glass, Mastran & Nett, 1986; Lehman et al. 1986;
Caldani et al. 1988) and also in the rat (e.g., see Silverman, Krey &
Zimmerman, 1979) they are more concentrated in the pre-optic and
anterior hypothalamic areas. Although Lehman et al. (1986) found only
1-2% of LHRH perikarya in the MBH, Caldani et al. (1988) found 15% of
the total number of LHRH cells in nuclei in this area. This rigorous study,
and that of Advis, Kuljis & Dey (1985), showed the great majority of
LHRH-ir cells in the sheep to be located in the preoptico-hypothalamic
area, mainly in the pre-optic area surrounding the OVLT.
The two major projections of neurones originating in the entire
preoptico-hypothalamic area are the OVLT and the ME (Lehman et al.
1986; Caldani et al. 1988). Caldani and co-workers concluded that there
were four major pathways for LHRH fibres. LHRH cells located in the
nore anterior structures of the POA send fibres to the anterobasal part of
:he OVLT. Three other pathways were observed to terminate in the ME: a
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mediobasal pathway from the POA to the anterior ME; a laterobasal path
from the lateral preoptic and lateral hypothalamic areas, joined also by
fibres from more dorsal areas around the anterior commisure, to the
dorsolateral edges of the central ME; and a periventricular pathway from
the POA, along the lateral walls of the supraoptic recess and the third
ventricle, to the infundibular recess. While some of these latter neurones
were observed to terminate in the ependyma of the ventricle, the majority
joined the laterobasal pathway to terminate in the dorsolateral ME. The
physiological significance of the different pathways, is currently unknown.
There is morphological evidence from this study (Caldani et al. 1988)
and from ultrastructural analysis (Jennes, Stumpf & Sheedy, 1985), that
suggests the existence of sub-populations of LHRH neurones in the
anterior hypothalamic regions. The function of these different LHRH
neurone sub-typ£s is likewise not known at present.
Pulsatile LHRH secretion is powerfully regulated by the feedback of
gonadal steroids and by photoperiod. It is clear that ovarian steroids exert
a major part of their effects on LH secretion in the ewe largely through a
hypothalamic action on LHRH secretion. However, the results of studies
utilizing a combination of autoradiographic methods to identify neurones
that sequester oestradiol and immunocytochemical techniques to localize
cells containing LHRH, suggest that target cells for oestradiol in the
hypothalamus may be different from LHRH neurones, though the
distributions of these neurones overlap (Shivers, Harlan, Morrell & Pfaff,
1983). Neurones nearby, however, have been observed to accumulate
abelled oestradiol and many appear also to contain y-aminobutyric acid
GABA; Fliigge, Oertel & Wuttke, 1986). Therefore, it is possible that
>estradiol could act through a GABAergic system to inhibit LHRH
iecretion (Lamberts, Vijayan, Graf et al. 1983). This does not necessarily
;xclude LHRH cells as targets for oestradiol as steroid hormones may act
lirectly on neurones through pathways other than classical receptor-
nediated genomic mechanisms (McEwen, Biegon, Davis et al. 1982).
Lehman, Robinson, Karsch & Silverman (1986) have suggested that
here may also be differences in the morphological characteristics of LHRH
leurones between the breeding and non-breeding seasons. Although the
mall number of animals in this study means that no firm conclusions
:an be made, the total dendritic length of LHRH neurones in luteal phase
wes appears to be much shorter than those neurones in anoestrous ewes.
Moreover, these authors have also shown that the density of synaptic
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inputs to LHRH neurones in the POA is significantly greater in the mid-
luteal phase of the oestrous cycle than in anoestrus (Karsch, Lehman &
Silverman, 1987). In addition, Glass, Mastran & Nett (1986) investigated
the effects of oestradiol and progesterone on LHRH-ir neuronal systems in
anoestrous ewes, and found the number of LHRH cell bodies that were
multipolar in animals treated with oestradiol was twice the number in
control ewes, while treatment with progesterone caused a significant
decrease in POA LHRH content.
In an ultrastructural analysis of LHRH neurones in anoestrous ewes,
Lehman, Karsch, Robinson & Silverman (1988) demonstrated that LHRH
axons and terminals in the ME were almost entirely surrounded by glial
processes, as were LHRH cell bodies in the POA. The authors suggested
that the encapsulation of LHRH terminals by glial cells could modulate
the activity [stimulus-secretion coupling] of the LHRH neurones, and that
the degree of glial ensheathment may change with season. This is
especially interesting as glial elements have been shown to play an
important role in regulating the activity of magnocellular neurosecretory
cells in the rat (Hatton, Perlmutter, Salm & Tweedle, 1984; Theodosis &
Poulain, 1984). In late pregnancy and lactation for instance, the
magnocellular neurones enlarge, the astrocyte processes retract from
between the neurones, and there is a concomitant increase in the number
of synaptic inputs to the magnocellular neurones. Glial elements also
appear to regulate the access of magnocellular neurosecretory axons to
blood vessels in the posterior pituitary gland (Tweedle & Hatton, 1987).
More dynamic changes of this type could contribute to the modulation of
pulsatile LHRH release. Additionally, it is clear from evidence obtained in
the rat that LHRH-containing synapses are located on dendrites and
perikarya of LHRH neurones (Leranth, Segura, Palkovits et al. 1985;
Pelletier, 1987); this observation could provide a further anatomical
substrate for the interaction between LHRH neurones and the
orchestration of pulsatile activity (Dyer & Robinson, 1989).
Light microscopic studies have suggested several candidates for the
neurochemical identity of afferents to LHRH cells in the POA, including
the catecholamines, dopamine and noradrenaline (Hoffman, Wray &
Goldstein, 1982; Jennes, Beckman, Stumpf & Grzanna, 1982) and several
peptides, including neurotensin and substance P (Hoffman, 1985). In
addition, Kiss & Halasz (1985) have shown the termination of
serotoninergic neurones on LHRH cells in the POA of the rat. Of these
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neurotransmitters, dopamine and noradrenaline have been implicated in
the control of seasonal breeding in the ewe (Meyer & Goodman, 1985;
1986). Close contacts between LHRH neurones and those staining for
tyrosine hydroxylase and dopamine [3-hydroxylase (the synthetic enzymes
for dopamine and noradrenaline) have also been observed (Lehman,
Karsch & Silverman, 1988).
As discussed later in this chapter, there is also much evidence from
studies of the rat—including immunohistochemical data (e.g., see Guy, Li
& Pelletier, 1988)—that the recently discovered hypothalamic peptide,
neuropeptide Y, may be of importance in modulating the activity of the
hypothalamic-ovarian axis and also the hypothalamic-adrenal axis.
2.1.10. Electrophysiological correlates of LHRH secretion
I
LHRH secretion is assumed to be evoked by action potential-induced
depolarization of LHRH nerve terminals and the consequent exocytosis of
secretory granules containing LHRH. As it is clear from analysis of
cephalic arterio-venous differences in concentration that LH pulses are
secreted over a very short (i.e., 2-6 min) time frame (Rasmussen &
Malven, 1982), a pulse of secretion is probably a result of a brief but
relatively synchronized burst of activity occurring throughout a
population of LHRH nerve endings (Lincoln, Fraser, Lincoln et al. 1985).
There is much evidence that electrical stimulation of the POA and the
ME readily evokes ovulation and release of LHRH and LH (Kawakami,
Terasawa & Ibuki, 1970; Fink & Jamieson, 1976; Dyer, Mansfield & Yates,
1980) and thus much research effort has been directed at determination of
the electrical events associated with pulsatile LHRH secretion. However,
this has proved to be difficult to achieve for several reasons. Firstly, the
rat—though much used for electrophysiological studies, particularly with
respect to the posterior pituitary—is just too small to monitor pulsatile LH
secretion reliably under conditions permitting effective electrical
recording. In addition, many of the anaesthetics used to facilitate the
recording of electrical activity adversely affect pulsatile LH secretion.
Secondly, as LHRH neurones are so relatively sparse, and as they are not
located in discrete nuclei but scattered throughout the pre-optic area and
anterior hypothalamus, detection for electrophysiological recording is a
major problem.
To overcome these difficulties, recordings of multi-unit activity (MUA)
have been made which integrate the electrical activity of the surrounding
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neural tissue, recording in an additive fashion the spike activity of many
cells, axons and nerve endings. Although early studies by Kawakami et al.
(1970) had shown a characteristic increase in MUA activity in the pre¬
optic/anterior hypothalamic areas of the rat on the afternoon of pro-
oestrus, it was not until more recently that explosive and transient
increases in hypothalamic electrical activity have been correlated with
pulsatile LH secretion in the plasma of the rat (Kawakami, Uemura &
Hayashi, 1982). Thiery & Pelletier (1981) recorded MUA of neurones in the
antero-medial hypothalamic areas adjacent to the anterior median
eminence in the sheep and described an increase in bursting at the
initiation of an LH pulse. However, not every increase in MUAwas associated
with a secretory episode of LH. In a further study in the ewe, Martin &
Thiery (1987) also observed a second type of cellular electrical activity in
addition to that which they had observed previously in the median
eminence/medial retrochiasmatic area. This second type of activity was
observed in more lateral areas and decreased before the onset of LH pulses,
increasing again once secretion had begun. This may represent the activity
of an inhibitory input to the LHRH neurones.
Recordings of great clarity have been obtained by Knobil's group in the
rhesus monkey by implanting electrode arrays in the arcuate nucleus
(Wilson, Kesner, Kaufman et al. 1984). In this study, the selection of an
electrode picking up a signal with a one-to-one relationship with the
release of LH pulses showed that each LH pulse was accompanied by an
abrupt rise in multi-unit activity of 1-2 min duration, followed by a
plateau phase of lesser, but still increased, activity. The duration of this
plateau phase is reduced by the administration of oestradiol to OVX
animals (Kesner, Wilson, Kaufman et al. 1987).
The results from the monkey, however, should be interpreted with
caution. The structure in the sheep brain equivalent to the monkey
arcuate nucleus is more commonly known as the infundibular nucleus,
and contains relatively much fewer LHRH cell bodies (Lehman et al. 1986;
Caldani et al. 1988). In the monkey, every increase in MUA was associated
with an LH pulse. However, recording from the medial POA of the sheep,
some increases in MUA were not associated with LH secretory episodes
and, recording from certain more lateral areas, LH pulses were correlated
with a decrease in MUA. It is possible, therefore, that in the experiments
in the monkey, recordings have been made from an input to the LHRH
neurones.
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The most likely explanation for the pattern of LHRH secretion
throughout the cycle as it relates to the pattern of electrophysiological
activity, is that it represents an interaction between or summation of two
or more periodic stimulatory and inhibitory signals (Martin & Thiery,
1987). The overall pattern in this composite signal throughout the
reproductive cycle may depend on the relative degree to which one of
these signals dominates the other(s).
2.2. Hypothalamic control of the pituitary-adrenal axis
Under conditions of physical and environmental stress, the body responds
with the activation of the hypothalamo-pituitary-adrenocortical axis.
Glucocorticoids—Cortisol in sheep and man, corticosterone in rat—are
released in pulses from the adrenal cortex in response to pulses of
adrenocorticotrophic hormone (corticotrophin; ACTH) secreted from the
pituitary corticotrophs.
As described above for the hypothalamo-pituitary-ovarian axis, the
neuroendocrine hypothesis of Harris led to a search for a hypothalamic
releasing factor for ACTH. However, the identity of this putative
neuropeptide has proved elusive and it has become evident that the
view of a single corticotrophin-releasing factor (CRF) was too simple and
that there are several neuropeptides involved in the control of ACTH
release.
The principal secretagogue for ACTH in the rat is corticotrophin-
releasing hormone (CRH), first isolated by Wylie Vale and co-workers
from ovine hypothalamus (Vale, Spiess, Rivier & Rivier, 1981; Vale,
Rivier, Brown et al. 1983). However, it is clear that arginine vasopressin
(AVP) also has corticotrophin-releasing properties and that CRH and AVP
act synergistically in the control of ACTH release (Gillies, Linton & Lowry,
1982; Rivier & Vale, 1983). In addition, substances such as oxytocin,
angiotensin II, adrenaline, noradrenaline and opioid peptides have all
been implicated as ACTH secretagogues (reviews: Antoni, 1986; Gaillard &
Al-Damluji, 1987). The terminology in this field is complicated by the fact
that the specific hormone, CRH, is often referred to as 'CRF'. However,
this is not very helpful as CRH, AVP and angiotensin II are all
corticotrophin-releasing factors, i.e. they are all CRFs. As discussed above,
the 'CRF complex' consists of many CRFs, including CRH. Therefore, to
avoid confusion CRH will be referred to as such throughout the thesis,
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and the general term CRF reserved for factor(s) with corticotrophin-
releasing properties.
Although AVP is only a weak secretagogue for ACTH in the rat, much
evidence suggests that it possesses far greater ACTH-releasing activity in
other species, particularly the sheep. The relative potency of CRH and
AVP as ACTH secretagogues in the sheep is controversial, however.
Pradier, Davicco, Safwate et al. (1986) reported a greater release of ACTH
after AVP than after CRH, following i.v. administration of the same
weight of peptide, whereas Brooks & Challis (1989) found CRH to be the
more potent of the two on an equimolar basis. Redekopp, Livesey, Toth &
Donald (1985) observed similar peak increases in ACTH, but a more
prolonged effect after CRH. Interestingly, while Brooks & Challis (1989)
demonstrated that CRH produced a greater peak ACTH response, they
found a greater 'peak Cortisol response after AVP. The total amount of
Cortisol released in the 240 min after injection, however, was no different
between the CRH- and AVP-treated animals. These differences in peak
Cortisol responses raise the possibility that AVP may have a direct
influence on Cortisol release from the adrenal gland, or alternatively that
different molecular forms of ACTH with different biological activities may
be released after CRH or AVP (Pradier, Dalle, Tournaire & Delost, 1988).
Brooks & Challis (1989) demonstrated clearly that CRH and AVP act
synergistically in the sheep—as in the rat and human (see Antoni, 1986)—
to release ACTH.
CRH is synthesized in cell bodies located in the parvocellular sub-
livisions of the PVN, and these areas project extensively to the external
:one of the ME (Swanson, Sawchenko, Rivier & Vale, 1983). In the intact
at, AVP is co-localized in 1-2% of the CRH-stained neurones in the
)arvocellular PVN, though this proportion is greatly increased by
Ldrenalectomy (Sawchenko, Swanson & Vale, 1984). Both CRH and AVP
ire present in portal blood in concentrations capable of stimulating ACTH
elease in vitro (Gibbs & Vale, 1982; Plotsky, Bruhn & Vale, 1984), and
lave been shown to increase sharply in the hypophysial portal blood of
at, rat and sheep in response to acute haemorrhage (Carlson & Gann,
984; Plotsky, Bruhn & Vale, 1985a; Caraty, Grino, Locatelli & Oliver, 1988).
Jasal secretion of both CRH and AVP from the hypothalamus into the
>ituitary portal system of the sheep is pulsatile (Caraty et al. 1988; Engler,
'ham, Fullerton et al. 1989) and is increased in response to insulin-
nduced hypoglycaemia—as is portal AVP secretion in the rat (Plotsky,
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Bruhn & Vale (1985b)—and to an audiovisual stress such as a barking dog
(Engler et al. 1989).
In summary, the hypothalamo-pituitary-adrenal axis is controlled by
complex regulatory mechanisms. Stress increases the secretion of CRH,
AVP and possibly other CRFs from the hypothalamus into the pituitary
portal blood which then act either alone or in synergy to control the
release of the stress hormone ACTH from the anterior pituitary gland.
ACTH secretion is also under the inhibitory influence of the adrenal
glucocorticoids which act at the hypothalamic and/or pituitary level.
2.3. Neuropeptide Y
In the last decade there has been a vast increase in the literature relating to
the recently discovered hypothalamic peptide, neuropeptide Y. This
introductory section can only aim to provide a selective overview of the
literature to set the studies reported in the main body of the thesis in
context. For additional information, see the comprehensive review by
McDonald (1988) and the series of monographs edited by Mutt, Fuxe,
Hokfelt & Lundberg (1989).
2.3.1. Historical aspects
The discovery of neuropeptide Y began with the isolation of gastro¬
intestinal peptides from the porcine small intestine by Viktor Mutt's
;roup at the Karolinska Institute in Stockholm. By the mid-1970s, these
vorkers had isolated several peptide hormones—including secretin,
:holecystokinin (CCK), and vasoactive intestinal polypeptide (VIP)—
vhich all had C-terminal a-carboxamide structures rather than free
:arboxyl groups (see Mutt, 1989). Although the nonapeptides oxytocin and
vasopressin share this C-terminal amide, as does LHRH, the structure is
mcommon amongst peptides. It therefore seemed possible to make use of
heir C-terminal amide groups to identify these peptides in tissue extracts,
t also seemed possible that a search for this characteristic structure in
ixtracted tissue might lead to the discovery of as yet unknown hormonal
)eptides (Mutt, 1976).
Tatemoto and Mutt therefore developed a new chemical method to
letect C-terminal amide groups. This involved endopeptidase cleavage of
he C-terminal amino acid a-amides, conversion of these into their
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fluorescent dansyl derivatives and subsequent identification using two-
dimensional thin-layer chromatography. The method was successfully
used to monitor the chromatographic purification of secretin (Tatemoto &
Mutt, 1978). Applying this technique to side-fractions of the purification of
secretin, it was clear that these fractions contained as yet unknown
peptides with the C-terminal a-amide structure. Two such peptides were
isolated in this fashion, one with a C-terminal isoleucine amide, and the
other with a C-terminal tyrosine amide (Tatemoto & Mutt, 1980).
The first was found to be a 27 amino acid peptide with an N-terminal
histidine and was named peptide histidine-isoleucine (PHI) on the basis of
its structure. The amino acid sequence was subsequently determined and
found to have a high degree of homology with VIP and secretin (Tatemoto
& Mutt, 1981).
At first, it seemed probable that the other peptide was pancreatic
polypeptide (PP) as this had already been isolated and found to have a C-
terminal tyrosine amide (Lin & Chance, 1974; Chance, Johnson, Hoffman
& Lin, 1979). However, this turned out not to be the case. Although it was
found (like PP) to be a 36 amino acid peptide, it had an N-terminal
tyrosine, unlike the alanine of porcine PP. It was therefore named peptide
tyrosine-tyrosine (PYY). The complete sequence of pPYY was determined
by Tatemoto (1982a) and found to have considerable homology with pPP.
2.3.2. Isolation and structure
It has been known for some years that many peptide hormones exist in the
Drain and periphery—particularly the intestine—in identical forms; e.g.,
angiotensin n, substance P, VIP and members of the CCK/gastrin family
^see Hokfelt, Johansson, Ljungdahl et al. 1980). Tatemoto and Mutt
therefore applied their new technique to extracts of porcine brain and
round peptides with C-terminal isoleucine amide and tyrosine amide.
These were expected to be PHI and PYY. However, although the first
peptide amide did indeed turn out to be PHI (Tatemoto, Carlquist,
McDonald & Mutt, 1983), instead of PYY they found a related 36 amino
acid peptide, also with an N-terminal tyrosine (Tatemoto, Carlquist &
Mutt, 1982). This was named neuropeptide tyrosine (neuropeptide Y;
MPY) to distinguish it from PYY. The complete amino acid sequence was
elucidated by Tatemoto (1982b) and found to have 69% homology with
dPYY and 50% with pPP (see Figure 2.1).
NPY has since been isolated from other mammals and shows
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Figure 2.1'. Comparison of the primary structure of porcine
neuropeptide Y with ovine and human NPYs. Compare also
the structures of porcine peptide YY, porcine pancreatic
polypeptide and salmon PP. Identities with pNPY are
enclosed by the box. Ovine NPY only differs from pNPY or
from hNPY by one [conservative] amino acid substitution.
Bovine NPY (not shown) is identical in structure to pNPY,
whereas rat, guinea pig and rabbit NPYs (not shown) are all
identical to hNPY. Note the close sequence homologies of
this family of peptides throughout evolution: the N-terminal
poly-proline helix is particularly highly conserved. See text
for further details.
Sources of the data shown are as follows: oNPY: Sillard et al.
(1989); hNPY: Corder et al. (1984), Minth et al. (1984); pNPY:
Tatemoto (19821;); pPYY: Tatemoto (1982a); pPP: Lin & Chance







































































































































ovineNPY humanNPY porcineNPY porcinePYY
Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-amide Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-amide Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-amide
porcinePPGln--Tyr--Ala-Ala-Glu--Leu-Arg--Arg--Tyr-Ile-Asn--Met-Leu-Thr-Arg--Pro--Arg-Tyr-amideArg-Tyr-Tyr--Ala-Ser--Leu-Arg-His-Tyr--Leu--Asn-Leu--Val--Thr-Arg-Gln-Arg-Tyr-amide salmonPPLys--Tyr-Tyr--Thr--Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-amide
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remarkable conservation between species. The amino acid sequences of
human (Corder, Emson & Lowry, 1984; Minth, Bloom, Polak & Dixon,
1984), rat (Corder, Gaillard & Bohlen, 1988), rabbit and guinea pig (O'Hare,
Tenmoku, Aakerlund et al. 1988) NPY are all identical and differ from
pNPY only at position 17, where the porcine structure has a leucine
residue and the others a methionine (see Figure 2.1). Recently, NPY has
been isolated from the brain of the cow and the sheep. Whereas the
amino acid sequence of bovine NPY is identical to that of pNPY
(Tatemoto, 1989), ovine NPY differs from pNPY by one amino acid at
position 10. The porcine structure has a glutamate residue at this position,
whereas the corresponding amino acid in oNPY is aspartate (Sillard,
Agerberth, Mutt & Jornvall, 1989). Moreover, NPY has strong structural
similarities to fish PP. Whilst pNPY has 50% homology with pPP, it
enjoys 83% with' salmon PP isolated from the endocrine pancreas of the
Pacific salmon, having 30 out of 36 amino acids in common with this
peptide (Kimmel, Plisetskaya, Pollock et al. 1986) (see Figure 2.1).
The degree of sequence homology between these various peptides and
the inability of investigators to isolate PP from the brain led to speculation
that the PP-ir previously observed in the brain was actually due to cross-
reactivity of these antisera with endogenous NPY (see McDonald, 1988).
This was shown when pre-absorption of PP antisera with NPY prevented
the appearance of PP-ir in neural tissue (Lundberg, Terenius, Hokfelt &
Tatemoto, 1984). In addition, further characterization by RIA of PP-ir from
:hromatographed rat brain extracts showed that this immunoreactivity
:oeluted with synthetic NPY (DiMaggio, Chronwall, Buchanan &
9'Donohue, 1985). These and other findings have led to a concensus view
hat accounts of PP-ir in the brain are in fact largely due to cross-reactivity
vith the endogenous peptide NPY (McDonald, 1988).
The inter-species homologies between the different NPYs and between
>ther members of the PP family suggest that these peptides have been
tighly conserved throughout evolutionary history. Moreover, the
nembers of this peptide superfamily are characterized by a common,
listinct tertiary structural feature, the TP-fold' (Glover, Barlow, Pitts et al.
985). This consists of two anti-parallel helices—an N-terminal poly-
>roline helix and a long hydrophilic a-helix, connected by a |3-turn,
erminating in a mobile polar C-terminal hexapeptide amide—held
ogether by tightly packed interdigitating hydrophobic side chains
Schwartz, Fuhlendorff, Langeland et al. 1989). Overall, the N- and C-
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termini are brought into close spatial proximity.
Certain structural requirements for the biological and pharmacological
actions of NPY are explained by the tertiary structure. At least two receptor
populations—Yi and Y2 of differing affinity and specificity—have been
identified on the basis of NPY fragment bioactivity (Wahlestedt, Yanaihara
& Hakanson, 1986) and radioligand binding (Schwartz et al. 1989). Based
on results from bioassays, Wahlestedt et al. (1986) proposed that two
distinct receptors were responsible for the pre- and post-synaptic effects of
the peptide respectively. In the test systems they used, the post-junctional
effect (vasoconstriction) could only be obtained from the whole NPY
molecule, whereas the NPY(i3_36) amide fragment was sufficient to elicit
the pre-junctional effect (inhibition of noradrenaline release). However,
this classification has not gained wide general acceptance as the long C-
terminal fragment has been shown to give significant post-junctional
effects in other test systems (see Schwartz et al. 1989). A classification has
therefore been proposed based on differing affinities and specificities for
the whole molecule and for the C-terminal fragment (residues 13-36).
Both receptors require the presence of the amide residue on the C-
terminal tyrosine. The Yj receptors have been identified mainly at post¬
synaptic sites in the sympathetic nervous system, and require the whole
NPY molecule for activation. This sub-type of receptors binds NPY with a
dissociation constant (IQ) in the lower nanomolar range, but does not bind
long C-terminal fragments such as NPY(i3_36) amide (K<j approximately
nicromolar) (Schwartz et al. 1989). This is in keeping with a compact
ertiary structure in which the N- and C-terminal regions are in close
proximity. The Y2 receptor, which is predominant in the CNS, was
originally defined as a pre-synaptic receptor (Wahlestedt et al. 1986), but it
s now clear that it is also found post-junctionally (see Schwartz et al.
1989). It binds NPY with a much lower K<j than the Yi receptor, i.e. in the
;ub-nanomolar range. The minimum active fragment length for the Y2
•eceptor is NPY(i3_36> amide, the Kd for the binding of this fragment being
ipproximately nanomolar. This fragment comprises the C-terminal polar
irm and the a-helix. Activity at this site is thus dependent on the
ntegrity of the a-helix.
On the basis of the receptor activities and distribution of the various
PP-fold' peptides, Schwartz et al. (1989) have proposed an evolutionary
icheme for the development of the PP peptide family from a common
incestral PP-fold peptide into two lineages, the NPY line and the PP line.
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They suggested that in each of these lines there is a central neuropeptide
and a peripheral peptide hormone. In the NPY line these correspond to
NPY and PYY; in the PP line they proposed PP as the peripheral hormone,
paired with an as yet unidentified central neuropeptide. Interestingly, in a
personal communication from Tatemoto, Schwartz et al. (1989) reported
structural evidence for the presence in porcine brain of a new PP-fold
peptide with an alanine residue in position one.
2.3.3. Biosynthesis
Minth et al. (1984) were the first to identify mRNA and synthesize cDNA
responsible for the structure of NPY. In-vitro translation of the
recombinant RNA demonstrated that the tumour contained a mRNA
encoding a 10.8 kDa protein, which could be immunoprecipitated with
antiserum raised against NPY. They isolated RNA from a human
pheochromacytoma and prepared a cDNA library from this, identifying
the NPY cDNA using a mixture of hybridization probes based on the
known amino acid sequence. Positive clones were isolated and their
nucleotide sequences determined. The coding sequence consisted of 291
bases, thus suggesting a precursor to NPY that was 97 amino acids in
length.
The deduced amino acid sequence of the precursor (preproNPY)
revealed two potential sites of proteolytic processing which Minth et al.
(1984) postulated would generate three peptides: a signal peptide of 28
Lmino acid residues, hNPY (36 amino acids), and a 30 amino acid residue
^-terminal flanking peptide. The mature 36 amino acid hNPY sequence is
lanked at the C-terminal tyrosine by a -Gly-Lys-Arg- tripeptide structure
vhich is converted to the amidated tyrosine residue during post¬
radiational processing.
Using the cDNA as a probe, Minth, Andrews & Dixon (1986) isolated,
haracterized and sequenced the cloned hNPY gene. They found the
ranscription unit to span ~8 kilobase pairs and to consist of 4 exons. The
irst exon contains only non-translated DNA. The second codes for the
ignal peptide and mature NPY. This exon begins with the initiator
nethionine for preproNPY and extends to the arginine residue which
(recedes the C-terminal tyrosine amide of mature NPY. The third exon
ontains the coding region for the 4 amino acids that are processed to the
yrosine amide structure, plus the first 23 amino acid residues of the C-
erminal flanking peptide of NPY (CPON). The fourth codes for the
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remainder of the CPON and also the 3' non-translated region. The hNPY
and hPP genes have been located on human chromosomes 7 and 17,
respectively (Takeuchi, Gumucio, Yamada et al. 1986).
The rat NPY gene has also been cloned and shows a very high degree of
homology with that of the human (Larhammar, Ericsson & Persson, 1987).
Larhammar and co-workers have also—very recently—cloned both the
chicken cDNA and the corresponding gene (see Minth & Dixon, 1989),
which again are highly conserved at both the nucleotide level and amino
acid sequence. This underlines the very high degree of conservation of
NPY, and of the gene encoding the peptide, throughout evolution.
Also of interest in this regard are the predicted sequences of the
flanking peptide (CPON), which are highly conserved between the human
and rat structures. There are only two, conservative, amino acid
substitutions: th£ rat sequence has alanine at position 19 in place of the
valine of the human structure, and serine is substituted for the human
alanine at position 28 in the rat (Allen, 1989). The presence of this peptide
has been demonstrated by specific RIA in many different tissues, such as
the heart, adrenals, hypothalamus and other parts of the brain (Allen,
Polak & Bloom, 1985; Gulbenkian, Wharton, Hacker et al. 1985). It is
unclear whether it has any physiological function(s), or is merely a
byproduct of NPY biosynthesis. However, CPON-ir has been identified in
plasma (Allen, Yeats, Causon et al. 1987), indicating that it is released.
Moreover, the remarkable conservation of the CPON sequence across
pedes—in contrast to the diversity reported between species of the
>eptide predicted to flank PP (Allen, 1989)—suggests that this peptide may
tave an as yet unidentified regulatory role.
:.3.4. Anatomical localization
Neuropeptide Y has been located using RIA and immunohistochemical
echniques throughout the central, peripheral and enteric nervous
ystems. It is one of the most abundant peptides in the central nervous
ystem—perhaps even more so than somatostatin. NPY-ir neurones are
videly distributed in all areas of the neocortex, hippocampus, basal
orebrain, striatum, limbic structures such as the amygdala, the
lypothalamus and the brain stem. In particular, NPY has been measured
a very high concentrations in rat and human hypothalamus (Adrian,
dlen, Bloom et al. 1983; Allen, Adrian, Allen et al. 1983; Chronwall,
)iMaggio, Massari et al. 1985). Additionally, NPY has been demonstrated
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in most organ systems including the gut, heart, lungs, adrenals, pancreas,
thyroid, and the vasculature—both peripheral and cerebral—and is also
localized to the peripheral nervous system and the intrinsic innervation
of many organs; it is found in reproductive tissues such as the ovary and
placenta, and also in follicular fluid and plasma (e.g., Edvinsson, Emson,
McCulloch et al. 1983; Lundberg, Terenius, Hokfelt & Goldstein, 1983;
Sundler, Moghimzadeh, Hikanson et al. 1983; Gu, Polak, Allen et al. 1984;
Lundberg, Hokfelt, Hemsen et al. 1986; McDonald, Dees, Ahmed et al. 1987;
Petraglia, Calza, Giardino et al. 1989; Petraglia, Coukos, Battaglia et al. 1989;
Jorgensen, CHare & Andersen, 1990; see also McDonald, 1988).
NPY is also of particular interest because of its co-existence with other
classical neurotransmitters (see Everitt & Hokfelt, 1989). In the PNS, NPY
has been co-localized with noradrenaline and adrenaline (Lundberg,
Terenius, Hokfelt et al. 1982; Lundberg et al. 1983; Ekblad, Edvinsson,
Wahlestedt et al. 1984). In the CNS, NPY-ir has been demonstrated in the
noradrenergic Al and adrenergic CI and C2 cell groups in the brain stem
and in many of the noradrenergic cell bodies of the A6 group in the locus
coeruleus (Hokfelt, Lundberg, Tatemoto et al. 1983; Everitt, Hokfelt,
Terenius et al. 1984; Everitt & Hokfelt, 1989). Sawchenko, Swanson,
Grzanna et al. (1985) have also demonstrated extensive co-localization of
NPY in adrenergic and noradrenergic neurones projecting to the PVN
which arise from the CI, C2, C3 and Al cell groups in the brain stem.
There are, however, other NPY-containing systems in the brain which
Hck noradrenaline. Bai, Yamano, Shiotani et al. (1985) have demonstrated
n important projection of NPY neurones from the arcuate nucleus to the
VN and the dorso-medial hypothalamus. NPY-ir has also been shown in
eurones throughout the neocortex which contain either somatostatin
;ee Everitt & Hokfelt, 1989) or GABA (Hendry, Jones, DeFelipe et al. 1984).
Neuropeptide Y synthesis and activity is not confined to cells of the
ervous systems, however. Ericsson, Larhammar, Mclntyre & Persson
.987) have shown that NPY and NPY mRNA are also found in tissues of
te immune system. A combination of in situ hybridization and
nmunocytochemistry has shown NPY peptide and mRNA for NPY in
le spleen, bone marrow and in the platelet-forming megakaryocytes
.arhammar, Ericsson & Persson, 1987; Ericsson, Schalling, Mclntyre et al.
?87). As NPY is a potent vasoconstrictor (see below), it is possible that
PY is released during platelet aggregation resulting in a long-lasting
asoconstriction. Also of interest in this connection is that the levels of
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megakaryote-derived NPY are much higher iri some auto-immune mice,
emphasizing the connection between the neuronal and immune systems.
2.3.5. General physiological aspects of NPY
There is physiological evidence that NPY acts at several loci. In vascular
tissue, for instance, it has a direct vasoconstrictor effect and enhances the
action of other vasoconstrictive agents such as noradrenaline, adrenaline
and histamine (Lundberg et al. 1982; Lundberg & Tatemoto, 1982;
Edvinsson, Ekblad, Hakanson & Wahlestedt, 1984; Ekblad et al. 1984). In
contrast, NPY inhibits the electrically stimulated contractions of vas
deferens and urinary bladder, without affecting the responses of these
tissues to exogenously applied transmitter substances, suggesting that NPY
also has a presynaptic action (Allen, Adrian, Tatemoto et al. 1982; Ohhashi
t
& Jacobowitz, 1983; Lundberg, Hua & Franco-Cereceda, 1984). In vas
deferens, NPY has been shown to inhibit the electrically stimulated release
of noradrenaline, also by a presynaptic mechanism (Lundberg & Stjarne,
1984). NPY also acts presynaptically in the CA1 region of the hippocampus
to reduce excitatory input to the pyramidal neurones (Colmers, Lukowiak
& Pittman, 1985; 1987). This particular action was a longer term effect than
the effects produced by other peptides such as somatostatin and oxytocin
(Pittman & Siggins, 1981; Muhlethaler, Charpak & Dreifuss, 1984).
NPY has been observed to have long-lasting effects both on the
physiology of peripheral tissues (Lundberg et al. 1982; Edvinsson et al.
984; Lundberg & Stjarne, 1984) and of the CNS (Carter, Vallejo &
.ightman, 1985; Potter, 1985; Stanley & Leibowitz, 1985). As NPY is co¬
lored with other neurotransmitters such as noradrenaline and GABA,
his suggests that the longer term effects of NPY may interact with the
horter term actions of the neurotransmitters as has been suggested for
ther co-localized peptides and transmitters (Hokfelt, Johansson,
.jungdahl et al. 1980; Hokfelt, Johansson & Goldstein, 1984; Hokfelt,
iveritt, Meister et al. 1986).
A role for NPY has been suggested in sympathetic neurotransmission,
s a selective increase in plasma NPY levels was observed during
hysiological activation of this system by physical exercise (Lundberg,
lartinsson, Hemsen et al. 1985). NPY increased in parallel with plasma
oradrenaline, which suggests that the origin of NPY is neural in this case,
ather than adrenal, and supports the hypothesis that NPY is co-secreted
zith noradrenaline.
Chapter 2 Background 35
In the CNS, exogenously applied NPY has many physiological effects
which appear to be independent of the action of noradrenaline. For
instance, intracerebroventricular (i.e.v.) injection of NPY in the
anaesthetized rat causes bradypnoea, hypotension and synchronization of
electroencephalograph activity (Fuxe, Agnati, Harfstrand et al. 1983).
Microinjection of NPY into the PVN or into the third ventricle causes a
potent increase in feeding behaviour (Clark, Kalra, Crowley & Kalra, 1984;
Stanley & Leibowitz, 1984; 1985). The hyperphagic effect appears to be due
to an enhancement of carbohydrate ingestion (Stanley, Daniel, Chin &
Leibowitz, 1985) which is of interest as i.e.v. injection of NPY stimulates
insulin secretion for up to 2 h after injection (Moltz & McDonald, 1985).
These authors also reported that NPY has direct inhibitory effects on
glucose-stimulated insulin release from the perfused pancreas in vivo and
from isolated pancreatic islet cells in vitro. Intracerebroventricular
injection of NPY also enhances memory retention and recall in untrained
mice (Morley & Flood, 1989). Although feeding enhances memory (Flood,
Smith & Morley, 1987), this response is not mediated via a stimulation of
food intake.
NPY has been implicated as a chemical messenger in the light-dark
cycle entrainment of circadian rhythms. Albers & Ferris (1984) have
shown that microinjection of NPY into the SCN of the hamster causes a
phase shift in the circadian activity rhythm. Injection of NPY into the
SCN in the 12 h before the onset of activity in free-running (constant light)
amsters advanced the phase, but phase-delayed the activity cycle when
njected in the 12 h after the onset of activity. A shift in free-running
ctivity rhythms had previously been observed when aPP was injected
ato the SCN (Albers, Ferris, Leeman & Goldman, 1984); however, the
ihysiological ligand is most likely to be NPY. The anatomical NPY-ir
euronal pathway subserving the effect projects from the intergeniculate
jaflet and ventral lateral geniculate nucleus of the thalamus, thus
roviding another pathway for the transmission of visual information
2ard & Moore, 1982; Moore, Gustafson & Card, 1984; Harrington, Nance &
Lusak, 1985).
.3.6. NPY and neuroendocrine function
Jerve fibres immunoreactive for NPY are especially abundant in the
reoptic area, paraventricular nucleus, mediobasal hypothalamus and
ther hypophysiotrophic areas of the brain (Everitt, Hokfelt, Terenius et al.
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1984). In particular, there is immunohistochemical evidence indicating
that NPY fibres are in close apposition to LHRH cell bodies in the area of
the OVLT (Guy, Li & Pelletier, 1988). NPY-ir has been localized in axons
and axonal terminals forming synaptic connections with ACTH-ir
neuronal perikarya and dendrites in the arcuate nucleus (Csiffary, Gores &
Palkovits, 1990). NPY neurones also project from the arcuate nucleus to
the PVN (Bai, Yamano, Shiotani et al. 1985) where NPY nerve terminals
have been visualized in the immediate vicinity of CRH nerve cell bodies
(Wahlestedt, Skagerberg, Ekman et al. 1987) and NPY-ir axons have been
shown to establish synaptic specializations with parvocellular neurones
expressing CRH-ir (Liposits, Sievers & Paull, 1988). Thus there is
morphological evidence that NPY may be important in the regulation of
the secretion of both LHRH and CRH. There is evidence in vivo and in
vitro that this is Indeed the case.
In the rat and rabbit, NPY has been shown to exhibit modulatory
activity at both the adenohypophysial and the central levels of the
hypothalamo-pituitary-ovarian axis and has a biphasic action on LH
secretion, ovarian factors being critical in the direction of the changes.
Centrally administered NPY stimulates the secretion of LH in intact
female rats (Kalra & Crowley, 1984; Crowley, Tessel, O'Donohue et al.
1985). However, LH secretion is inhibited by central NPY in
ovariectomized female and intact male rats (Kalra & Crowley, 1984;
Crowley et al. 1985; Kerkerian, Guy, Lef&vre & Pelletier, 1985; McDonald,
T umpkin, Samson & McCann, 1985), an effect which appears to be due to
a inhibition of pulsatile LHRH secretion from the hypothalamus
dcDonald, Lumpkin & DePaolo, 1989). Push-pull perfusion studies in
ie rabbit and experiments in the rabbit and the rat in vitro also support
le hypothesis that the effects on LH release are due to stimulatory or
Lhibitory effects on hypothalamic LHRH release (Crowley & Kalra, 1987;
horram, Pau & Spies, 1987; 1988). The biphasic effects of NPY on LH
ilease are identical to those observed with noradrenaline (e.g., see Kalra
Crowley, 1984; McDonald et al. 1985), which is of interest in the light of
Le co-localization of NPY and noradrenaline described above.
Central administration of NPY increases ir-CRH in the hypothalamus
: the rat (Haas & George, 1987). Furthermore, NPY evokes the release of
RH from rat hypothalamus in vitro in a dose-dependent manner
'saragarakis, Rees, Besser & Grossman, 1989). Moreover, injection of
PY into the SON increases circulating levels of vasopressin (Willoughby
Chapter 2 Background 37
& Blessing, 1985). In addition, direct injection of NPY into the PVN of the
anaesthetized rat increases plasma ACTH levels (Wahlestedt, Skagerberg,
Ekman et al. 1987) as does intracerebroventricular administration of NPY
in the rat and dog (Harfstrand, Eneroth, Agnati & Fuxe, 1987; Inoue, Inui,
Okita et al. 1989). NPY also potentiates the effectiveness of CRH as a
secretagogue for ACTH in the dog, acting at sub-threshold doses in
synergism with CRH (Inoue et al. 1989). Thus NPY appears to have a
stimulatory role on the hypothalamo-pituitary-adrenal axis, acting at the
level of the hypothalamus.
Although the neuroendocrine aspects of NPY still require much
investigation compared with the vast literature on the cardiovascular
effects, it is clear that NPY has a major potential role in the regulatory
control and /or modulation of the reproductive and stress axes.
3. General materials and methods
The materials and methods described in the following chapter are
common to all experiments performed. Those details unique to a
particular experiment are described in the relevant chapters.
3.1. Animals and management
Adult Scottish Blackface ewes, obtained from the Macaulay Land Use
Research Institute flock at Sourhope Research Farm, Yetholm, Roxburgh¬
shire, were used for the majority of the studies described in this thesis.
Finn x Dorset crossed ewes from the Institute of Animal Physiology and
Genetics Research farm at Blythbank, Peeblesshire, were used for some of
those reported in Chapters 8 and 9.
For the majority of experiments, animals were housed indoors in
individual pens (1.5 m x 2 m) in the University of Edinburgh Marshall
Building at Dryden-Mountmarle, near Roslin, Midlothian. The animals
were fed 500 g supplementary pelleted feedstuff (Moredun Nuts, Dalgety
Agriculture, Bristol) each morning and had access to hay and water ad
libitum. For the infusion experiments described in Chapter 6 and the
leripheral immunization experiments in Chapter 9, sheep were kept in
pproved restraint crates which allowed them room to stand up and lie
[own and access to food and water, but not to turn around. Experiments
/ere performed under light-controlled conditions as described in each
hapter.
All experiments were approved by the Home Office under the terms of
he Animals (Scientific Procedures) Act 1986; Project Licence PPL 60/00612,
'ersonal Licence PIL 60/01087.
.2. Surgical preparation of animals
.2.1. Anaesthesia
anaesthesia was induced with Saffan (9 mg/ml alphaxolone, 3 mg/ml
lphadolone acetate, solubilized in saline by 20% (w/v) polyoxyethylated
38
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castor oil, Glaxovet, Harefield, Middlesex). Depending on the size of the
animal, 18-25 ml was injected intravenously. The ewe was then intubated
with an endotracheal tube 8.5-9.5 mm in diameter, and connected to a
portable anaesthetic machine (Cyprane, Keighley, Yorkshire). Anaesthesia
was maintained with -3-4% halothane (Fluothane, ICI Pharmaceuticals,
Macclesfield, Cheshire) in a nitrous oxide/oxygen mixture (both -0.8
1/min).
3.2.2. Ovariectomy
Anaesthesia was induced and maintained as described above. The animal
was then secured on the operating table in the supine position. The wool
over the abdomen was clipped and the area exposed cleansed and
disinfected with surgical scrub and antiseptic solutions (Betadine, Napp
Laboratories, Cambridge).
A midline incision (-12 cm) was then made in the skin overlying the
abdomen, starting just above the mammary gland and avoiding the
mammary vein. The peritoneum was exposed by blunt dissection with
forceps and an incision made just adjacent to the midline ridge. Great care
was taken to prevent accidental damage to the intestine underlying the
site of incision and to avoid the abdominal musculature. The uterus was
then located and the first ovary clamped off with curved forceps. The
tissue between the ovary and the uterus was tied off in two halves with
Mersilk (size 4 metric, Ethicon, Edinburgh) using a locking stitch and then
reef knot, the grip of the clamp being released as the ligatures were tied.
ie ovary was then sliced off with a scalpel, ensuring complete removal
all ovarian tissue. This procedure was then repeated for the contra-
teral ovary.
After careful replacement of the uterus, the peritoneum was sewn up
ith individual stitches of sterile chromic catgut (size 6 metric, Ethicon)
>proximately every 1 cm using a round-bodied needle, taking care to
roid the intestine underneath. The wound was treated with an
itibacterial spray containing Bacitracin, Neomycin and Polymyxin
'olybactrin, Wellcome, London) and closed with a running stitch
rough the skin. Animals were usually alert and eating again within 20
in of removal from the operating table. Each animal received 4 ml
reptopen (250 mg/ml procaine penicillin and 250 mg/ml dihydro-
reptomycin sulphate, Glaxovet) daily for 4 days post-operatively.
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3.2.3. Intracerebroventricular cannulation
Anaesthesia was induced and maintained as described above. The animal
was secured on the operating table in the prone position and its head
secured firmly in a stereotaxic frame made in the Preclinical Veterinary
Sciences workshop of the Royal (Dick) Veterinary School, University of
Edinburgh. The skin overlying the superior aspect of the head was shaved
of wool and cleansed and disinfected with Betadine surgical scrub and
antiseptic solutions.
Using aseptic technique throughout, a midline incision was made
(~8 cm), starting between the horns and passing rostral towards the gristle
pad. The skin was retracted and the skull surface exposed. Bregma was
identified and marked with a small depression using a dental drill
(Osteon, Amsco'Hall Surgical). A bore hole, 11 mm in diameter, was
made through both tables of the skull at bregma with a purpose-built
surgical drill (Aesculap-Werke AG, Tuttlingen, FRG) using this mark as a
guide. The drill was designed to stop immediately upon reaching the dura
mater. The sliver of bone remaining was removed with a fine pair of
tweezers thus exposing the sagittal sinus.
With the stereotaxic atlas drawn by Dr Ph. Richard (1967) for the
Prealpes-du-Sud breed as an approximate guide, a sterile stainless steel
cannula 45 mm long, fashioned from the tip of an 18-gauge spinal needle
(Becton-Dickinson, Rutherford, NJ, USA) was then inserted at bregma
irough the brain tissue to a depth of approximately 20 mm. In order to
void piercing the sinus, the point of insertion was just lateral to this
lood vessel and the cannula was angled so as to reach the midline and
terefore the third ventricle (see Figure 3.1). This usually produced a
apious flow of cerebrospinal fluid up the cannula which was stemmed by
re insertion of a 20-gauge stylette into the spinal needle. Immediately
fter the insertion of the cannula into the brain tissue, the base of the drill
ole was filled with absorbable gelatin sponge (Sterispon, Allen &
lanburys Ltd, Greenford, Middlesex), to form a stable matrix for sealing
re cavity. The hole was then filled with dental cement (Formatray, Kerr
urope, Basel, Switzerland).
The top of a 500-ml screw-top polyethylene bottle (BDH, Poole, Dorset)
ras cut to shape to form a protective covering over the skull wound and
icured to the skull with self-tapping stainless steel screws just rostral and
ist caudal of the drill hole. The screw heads were covered and the space
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Figure 3.1. Schematic diagram showing the placement of
the third ventricular guide cannula relative to the
ventricular system and the hypothalamus in the ewe. This
cannula allows easy access to the cerebrospinal fluid and
therefore to periventricular structures involved in the
control of the anterior pituitary gland. The top of the
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between cannula and cap filled with dental cement. Finally, the wound
was treated with antibacterial spray (Polybactrin) and closed with sutures.
A rubber disc, cut to fit, was placed inside the cap to keep the cannula
assembly clean.
The animals were invariably alert, standing and eating within 1 hour.
As above, all received 4 ml Streptopen daily for 4 days post-operatively.
The Finn x Dorset ewes (Chapters 8 and 9) were also given an anti¬
inflammatory analgesic. Each animal received 3 ml Tomanol (240 mg/ml
isopyrin and 130 mg/ml phenylbutazone sodium, Intervet Laboratories,
Cambridge) by slow intravenous injection daily for 2 days post-operatively.
3.3. Experimental procedures
3.3.1. Blood sampling
During intensive sampling regimes, ewes were chronically cannulated.
On the day before each sampling period, a cannula (Brauniile, Braun AG,
Melsungen, FRG) was inserted into the jugular vein, stitched securely to
the neck close to the point of entry and attached to a three-way stopcock
(Connecta, Viggo AB, Helsingborg, Sweden) via 60 cm of polythene
manometer connecting tubing with luer lock fittings (Portex, Hythe, Kent).
The cannula was kept patent with heparinized saline [20 units heparin
(Leo Laboratories, Aylesbury, Bucks)/ml 0.9% (w/v) NaCl (Travenol
Laboratories, Thetford, Norfolk)]. Blood samples (1-3 ml) were collected at
)-min intervals for 11-12 h from 08.00 h. Samples were withdrawn using
ml sterile syringes and immediately placed in 7-ml polystyrene tubes
arstedt, Leicester) containing heparinized beads (Lithium Heparin
irrier Beads, Sarstedt). The sampling line was immediately flushed with
^proximately 2 ml heparinized saline. Samples were spun at 3 000 rpm
510 #) (MSE Chilspin 2, Fisons Instruments, Crawley, Sussex) for 15 min
id the separated plasma decanted into 2-ml plastic sample tubes (Teklab,
icriston, Durham) which were then stoppered and stored at -20 °C until
sayed.
3.2. Intracerebroventricular injections
most cases, two i.e.v. injections were given, the first after an initial 4-h
introl period, the second 1.5 h later. Immediately before each injection,
e stylette was removed from the guide cannula and a 20-gauge injector
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needle, connected to a length of PE 100 tubing (Becton-Dickinson)
containing the solution to be injected, was lowered to the required depth,
i.e., just beyond the end of the guide cannula. The peptides, dissolved in
sterile 0.9% saline immediately prior to injection as required, were
delivered by gravity flow into the third ventricle in a volume of 50 jrl.
The injection tubing was usually back-loaded with enough doses of the
peptide for 2-3 animals. After use, the needles and tubing were flushed
thoroughly with sterile saline and 70% ethanol. In treatments where
animals received both LHRH and LHRH antagonist, the antagonist was
delivered (i.e.v.) 15 min before i.c.v. injection of LHRH. The order of the
various injections was based on a cross-over design where possible, with
each ewe serving as its own control and receiving each treatment.
3.4. Neuropeptides and drugs
Synthetic LHRH and the LHRH agonist, Buserelin, ([D-Ser-(tBu)6, Pro9]-
LHRH-(l-9)-nonapeptide-ethylamide) were generous gifts from
Dr J. Sandow (Hoechst AG, Frankfurt, FRG). The LHRH antagonist,
Detirelix, ([N-Ac-D-NalG)1, D-pCl-Phe2, D-Trp3, D-hArg-(Et2)6, D-Ala10]-
LHRH) was a generous gift from Dr B.H. Vickery (Syntex, Palo Alto, CA,
USA). I should like to thank Dr Hamish Fraser for his kind help in
obtaining these peptides. Synthetic ovine corticotrophin-releasing
hormone (oCRH) was purchased from Bachem UK Ltd (Saffron Walden,
5sex), naloxone (as N-allylnoroxymorphone-hydrochloride) and Cortisol
s hydrocortisone sodium semisuccinate) from Sigma (Poole, Dorset), and




oncentrations of LH in plasma were measured by the specific double-
\tibody radioimmunoassay of McNeilly, Jonassen & Fraser (1986).
uffer Assay buffer (0.1% BSA 0.075 M phosphate-buffered saline, pH
5) (0.1% BSA/PBS) was made by dissolving 8.76 g NaCl and 2.0 g bovine
bumin (Sigma RIA grade, fraction V) in 300 ml 0.5 M phosphate buffer
>H 7.5) and 1700 ml distilled water. The pH was then re-adjusted to 7.5.
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Antibody The assay used a rabbit antiserum (R 29) raised by Dr Alan
McNeilly against ovine LH (NIH-oLH-S19) at a final dilution of 1: 600 000.
This shows < 0.1% cross-reaction with ovine FSH, LH a-subunit or
prolactin or bovine TSH (McNeilly et al. 1986).
Radioiodination Highly purified ovine LH (LER-1056-C2)—a generous
gift from Dr L.E. Reichert Jr., Albany Medical College of Union University,
Albany, NY, USA—was used to prepare radioiodinated LH label. 500 pi of
thiomersal-free 0.075 M phosphate-buffered saline (PBS) was added to
100 pg LER-1056-C2 to make a stock solution, which was stored at -20 °C in
aliquots of 25 pi, each containing 5 pg hormone.
The lactoperoxidase method was used to prepare the label. 5 pi (500
pCi) of Na125I (Amersham International, Aylesbury, Bucks) and 5 pg of
lactoperoxidase (Sigma) in 10 pi thiomersal-free PBS were added to 5 pg
LER-1056-C2. 10 pi hydrogen peroxide (10 pi H2O2/I5O ml distilled water)
was then added to start the reaction. After 20 sec, the reaction was stopped
by the addition of 10 pi of a 1.0 mg/ml solution of 2-mercaptoethyl-
ammonium chloride (cysteamine hydrochloride) in distilled water. 1 ml
of thiomersal-free 1% BSA/PBS was added to increase the volume of the
reaction mixture. The resulting 'cocktail' was subjected to gel filtration on
a Sephadex G-100 column (G-100 from Pharmacia AB, Uppsala, Sweden;
column from Amicon, Stonehouse, Gloucestershire). The gel was allowed
to swell in thiomersal-free PBS that had first been allowed to equilibrate to
room temperature. After the column was poured and allowed to pack
own, it was coated with thiomersal-free 1% BSA/PBS. The iodination
ocktail was added to the column and eluted with 0.1% BSA/PBS. The
lutate from the column was collected in 8-ml polystyrene tubes using a
rogrammable electronic fraction collector (Gilson model 203, Middleton,
W, USA) and the radioactivity in each fraction monitored (Mini-assay
^pe 6-20, Mini Instruments, Burnham-on-Crouch, Essex). The first peak
luted from the column was purified radiolabeled LH tracer, free from
amaged hormone and unbound 125I (see Figure 3.2). The four fractions of
ris peak containing the highest radioactivity were pooled and stored in
liquots of 250 pi at -20 °C until required. Incorporation of 125I into the
rotein peak was typically 70-80% and the specific activity 30-50 pCi/pg LH.
When 1 mCi (10 pi) of 125I was used to prepare radioiodinated LH, rapid
)ss of binding occurred and quality control results were altered. The
kely reason for this was that the specific activity of the label was too high,
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Figure 3.2. Radioactivity in fractions eluted from Sephadex
G-100 column after radioiodination of oLH, showing
incorporation of 125I into the first (protein) peak. The
fractions that were pooled and used as 125I- oLH tracer are also
shown.
Separation of radiolabeled oLH
• Pooled fractions
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causing degradation of the hormone. Therefore, 500 jiCi was used for all
iodinations.
Standards Each assay contained at least a standard curve at the
beginning and end, with further curves if required. Each comprised a set
of standard points double-diluted from 50-0.1 ng/ml. Standards were
kindly supplied by the National Hormone and Pituitary Program of the
NIDDK, Bethesda, MD, USA. NIH-LH-S18 was used for all experiments
apart from those in chapters 8 and 9 where NIH-LH-S23 was used as
standard. In our hands, we have found 1 ng/ml NIH-LH-S23 = 2 ng/ml
NIH-LH-S18 (see Figure 3.3). Results are expressed in terms of ng NIH-LH-
S18/ml unless otherwise indicated.
Separation The bound and free fractions were separated by liquid phase
second antibody .precipitation using donkey anti-rabbit serum and normal
rabbit serum obtained from the Scottish Antibody Production Unit (SAPU)
(Carluke, Lanarkshire).
Procedure Samples, standards and quality control plasma samples were
dispensed and diluted as appropriate using a programmable electronic
pipetting station (Hamilton Microlab M, Hamilton Bonaduz AG,
Switzerland). 100 |il of standard or sample (after dilution if required) was
added to 200 (il assay buffer in 3-ml polystyrene tubes. Each standard curve
was set up in triplicate and samples assayed in duplicate. The anti-serum
(R 29) was diluted in assay buffer to give a dilution of 1:120 000. 100 (il of
■-uis solution was then added to each tube. In addition to standards as
)ove, a set of tubes including no 'cold' hormone, to assess undisplaced
nding of the antibody to the labelled trace and a set of tubes containing
) antibody and no cold hormone, to assess the non-specific binding, were
eluded. These tubes received buffer in place of the standard and/or
itibody. All tubes were vortexed and incubated at 4 °C for 24 h.
Radiolabeled hormone was then added to all tubes. The stored label
as diluted in assay buffer to give approximately 15 000 cpm/100 |il and
)0-pl aliquots added to each tube. A set of tubes containing trace alone
as also prepared to determine the total number of counts added to each
be. All tubes were again vortexed and incubated at 4 °C for another 24 h.
All tubes then received 100 |xl of normal rabbit serum, diluted 1: 800 in
say buffer, followed by 100 (il of a 1: 32 dilution of second antibody
onkey anti-rabbit serum) to precipitate the bound fraction. Tubes were
;ain vortexed and incubated overnight at 4 °C.
Chapter 3 General methods 47
Figure 3.3. Comparison of typical NIH-LH-S18 and NIH-
LH-S23 standard curves, showing parallelism of standards.
Data shown is after subtraction for non-specific binding.
Comparison of NIH-LH-S18 and -S23 standards
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1 ml of 0.9% saline was added to all tubes (except total counts) which
were immediately centrifuged at 3 000 rpm (2 110 g) for 30 min at 4 °C
(Sorvall Omnispin R, DuPont, Wilmington, DE, USA). The supernatant
was then decanted and the precipitate counted for 60 s on a "/-counter (1261
Multigamma, LKB Wallac OY, Turku, Finland).
Sensitivity The lower limit of sensitivity of the assay, defined as the
lowest standard to depress the binding by more than two standard
deviations from the zero binding level, was 0.2 ng/ml using NIH-LH-S18
as a reference standard. The intra- and interassay coefficients of variation
assessed using three pooled plasma samples containing 0.95, 3.92 and 6.58
ng/ml, were 7.3 and 15.9%, 6.1 and 10.1% and 6.2 and 13.2% respectively.
3.5.2. Follicle-stimulating hormone
»
The concentration of FSH was measured in plasma using the double-
antibody radioimmunoassay described by McNeilly, McNeilly, Walton &
Cunningham (1976). except that NIAMDD-anti-oFSH-1 was used as first antibody.
Briefly, duplicate 150-pl aliquots of sample, diluted as required, or
triplicates of standard (0.5-125 ng/ml NIH-FSH-S14, NIDDK) were added
to 150 pi assay buffer (0.1% BSA/PBS). Anti-ovine FSH antiserum
(NIAMDD anti-oFSH-1), raised in a rabbit and obtained from NIH, was
diluted 1:12 000 in assay buffer and 50 (il added to all tubes apart from
NSBs. Tubes were vortexed and incubated at 4 °C for 24 h.
Radiolabeled FSH was prepared by the lactoperoxidase method
scribed above from purified ovine FSH (NIDDK-oFSH-I-1) obtained
>m NIH. Tracer was diluted in assay buffer (15 000 cpm/50 pi) and 50 |il
ded to all tubes which were then vortexed and incubated for a further
h at 4 °C. Tubes then received second antibody as above and were
:ubated overnight, followed by centrifugation and counting.
Assay sensitivity was 2 ng NEH-FSH-S14/ml; the intra- and interassay
efficients of variation were both less than 10%.
i.3. Prolactin
olactin was measured in plasma by the double-antibody radioimmuno-
;ay of McNeilly & Andrews (1974).
Briefly, samples were assayed in duplicate in a volume of 30 pi, diluted
required. 30 pi of sample or standard (0.4-200 ng/ml NIH-oPRL-S15)
is added to 100 pi assay buffer (1% BSA/PBS). The anti-ovine prolactin
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antiserum used (#50) was raised by Dr Alan McNeilly in a rabbit and added
at a dilution of 1:128 000 in a volume of 100 pi. 100 pi radiolabeled
prolactin, prepared by the lactoperoxidase method from purified ovine
prolactin (NIADDK-oPRL-19) supplied by NIH, was added to each tube and
the assay incubated at 4 °C for 24 h. Tubes then received second antibody
as previously described, were incubated overnight and then centrifuged
and counted.
Assay sensitivity was 0.8 ng NIH-PRL-S15/ml; the intra- and interassay
coefficients of variation were both less than 8%.
3.5.4. Cortisol
Plasma Cortisol concentrations were measured by the double-antibody
radioimmunoassay described by Porter, Lincoln & Naylor (1990) and in
more detail below.
Buffer Assay buffer (0.1% gelatin 0.1 M phosphate-buffered saline, pH
7.4) was made by dissolving 22.92 g Na2HP04, 5.22 g NaH2P04.2H20 and
18.0 g NaCl in 2 1 distilled water. About 50 ml of the measured distilled
water was set aside and warmed to 37 °C to dissolve 2.0 g gelatin. Once the
gelatin was in solution, this was returned to the rest of the buffer and the
pH adjusted to 7.4.
Extraction All samples from a particular treatment of an individual
animal were extracted together and included in the same assay. Steroids
~
ere extracted from 100 jj.1 plasma with 2.5 ml diethyl ether (BDH Analar
ade). After vortexing for a minimum of 10 min, the aqueous phase was
jzen in a dry ice/methanol bath and the organic phase decanted into
w borosilicate tubes and evaporated to dryness under nitrogen. At this
•int, the dried-down tubes were stored, if required, at -20 °C for assay at a
:er date. The steroid fraction was then reconstituted in 500 pi assay
iffer, vortexed thoroughly and left for at least 0.5 h at room temperature.
Correction was made for methodological losses in the extraction of
ch batch of samples. Six 100-pl aliquots of dexamethasone-suppressed
eep plasma, with 10 pi of label containing 15 000 cpm 125I-cortisol added,
jre subjected to the same extraction procedures and the amount of label
:overed was counted. The mean extraction efficiency was 75%.
itibody Anti-cortisol antibody (S004-201), raised in a sheep against
rtisol-3-(carboxymethyl)-oxime-BSA conjugate, was obtained from the
ottish Antibody Production Unit (Carluke, Lanarkshire). A stock solu-
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tion of this antibody was made up in assay buffer to a dilution of 1:10 and
stored at -20 °C in aliquots of 100 pi. This was further diluted to a working
dilution of 1: 8 000 immediately before use. Cross-reactivities of the anti¬
body as quoted by the supplier are as follows: corticosterone, 0.18%; corti¬
sone, 0.07%; 21-deoxycortisone, 0.30%; 11-deoxycorticosterone, 0.03%; 11-
deoxycortisol, 0.58%; 17a-OH progesterone, 2.10%.
Radioiodination The Cortisol for iodination was first conjugated to
histamine by Ian Swanston using the mixed-anhydride method and stored
dried down in glass test tubes at -20 °C in aliquots of 500 ng.
The cortisol-histamine conjugate, in its glass tube, was iodinated using
the chloramine-T technique as follows. After drying down any residual
ethanol from the conjugation reaction, the conjugate was solvated in 40 pi
0.05 M phosphate buffer for 20 min at room temperature. 10 pi (1 mCi)
Na125I and then'10 pi chloramine-T (5 mg/ml 0.25 M phosphate buffer)
were added and the mixture vortexed for 60 s. The reaction was stopped by
the addition of 10 pi sodium metabisulphite (8 mg/ml 0.05 M phosphate
buffer) and the mixture then counted to determine the total radioactivity
present. 180 pi 0.05 M phosphate buffer was added and the steroid fraction
extracted by vortexing for 60 s with 400 pi ethyl acetate. The two phases
were allowed to separate and the (upper) steroid fraction transferred to a
small glass test tube with a pasteur pipette. This was counted to determine
the radioactivity in the steroid fraction. The labelled Cortisol was then
separated from the free 125I in the steroid fraction by thin-layer
romatography (Merck silica gel 60 F254 aluminium TLC plate, Merck AG,
irmstadt, FRG) using 150 ml toluene, ethanol and glacial acetic acid
5: 24: 1 v/v) as the solvent. After the plate had run for 1.5-2 h the
dioactive bands were located using a geiger counter shielded with a lead
t. The lower band (Rf -0.35) was cut out into 1-cm pieces and placed in 5
. ethanol in a glass-stoppered test tube at 4 °C. When required for assay,
2 aliquot of labelled Cortisol was dried down in a beaker under nitrogen
d reconstituted in assay buffer. Incorporation of 125I into the steroid
iction was typically 30-35% and the specific activity of the labelled
rtisol 0.6-0.8 pCi/100 pi.
For the Cortisol assays in chapters 8 and 9, 125I-radiolabelled Cortisol
ortisol-3-(carboxymethyl)-oximino-(2-[ 125I ]-iodohistamine) ] was pur-
ased from Amersham. This increased the binding from 35% to 60%, but
terwise did not alter any characteristic of the assay.
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Procedure Cortisol for use as standard was obtained from Sigma (Poole,
Dorset). A stock solution of 100 M-g/10 ml assay buffer was made from a
solution of 1 mg/ml Cortisol in ethanol. Standards were prepared by
double dilution in assay buffer from 8 000-15.6 pg/100 |il. Duplicate 100-jil
aliquots of the extracted sample, reconstituted in 500 pi assay buffer as
above, were incubated for a minimum of 4 h at room temperature, or
overnight at 4 °C, with 100 pi anti-cortisol antibody and 100 pi 125I-labelled
Cortisol (15 000 cpm/100 pi). The bound fraction was separated by liquid
phase second antibody precipitation by incubating overnight at 4 °C with
100 pi donkey anti-sheep serum (1: 30) and 100 pi normal sheep serum
(1: 600) (SAPU). 1 ml 0.9% saline/0.2% Triton X-100 was added to all tubes
except total counts before centrifugation and counting as above.
Sensitivity The( sensitivity of the assay was 31 pg/tube and the detection
limit 1.55 ng/ml. Dexamethasone-suppressed sheep plasma with Cortisol
added at three concentrations was used for quality controls. The mean
intra-assay coefficient of variation (CV) was 11.8% at a mean plasma
Cortisol concentration of 21.8 ng/ml, 7.7% at 65.2 ng/ml and 5.3% at 228
ng/ml for triplicates of three quality control plasma pools; the interassay




iring counting (see above) the output from the Multigamma counter
is written to a digital data logger (Datagrabber, Mutek, Box, Wiltshire),
lis allowed subsequent input to an assay calculation program written by
■ Phil Taylor for the Apple Macintosh computer (AssayZap, Elsevier
osoft, Cambridge). Essentially, this program uses a four-parameter
jighted-regression model of the displacement curve. This starts from
2 two-parameter Logit-log model as a first estimate but then adjusts the
ymptotes, slope and point of inflection (the four parameters) of the
adel curve reiteratively, giving more weight to the standard points with
taller variance, until the least squares fit is obtained. The program also
)res information about assay history so that comparisons with previous
rves, quality control samples, binding levels etc. are possible.
\
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3.6.2. Data interpretation
For analysis of the data the sampling period was condensed, in most cases,
by splitting it into three divisions. These corresponded to times before,
during and after treatment. In all cases, these were less than one third of
the total sampling time, due to the time taken to inject each animal. The
injections had to be staggered, sometimes taking up to 45 min for all
injections to be complete. For analysis of pulsatile data, pulses of LH were
defined as occurring when the concentration of LH measured in one
plasma sample was greater than the mean of the concentrations of the
previous two samples by at least three times the CV of the assay. Pulse
amplitude was calculated by subtracting the concentration at the onset of
the pulse from the peak concentration; mean LH concentration by
averaging the concentrations over the sampling window and pulse
frequency by counting the number of peaks in the sampling window. The
area under the curve was calculated by treating the area as composed of a
series of trapezoids of the width of the sampling interval and calculating
the sum of these small areas.
3.6.3. Statistical analysis
The effects of treatments were assessed statistically by analysis of variance
either within- or between-groups and for repeated measures as appropriate
(Winer, 1971) using a statistics program written for the Apple Macintosh
mputer (CLR Anova, Clear Lake Research, Houston, TX, USA). Pairwise
mparisons were made using Neuman-Keuls test of significance.
4. Effect of central administration of LHRH
and LHRH analogues on LH secretion
in the ovariectomized ewe
4.1. Introduction
The experiments described in this and the following two chapters were
designed to address the concept of an autoregulatory mechanism, whereby
hypothalamic neuropeptides alter the pattern of their own release. Such
autoregulation was first postulated by Hyyppa, Motta & Martini (1971) for
the putative follicle-stimulating hormone-releasing factor. They coined
the term 'ultrashorf-loop feedback to differentiate this type of control
from 'short'-loop feedback and 'long'-loop feedback. By these terms they
meant, respectively, the control of secretion of the releasing factor by an
intrahypothalamic action of the pituitary hormone (such as, in this case,
FSH) and control by those hormones, such as the sex steroids, released
from the peripheral target organs.
Autoregulatory mechanisms have been demonstrated for a number of
hvDOthalamic releasing and inhibiting hormones. Somatostatin (Abe,
o, Iwasaki et al. 1978; Lumpkin, Negro-Vilar & McCann, 1981), growth
mone-releasing factor (Lumpkin, Samson & McCann, 1985) and
dnizing hormone-releasing hormone (Bedran de Castro, Khorram &
Cann, 1985) all act within the brain to alter the release of anterior
ritary hormones in the opposite direction to their actions at the level of
pituitary gland.
In the rat there is evidence, both in vivo and in vitro, that central
ninistration of exogenous LHRH and LHRH agonists reduces
jinizing hormone (LH) secretion (Bedran de Castro et al. 1985;
irguignon, Gerard, Debougnoux et al. 1987; DePaolo, King & Carrillo,
7; Sarkar, 1987). When LHRH was administered intracerebroventric-
rly to ovariectomized rats, plasma levels of LH decreased, suggesting
t exogenous LHRH might prevent the release of endogenous LHRH.
i physiological significance of endogenous LHRH in controlling LHRH
53
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release has also been examined in vitro. When median eminence
fragments were incubated in the presence of an LHRH antagonist
([D-pGlu1, D-Phe2, D-Trp3'6] LHRH), basal secretion of LHRH increased in a
dose-related manner (Valenga, Johnston, Ching & Negro-Vilar, 1987),
suggesting that endogenous LHRH may exert a tonic inhibitory influence
on LHRH release. Thus, it is conceivable that centrally-released LHRH
may be involved in the mechanisms governing the pulsatile secretion of
LHRH, possibly through direct contacts between LHRH neurones (Leranth,
Segura, Palkovits et al. 1985; Pelletier, 1987). The work described in this
chapter was designed to expand on the findings in the rat and to
investigate further the hypothesis of an LHRH 'ultrashort'-loop feedback.
As reviewed in more detail in Chapter 2, the pulsatile secretion of
LHRH from the brain is thought to be brought about by the synchronous
firing of LHRH heurones located within the hypothalamus. The resultant
release of LHRH into the portal system is then responsible for the pulsatile
secretion of LH from the pituitary gland. It is therefore possible to
monitor LH pulses as an indicator of the activity of the hypothalamic
LHRH pulse generator. The sheep is a particularly good animal model in
which to study changes in the pulsatile secretion of LH over long periods
of time as it has a large blood volume and well defined characteristics of
LH release.
The following studies were therefore undertaken in the
ovariectomized ewe to determine the effects of centrally administered
TTIRH and an LHRH antagonist on the pulsatile secretion of LH in vivo.
ecifically, the aims were to investigate the effect of third ventricular
ection of LHRH on the pulsatile properties of LH secretion, the effect of
LHRH antagonist on this response and also the possible role of
dogenous LHRH in the feedback control of pulsatile LHRH secretion.
I. Experimental Design
c Scottish Blackface ewes were housed in individual pens in the
liversity of Edinburgh Marshall Building, under artificial lighting
aditions (14 h light; 10 h dark) from October 1987 to January 1988. The
2ep were fed concentrated pellets once a day; hay and water were
ailable ad libitum.
Three to four weeks before experimentation, the animals were
ariectomized (Section 3.2.2) using aseptic conditions. Several days later
Chapter 4 Central LHRH and LH secretion 55
the sheep were anaesthetized again and a stainless steel cannula directed
towards the third ventricle was implanted (Section 3.2.3).
The experiments described in this chapter were designed to investigate
the concept of LHRH-autoregulation by means of the intracerebro-
ventricular injection of LHRH and its analogues. Thus, central injections
of LHRH with or without antagonist and of the antagonist alone were
made and their effects on the secretion of LH studied. Also, in a
preliminary experiment, LHRH agonist was administered centrally.
Details of the agonist and antagonist are given in the previous chapter
(Section 3.4). Two doses of LHRH were used; 2.1 pmol (2.5 ng) and 21
pmol (25 ng). The dose of antagonist was 69 pmol (100 ng) and those of the
agonist, 0.8 pmol (1.0 ng) and 8.0 pmol (10 ng). All were delivered, under
gravity, in a volume of 50 pi sterile saline. When the antagonist was
given together With LHRH, 69 pmol antagonist was injected 15 min prior
to each injection of 21 pmol LHRH.
On the day before each experiment began, a jugular venous cannula for
blood collection was inserted into each ewe and kept patent with
heparinized saline. Blood samples (3 ml) for the measurement of LH were
collected at 10-min intervals for 12 h between 08.00 h and 20.00 h on the
day of each experiment. After an initial 4-h control period, the first of two
i.c.v. injections was made and a second given after a further 1.5 h. The
order of the various injections was based on a cross-over design so that
each ewe served as her own control and received each treatment. In some
^aces, the sampling period was extended to 13 h and a test of the response
he pituitary gland to exogenous LHRH was made by injecting 425 pmol
) ng) LHRH intravenously.
For the analysis of the LH data, the sampling period was split into three
h divisions corresponding to times before, during and after the central
■ctions.
. Results
t concentration of LH in blood samples obtained every 10 min from
riectomized control ewes injected with 50 pi sterile saline was pulsatile
jughout the 12-h sampling period. During this time, the LH pulse
juency, pulse amplitude and mean LH concentration did not change
lificantly with time. The central administration of LHRH, however,
llted in a dose-related inhibition of LH secretion.
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The 12-h LH profiles demonstrating the effects of injection of saline
and two doses of LHRH into the third ventricle of an individual ewe are
shown in Figure 4.1. We found no effect of i.e.v. saline on LH release
(Figure 4.1a). However, when 2.1 pmol LHRH was injected i.c.v. (Figure
4.1b) there was a gradual reduction in the pulsatile nature of LH secretion
which, in the particular ewe illustrated, gradually returned towards the
end of the sampling period. The dose-related nature of this effect of
central LHRH is also shown in this figure. Injection of 21 pmol LHRH
(Figure 4.1c) completely inhibited the pulsatile release of LH, although the
effect was not immediate. In an attempt to find out how long this
suppression continued, the animals' sampling cannulae were left in place
on one occasion and a brief (4-h) bleed undertaken the next day, starting at
09.00 h (i.e., 21 h after the first i.c.v. injection). In a few cases the pulsatile
secretion of LH Was still suppressed, whereas in other animals LH pulses
had returned to the normal ovariectomized pattern.
The grouped effects of saline and LHRH administration on LH pulse
frequency, pulse amplitude and mean LH levels in all six animals are
shown in Figures 4.2a-c, 4.2d-f and 4.2g-i, respectively. The higher
concentration (21 pmol) of LFFRH suppressed pulse frequency significantly
(Figure 4.2c) whereas the lower concentration (2.1 pmol) showed a much
less consistent effect (Figure 4.2b). Both doses of LHRH, however,
suppressed pulse amplitude in the third time period when compared with
the first two (Figure 4.2e, f). Overall, both doses reduced mean LH levels,
^"t not until the third time period (Figure 4.2h, i). From this figure, it
ght appear that the higher dose had an initial stimulatory effect;
wever, any such effect was not statistically significant and was largely a
ult of a wide inter-animal variation in pulse amplitude.
During the LFIRH-induced inhibition of LH release, the pituitary gland
ponded to an i.v. bolus of 425 pmol LHRH with the release of a large
Ise of LH. This is shown in Figure 4.3 for two individual ewes.
The effects of the LHRH antagonist on the inhibitory effect of central
[RH are shown for an individual ewe in Figure 4.4. Injection of 69 pmol
[RH antagonist (Figure 4.4a) had little or no effect on LH release,
ereas 21 pmol LHRH (Figure 4.4b) inhibited LH secretion throughout
t period of measurement. However, when the same amount of LHRH
s injected into the third ventricle after the ewe had received a central
action of the LHRH antagonist 15 min earlier, the pattern of LH
retion was unaffected (Figure 4.4c).
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Figure 4.1. Concentration of LH in 10-min plasma samples
obtained over a 12-h sampling period in an individual ewe
(No. 6E96) showing the dose-related inhibition of LH
secretion by central LHRH. (a) effect of i.c.v. saline (50 pi), (b)
effect of i.c.v. LHRH (2.1 pmol). (c) effect of i.c.v. LHRH (21
pmol). Injections were made into the third ventricle at
arrows.
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Figure 4.2. Grouped data demonstrating the effect of 3 i.c.v.
treatments (saline and 2 concentrations of LHRH) on 3
parameters of LH secretion, pre-, during- and post-injection,
(a-c) LH pulse frequency (pulses per 3.5-h sampling period),
(d-f) LH pulse amplitude, (g-i) mean LH levels. Values are
expressed as the mean ± s.e.m. (n = 6). Levels of significance
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Figure 4.3. Concentration of LH in 10-min plasma samples
obtained over a 13-h sampling period in two individual ewes
(Nos. 106 and 6DF7) showing the effect of a bolus i.v.
injection of LHRH (425 pmol at arrow) on LH release during
the period of suppression. Central injections of LHRH (21
pmol) were made into the third ventricle as previously at
arrows.
i.c.v. LHRH (21 pmol) i.v. LHRH (425 pmol)
X
TIME (h)
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Figure 4.4. Concentration of LH in 10-min plasma samples
obtained over a 12-h sampling period in an individual ewe
(No. 115) showing that pretreatment with the LHRH
antagonist (injected i.c.v. 15 min before i.c.v. LHRH, twice)
prevented the inhibitory effect of central LHRH. (a) effect of
i.c.v. LHRH antagonist (69 pmol). (b) effect of i.c.v. LHRH (21
pmol). (c) effect of i.c.v. LHRH (21 pmol) in the presence of
LHRH antagonist (69 pmol, i.c.v.). Injections were made into
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Figure 4.5 shows the grouped effects of LHRH antagonist and LHRH
plus antagonist on LH pulse frequency and mean LH levels for all six
animals. Pretreatment with the LHRH antagonist blocked the ability of
central LHRH to reduce pulse frequency (Figure 4.5, left) and pulse
amplitude (data not shown). Likewise, the inhibitory effect of central
LHRH on mean LH levels was blocked by prior treatment with the
antagonist (Figure 4.5, right).
In contrast to its effect on LH, central injection of LHRH did not alter
the pattern of FSH or prolactin secretion when compared with the control
responses to saline (Figure 4.6).
In a preliminary experiment the LHRH agonist, Buserelin, was injected
centrally. Somewhat surprisingly, we found that despite the action of
LHRH itself, the analogue had no effect on LH pulse frequency, pulse
amplitude or m£an LH levels. The grouped effects of Buserelin on LH
pulse frequency and mean levels are shown in Figure 4.7.
4.4. Discussion
Injection of LHRH into the third cerebral ventricle of the ovariectomized
ewe caused a delayed (2-3 h) inhibition of LH secretion that was sustained
for at least 6 h in most cases and possibly for up to 20 h or more. Pulse
frequency and mean LH levels were reduced significantly following
central LHRH administration when compared with the control responses
aline. In addition, the pulses of LH that were evident were reduced
siderably in magnitude. In contrast, plasma levels of FSH and
lactin were unaffected by centrally injected LHRH. An absence of an
;bitory effect of central LHRH on FSH secretion has been described
/iously in the rat (DePaolo et al. 1987) and is not unexpected in view of
fact that the half-life of FSH in plasma is 2-3 h or more (Fry, Cahill,
nmins et al. 1987). In addition, FSH secretion is normally unaffected by
rt-term interruptions in the supply of LHRH to the pituitary gland
ser & McNeilly, 1983). The unchanged prolactin levels suggest that the
need secretion of LH is not a consequence of hyperprolactinaemia
hen-Becker, Selmanoff & Wise, 1986).
The inhibitory effect of central LHRH was dose-related in that the
ter dose always suppressed LH release whereas the lower dose exerted
consistent effects, suppressing mean LH levels significantly but not
ring pulse frequency. Both concentrations of LHRH suppressed pulse
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Figure 4.5. Grouped data illustrating the effects of 2
treatments (antagonist alone and LHRH plus antagonist) on
LH pulse frequency (left) and mean LH concentration (right).
Doses are given in the figure. For effects of LHRH on LH
pulse frequency and mean LH, see Figures 4.2a-c and 4.2g-i,
respectively. Pretreatment with antagonist blocked the
LHRH-induced suppression of LH secretion. Values are
expressed as the mean ± s.e.m. (n = 6).
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Figure 4.6. Effects of central saline (50 pi) or LHRH (21
pmol) on the mean hourly plasma levels of FSH (upper) and
prolactin (lower). Central injection of LHRH had no effect on
FSH or prolactin secretion. Values are expressed as the mean
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Figure 4.7. Grouped data showing the effects of i.c.v. LHRH
agonist (Buserelin, 0.8 pmol and 8.0 pmol) on LH pulse
frequency (left) and mean LH concentration (right). LHRH
agonist had no effect on LH secretion. Compare effects of
LHRH, shown in Figures 4.2a-c and 4.2g-i. Values expressed
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amplitude significantly. One question that arises is whether the decrease
in pulse frequency is due to a slowing down of the LHRH pulse generator
or whether a reduction in LHRH pulse amplitude is responsible. From
the results of these experiments it is tempting to speculate that the latter
may be the case since in ovariectomized hypothalamo-pituitary
disconnected sheep, there is an inverse relationship between LHRH/LH
pulse frequency and LH pulse amplitude (Clarke, Cummins, Findlay et al.
1984). Although fewer pulses were observed in the post LHRH period,
those that were evident were reduced considerably in magnitude. This
suggests that, in the sheep, the effect of central LFLRH may be to suppress
pulse amplitude (i.e., reduce LHRH release) rather than to slow down the
actual frequency of the pulse generator. In support of this view, an LHRH
agonist suppresses the release of LHRH in vitro (Bourguignon et al. 1987;
Zanisi, Messi, Motta & Martini, 1987). However, in the rat, central
injection of an LHRH agonist suppresses both the amplitude and
frequency of LITRH pulses (Sarkar, 1987).
A common feature we observed was the delay in response following
an i.c.v. injection of LHRH. The reason for this is unclear from the results
of these experiments but it is highly possible that it may be due to the
activation of another neuronal system, which is then responsible for the
reduction in LHRH and therefore in LH. Indeed, the next two chapters
describe experiments investigating two possible candidate systems.
Alternatively, it may be due to the time required for centrally injected
T TTIH to reach active sites in the brain. This appears unlikely as the
RH would presumably be inactivated by enzymes in the CSF and
racellular spaces. Similarly, the mechanisms underlying the sustained
ure of the inhibition remain unclear. It might be argued that the
genously administered LHRH caused a pituitary desensitization to
logenous LHRH. However, this is unlikely for two reasons. Firstly,
re was no evidence of 'sensitization' which usually precedes a
ensitization and secondly, bolus intravenous injection of LHRH still
iked a prompt and marked release of LH from the pituitary gland
pite the lack of endogenous activity. These observations, coupled with
relatively low dose of LHRH required, suggest that the LHRH-induced
'pression of LH secretion is a central phenomenon.
A similar inhibitory effect of central LHRH has been reported for the
in vivo (Bedran de Castro et al. 1985; DePaolo et al. 1987; Sarkar, 1987).
wever, in the rat, the effect of LHRH was not so delayed nor so
Chapter 4 Central LHRH and LH secretion 66
sustained as that described here in the sheep. However, in both the rat
and the sheep, the evidence implicates the central nervous system (CNS)
rather than the pituitary gland in the response. In the rat, there is
evidence from in-vitro studies that cell bodies (DePaolo et al. 1987) and
nerve terminals (Valenga et al. 1987) in the mediobasal hypothalamus are
involved. However, it is impossible to determine from these experiments
the relative contribution of each to the LHRH-induced inhibition of LH
secretion in the ewe.
Although no studies have been undertaken to characterize LHRH
receptors in the sheep brain, the fact that we have shown LHRH to exert
central actions supports the hypothesis that they exist. Also, our
demonstration that an LHRH antagonist is capable of preventing the
LHRH-induced suppression of LH release strengthens the suggestion that
the inhibitory effect of LHRH involves an interaction with LHRH
receptors, rather than a non-specific action. This was achieved using a
concentration of LHRH antagonist that did not affect any characteristic of
LH secretion when administered alone. A similar reversal of inhibitory
action (induced by an LHRH agonist) has been described using another
LHRH antagonist ([Ac-D-Ala1, D-Phe2, D-Trp3<6]LHRH) (Sarkar, 1987).
In an attempt to determine the functional significance of endogenous
LHRH in regulating pulse generator activity, a 5-fold higher concentration
of the LHRH antagonist (345 pmol) was injected into the third ventricle.
However, at this high dose, the antagonist exerted inhibitory actions,
"rosumably by travelling in the portal system to the pituitary where it
:ked LHRH receptors. Therefore, the current experiments produced no
ience to suggest that endogenous LHRH is involved in the
siological control of LHRH secretion. However, it is possible that
rete microinjection of relatively low doses of LHRH antagonist into
:tionally important sites in the sheep hypothalamus may reveal a role
endogenous LHRH in the control of the LHRH pulse generator. In
port of this, there is evidence from studies using LHRH antagonists in
? that endogenous LHRH exerts a tonic inhibitory influence on LHRH
etion in the rat (Valenga et al. 1987).
The experiments described in this chapter were carried out in long-
t ovariectomized ewes and so the inhibitory effect of central LHRH
we observed occurred in the absence of ovarian steroids. The
;atility of LHRH secretion under these conditions is nearly maximal
so this provides an explanation of why we were unable to show an
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effect of the antagonist alone. Since oestradiol and progesterone exert such
potent modulatory actions on the LHRH pulse generator (see Chapter 2),
the question of the precise physiological significance of LHRH feedback
remains open. It would be of great interest to determine the effects of
central administration of LHRH antagonist during the luteal phase, for
instance, as it seems highly probable that it would be possible to
demonstrate a role for endogenous LHRH under these conditions.
In conclusion, the work described in this chapter indicates that in the
sheep, administration of LHRH into the brain exerts a dose-related and
receptor-mediated inhibition of pulse generator activity. This supports the
hypothesis that central LHRH is involved in a system to regulate its own
release. However, the delayed and sustained nature of the inhibitory effect
suggests strongly that another neural or endocrine system is involved in
LHRH autoregulktion. Experiments designed to investigate two potential
mechanisms whereby this may be achieved are described in the following
two chapters.
5. Effect of the opiate antagonist naloxone on the
LHRH-induced inhibition of LH secretion
5.1. Introduction
In the preceding chapter, evidence was presented to support the
hypothesis that an autoregulatory mechanism exists in the control of
central LHRH in the sheep. Centrally administered LHRH was observed
to cause a marked inhibition of LH secretion, in agreement with the
findings of Bedr&n de Castro et al. (1985) and DePaolo et al. (1987) in the
rat. As discussed previously, a reduction in the sensitivity of the pituitary
gland to endogenous LHRH is unlikely to account for these findings. The
inhibition of plasma LH is more likely to be due to an inhibition of LHRH
release from LHRH nerve terminals (Bourguignon et al. 1987; DePaolo et
al. 1987; Sarkar, 1987; Valen^a et al. 1987; Zanisi et al. 1987).
Bedran de Castro et al. (1985) and DePaolo et al. (1987) observed a
transient reduction in LH secretion within minutes of injection of LHRH
into the third ventricle of the rat. In contrast, we found the onset of the
suppressive effects of central LHRH to be delayed by 2-3 h and the
bition itself to last for at least 6 h and possibly for up to 20 h after
:tion. This suggests that, in the sheep, the activation of another
ral or endocrine system may ultimately be responsible for the
action in LHRH and therefore in LH. Several possible candidate
hanisms could be responsible. Firstly, a raised plasma prolactin
:entration might mediate the response. Secondly, activation of one of
'classical' neurotransmitter pathways such as those involving
rinobutyric acid, noradrenaline, or the endogenous opioid peptides
• be responsible. Thirdly, our findings could also be accounted for by
/ation of another neuroendocrine system such as the hypothalamo-
itary-adrenal axis.
The first putative mechanism can be discounted. Although
erprolactinaemia has been shown to reduce pulsatile LH secretion
ren-Becker et al. 1986) and to reduce pituitary portal levels of LHRH
kar & Yen, 1985), we found no evidence of any alterations in plasma
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prolactin (see Chapter 4).
We decided to investigate further the possible actions of the
endogenous opioid peptides and the hypothalamo-pituitary-adrenal axis
in the autoregulation of LHRH. This chapter describes our experiments
on the role of the EOPs. Our studies investigating the role of the
hypothalamo-pituitary-adrenal axis are described in Chapter 6.
Endogenous opioid peptides have been implicated in the inhibitory
control of LHRH release in a number of species (Cicero, Schainker &
Meyer, 1979; Kinoshita, Nakai, Katakami et al. 1980; Schultz, Wilhelm,
Pirke et al. 1981; Sarkar & Yen, 1985; Wiesner, Koenig, Krulich & Moss,
1985; Orstead & Spies, 1987), including the sheep (Brooks, Lamming &
Haynes, 1986; Horton, Francis & Clarke, 1988). In particular, intracerebro-
ventricular (i.e.v.) injection of naloxone or of anti-(3-endorphin antiserum
augments LH rfelease in the ewe (Weesner & Malven, 1988). Since
endogenous opioid peptides mediate the inhibitory effects on LHRH/LH
release of a number of neuropeptides including corticotrophin-releasing
hormone (CRH) (Gindoff & Ferin, 1987; Almeida, Nikolarakis & Herz,
1988; Nikolarakis, Almeida & Herz, 1988; Nikolarakis, Almeida,
Sirinathsinghji & Herz, 1988) and atrial natriuretic factor (ANF) (Samson,
Aguila & Bianchi, 1988), it is conceivable that activation of endogenous
opioid pathways, e.g. those containing (3-endorphin, may participate in the
prolonged inhibition of LH secretion described in the preceding chapter.
The following studies were therefore undertaken in ovariectomized
s to determine whether, like their involvement in the suppressive
:t of CRH and ANF, endogenous opioid peptides are involved in
iating the delayed and sustained inhibitory effects of central LHRH on
;atile LH secretion. In addition, we were able to investigate the
ence of an opioid-mediated tonic inhibitory influence on LHRH/LH
ase in long-term ovariectomized ewes by administering the opioid
gonist naloxone on its own.
Experimental design
1 Scottish Blackface ewes were housed in individual pens in the
yersity of Edinburgh Marshall Building, near Edinburgh, under
icial lighting conditions (14 h light; 10 h dark) from January to March
!. The sheep were fed concentrated pellets once a day, and hay and
?r were available ad libitum.
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Two to three months before experimentation, the animals were
ovariectomized and implanted with a stainless steel cannula directed
towards the third ventricle as described in Chapter 3.
To study whether endogenous opioids are involved in mediating the
inhibition of LH secretion described in the previous chapter, we repeated
the i.c.v. injections of LHRH at the higher dose (21 pmol) with or without
a concomitant intravenous administration of naloxone. The animals also
received control injections of i.c.v. saline and i.v. naloxone alone. 25 mg
naloxone (see Section 3.4) was injected four times intravenously at
intervals of 1.5 h. Injections of naloxone were made down the sampling
cannula immediately after a blood sample was taken and before the line
was flushed with heparinized saline.
On the day before each experiment began, a jugular venous cannula
was inserted into' each ewe and kept patent with heparinized saline. Blood
samples (3 ml) for the measurement of LH were collected at 10-min
intervals for 11 h between 08.00 h and 19.00 h on the day of each
experiment. After an initial 4-h control period, the first of two i.c.v.
injections was made. The second injection was made after a further 1.5 h.
Naloxone (4 x 25 mg) was injected intravenously at 4, 5.5, 7 and 8.5 h into
the sampling period. Each ewe received each treatment (i.c.v. saline, i.c.v.
LHRH, i.v. naloxone, i.c.v. LHRH plus i.v. naloxone) in random order and
so acted as her own control.
For the analysis of the LH data, the sampling period was divided into
2e equal 3.5-h windows corresponding to times before, during and after
central injections.
. Results
? concentration of LH in blood samples obtained every 10 min from
g-term ovariectomized control ewes injected with 50 |il saline i.c.v. was
satile throughout the 11-h sampling period.
The 11-h pulse profiles obtained from an individual ewe, showing the
;cts of the four treatments on pulsatile LH secretion, are shown in
ure 5.1. Injection of saline into the third cerebral ventricle (Figure 5.1a)
not influence the normal pulsatile pattern of LH secretion. However,
en 21 pmol of LHRH was injected i.c.v. (Figure 5.1b) the normal profile
JT secretion was altered. There was a gradual reduction in the pulsatile
;ase of LH which, 7 h after injection, was almost completely inhibited
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Figure 5.1. Concentration of LH in 10-min plasma samples
obtained over an 11-h sampling period in an individual ewe
showing the effects of four treatments, (a) effect of i.e.v.
saline (50 (il). (b) effect of i.c.v. LHRH (21 pmol). (c) effect of
i.v. naloxone (4 x 25 mg) (note change of scale), (d) effect of
i.c.v. LHRH (21 pmol) plus i.v. naloxone (4 x 25 mg). Times
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in the ewe shown. Despite the stimulatory effects of naloxone alone
(Figure 5.1c), the sustained inhibition of LHRH/LH produced by central
LHRH persisted in the presence of the opioid antagonist (Figure 5.Id).
The grouped effects of the treatments on two parameters of LH
secretion, mean concentration and pulse frequency, are shown for all five
animals in Figures 5.2 and 5.3 respectively. Injection of 50 (il saline i.c.v.
did not affect mean LH levels (Figure 5.2a) or LH pulse frequency (Figure
5.3a). Central LHRH (21 pmol) reduced mean plasma LH concentrations
significantly compared with the time periods before and during i.c.v.
injection (Figure 5.2b), confirming our previous findings (Chapter 4).
Intravenous administration of naloxone (4 x 25 mg) resulted in a
significant increase in LH release which was evident throughout the
sampling period (Figure 5.2c). However, in the presence of naloxone,
third ventricular'injection of LHRH still caused a significant reduction in
mean LH concentration (Figure 5.2d). The effects of saline, LHRH and
LHRH plus naloxone on LH pulse frequency are shown in Figure 5.3.
Third ventricular administration of LHRH caused a significant reduction
in pulse frequency (Figure 5.3b) which was not reversed by naloxone
(Figure 5.3c). The large increase in mean LH concentration after i.v.
naloxone was due to an increase in pulse frequency in four out of five
ewes (p = 0.085) and a significant increase (p < 0.05) in pulse amplitude
(Figure 5.4).
Discussion
ction of LHRH into the third cerebral ventricle of the ovariectomized
resulted in a delayed but sustained inhibition of LHRH/LH secretion.
>e frequency and mean LH levels were significantly reduced. In
ition, the pulses of LH that were recorded were reduced considerably in
;nitude. This confirms the findings of the previous chapter. The data
demonstrate that concomitant infusion of naloxone has no effect on
response to LHRH. Therefore, in contrast to their role in mediating
inhibitory actions of CRH and ANF on LHRH release, endogenous
)id peptides are unlikely to be involved in the LHRH-induced
bition of LHRH/LH secretion.
The concept of autoregulation (or 'ultrashort'-loop feedback as
:ribed in Section 5.1) has been used to describe the inhibitory effect of
ral LHRH on LHRH/LH secretion in the rat (Bedran de Castro et al.
Chapter 5 Opioids and 'ultrashort'-loop feedback 73
Figure 5.2. Grouped data showing the effects of 4 treatments
on mean LH concentrations in the time periods before,
during and after i.e.v. injection, (a) i.e.v. saline (50 pi), (b)
i.c.v. LHRH (21 pmol). (c) i.v. naloxone (4 x 25 mg) (note
change of scale), (d) i.c.v. LHRH plus i.v. naloxone. Values
are expressed as the mean ± s.e.m. (n = 5).
MEAN LH CONCENTRATION
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Figure 5.3. Grouped data showing the effects of 3 treatments
on LH pulse frequency before, during and after i.c.v.
injection, (a) i.c.v. saline (50 pi), (b) i.c.v. LHRH (21 pmol).
(c) i.c.v. LHRH plus i.v. naloxone. Values are expressed as
the mean ± s.e.m. (n = 5).
LH PULSE FREQUENCY
(a) Saline (50 jxl)
(b) LHRH (21 pmol)
p<0.05
r
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Figure 5.4. Effect of intravenous injection of naloxone (4 x
25 mg) on LH pulse frequency and pulse amplitude for all 5
ewes in the 3.5 h periods before and during treatment.
Individual responses are shown for pulse frequency (p =
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1985). In this species, the inhibitory action of central LHRH is immediate,
short-lived and occurs in vitro (Bourguignon et al. 1987; DePaolo et al.
1987; Zanisi et al. 1987). In the rat, there is morphological evidence for
such a feedback system as LHRH neuronal terminals have been observed
to synapse on LHRH cell bodies (Leranth et al. 1985; Pelletier, 1987). If a
similar process of autoregulation were occurring in the sheep, it might be
expected that the inhibitory response would be observed sooner and be of a
shorter duration. The mechanisms responsible for the actions of LHRH in
the two species may, however, be quite different. Although the possibility
of a direct action of LHRH remains, the injected LHRH would presumably
be inactivated by enzymes in the cerebrospinal fluid (CSF) or brain
extracellular spaces within the period of inhibition as discussed in the
previous chapter.
Interestingly,'the LHRH-induced inhibition persisted during naloxone
administration whereas, when the same animals were treated with
naloxone alone, there was a marked stimulation of LHRH/LH release.
These data suggest that endogenous opioid peptides that may be
antagonized by naloxone are unlikely to mediate the inhibitory effect of
LHRH in the ewe and secondly, that the central inhibitory effect of LHRH
blocks the stimulatory effect of naloxone.
An alternative explanation for the delayed response may be that the
inhibitory effect of central LHRH is in fact very rapid but masked by a
simultaneous, but short-lived, augmentation of LHRH/LH release. In
port of this proposal is the following. The inhibitory effect of central
3H has a long latency, but the stimulatory effect of naloxone is
aediate. However, when naloxone and LHRH are administered
?ther naloxone has no stimulatory effect. This could be taken to imply
, in fact, there is an early onset of the LHRH effects, comparable with
time course of the effects of naloxone. From the results, there is no
elusive evidence to determine whether or not this is the case.
:t might be argued that an insufficient dose of naloxone was used to
/ent the actions of all endogenous opioids since this opioid blocker is a
:erential p-receptor antagonist with a much lower affinity for the 5-
K-receptors. The relative binding of naloxone at the p-, 5- and
tes is 0.85, 0.06 and 0.09, respectively (Paterson, Robson &
terlitz, 1983). However, since injection of naloxone alone exerted
cts on LHRH/LH release it seems reasonable to assume that an
quate amount of antagonist was present to influence opioid/LHRH
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regulatory systems.
In this experiment, the mean levels of LH increased following
naloxone treatment as a consequence of an increase in pulse frequency (in
four out of five animals) (p = 0.085) and a significant increase in pulse
amplitude (p < 0.05). The increase in LH pulse frequency suggests a hypo¬
thalamic (i.e., on LHRH release) rather than a pituitary site of action for
naloxone. In support of this, naloxone implants placed in the medial pre¬
optic area and median eminence arcuate region stimulate LH release in
rats (Kalra, 1981) as does intrahypothalamic injection of anti-(3-endorphin
antiserum or naloxone in sheep (Weesner & Malven, 1988). Since
naloxone crosses the blood brain barrier and is detectable in significant
amounts in the brain following intravenous administration (Berkowitz,
Ngai, Hempstead & Spector, 1975; Berkowitz, 1976), it is likely that the
effects of naloxohe on LH release that we observed are mediated at the
hypothalamic level.
The results of the experiment in this chapter also demonstrate that in
the long-term ovariectomized ewe (i.e., 2-3 months), endogenous opioid
peptides exert a tonic inhibitory influence on LHRH/LH secretion. This
observation is in contrast to other reports where naloxone stimulated LH
release in ovariectomized ewes only if they had been implanted with
progesterone at the time of gonadectomy (Brooks, Haynes, Yang &
Lamming, 1986; Trout & Malven, 1984). However, it is in agreement with
other studies reporting the stimulatory effect of naloxone (Schillo, Kuehl
°
Tackson, 1985) and another opioid antagonist, WIN-44441-3, (Yang,
rnes, Lamming & Brooks, 1988) on LHRH/LH release in ovari-
mized ewes. Evidence obtained from other species also suggests that
)xone-stimulated LHRH/LH release is not diminished following
riectomy (Orstead & Spies, 1987; Karahalios & Levine, 1988), although
adal steroids do exert a major influence on the effects of naloxone and
?r opioid antagonists on LH secretion (Haynes, Lamming, Yang et al.
>)•
n conclusion, the results of this experiment indicate that central
IH inhibits LHRH pulse generator activity by a mechanism that
?ably does not involve opioid peptides. However, the hypothesis that
ther neuroendocrine mechanism is responsible for mediating the
bition still remains. This is addressed further in the next chapter, in
ch experiments to investigate the possible role of the hypothalamo-
itary-adrenal axis are described.
6. Involvement of the hypothalamo-pituitary-
adrenal axis in the suppression of LH secretion
by centrally-administered LHRH
6.1. Introduction
The experiments in this chapter follow on from the results of the previous
two. In Chapter 4, experiments revealing an autoregulatory mechanism
for LHRH in the sheep were described. Central administration of LHRH
resulted in a suppression of LH secretion that lasted for at least 6 h after an
apparently delayed onset. These two features differed from previous
studies in the rat, where the effects on LH secretion were immediate and
transient, and prompted us to investigate LHRH self-regulation further.
Several putative mechanisms were suggested in the previous chapter
(Section 5.1) and one of these, the endogenous opioid peptide system, was
investigated. Our experiments indicated that the opioid peptides were
probably not involved in the inhibition of LHRH pulse generator activity
by central LHRH.
The experiments described in this chapter address the hypothesis that
central inhibition of LHRH secretion involves some aspect of the
othalamo-pituitary-adrenal axis, which is activated under conditions
hysical and environmental stress. There is clear evidence for a role for
i of the components of this axis in the suppression of LHRH/LH
etion. In the ovariectomized rhesus monkey, intravenous infusion of
I (Gindoff & Ferin, 1987; Olster & Ferin, 1987) although not of ACTH
o & Ferin, 1988) suppresses both pulsatile LH and FSH release,
icerebroventricular injection of CRH induces a rapid decline in LH
not FSH) secretion in the ovariectomized rat and abolishes the pro-
rous LH surge in 50% of intact rats (Rivier & Vale, 1984).
adotrophin secretion is also suppressed by long-term administration
:>rtisol in castrate male rhesus monkeys (Dubey & Plant, 1985), but is
>red in response to intravenous infusion of pulsatile LHRH, implying
Cortisol acts at a suprapituitary level to interrupt hypothalamic LHRH
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release. Moreover, Cortisol, implanted into the mediobasal hypothalamus,
prevents the onset of puberty (Smith, Johnson, Weick et al. 1971) as do
ACTH and adrenalectomy (giving rise to increased endogenous ACTH
levels) (MacFarland & Mann, 1977). Furthermore, both acute and chronic
glucocorticoid treatment in the rat suppresses plasma LH and both the pre¬
ovulatory and the oestradiol-induced LH surge (Baldwin & Sawyer, 1974;
Baldwin, 1979).
Thus, the inhibition of LH secretion observed following central
administration of LHRH may be due to activation of one or other
components of the hypothalamo-pituitary-adrenal axis. We therefore
investigated this hypothesis by determining the effect of injection of
LHRH into the third ventricle on the concentrations of Cortisol in the
plasma samples we had taken in Chapter 4. Unfortunately, we were
unable to measure ACTH in these samples as they had been thawed and
re-frozen several times for the estimation of LH, FSH and prolactin.
ACTH bio- and immunoactivity is destroyed by such treatment, so we had
to use plasma levels of Cortisol as an index of the activity of this axis. In
addition, we looked at the effect of an LHRH antagonist on the Cortisol
response and, in order to investigate the possible role that Cortisol may
play in the suppression of LH by central LHRH, we attempted to determine
the effect of intravenous administration of Cortisol on LHRH/LH
secretion.
Experimental design
experiments described in this chapter are of two types. Firstly, central
jriments to determine the effect of i.c.v. injection of LHRH and an
1H antagonist on plasma Cortisol concentrations; and secondly,
pheral experiments to determine whether LHRH/LH secretion is
:ted by intravenous injections or infusions of Cortisol.
. Intracerebroventricular experiments
:isol concentrations after central treatment with both doses of LHRH
the LHRH antagonist, alone and together, were measured in the
ma of five of the six Scottish Blackface ewes described in Chapter 4.
sixth ewe, although included in the analysis of the LH data reported
hat chapter, did not respond to any of the treatments. When we
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measured this animal's Cortisol levels after central administration of the
higher dose of LHRH, there was no effect on Cortisol levels either, again in
contrast to the responses of the other five animals. Although the LH
responses were sufficiently robust to accommodate a non-responding
animal, we did not feel that anything further would be achieved by
extracting and assaying this ewe's samples for Cortisol for all the
treatments. Cortisol concentrations are therefore presented here for the
five responding animals only.
As described earlier, the sheep were housed in individual pens under
artificial lighting conditions (14 h light; 10 h dark) in the University of
Edinburgh Marshall Building, near Edinburgh, between November 1987
and January 1988. They were fed concentrated pellets each morning and
had unlimited access to hay and water.
Three to fohr weeks before experimentation, the animals were
ovariectomized and implanted with a stainless steel cannula directed
towards the third cerebral ventricle. The animals were prepared for blood
collection as described previously. Central injections of LHRH with or
without antagonist and of antagonist alone were made into the third
ventricle at 4 and 5.5 h into the 12-h sampling period (for details of doses,
see Section 4.2; details of drugs are given in Section 3.4). All animals also
received a control injection of 50 (il saline as described previously.
Plasma Cortisol concentrations were measured by radioimmunoassay
(see Section 3.5.4) in half-hourly blood samples and in 10-min samples for
i after each i.e.v. injection.
. Cortisol injections
he first experiment to determine whether intravenous Cortisol
inistration could affect the secretion of LHRH and LH, we injected
isol intravenously at half-hourly intervals in a group of six
iectomized ewes. Four to eight months prior to experimentation, the
aals were ovariectomized as described previously. During the
criment, in July 1988, the animals were housed in approved restraint
?s in the University of Edinburgh Marshall Building (16 h light; 8 h
) and received feed and water as previously.
)n the day before experimentation, bilateral jugular venous cannulae,
patent with heparinized saline, were inserted into each ewe. On the
of the experiment, after an initial 4-h sampling period from 08.00 h,
animals were injected with 10 mg Cortisol (see Section 3.4) at half-
Chapter 6 Central LHRH and plasma Cortisol 81
hourly intervals for 4 h. Cortisol was injected in a volume of 2 ml
heparinized saline, down the contralateral venous cannula from the one
used for blood sampling. Blood samples were taken at 10-min intervals
for 12 h for the estimation of LH and Cortisol levels.
The mean plasma LH concentration during the 4 h of half-hourly
Cortisol injections was compared using Neuman-Keuls test with the mean
plasma LH concentration during the pre-injection 4-h control period.
6.2.3. Cortisol infusions
As the Cortisol concentrations we obtained after intravenous injection of
Cortisol were unsatisfactory with respect to both level and profile (see
Section 6.3.2 and Figure 6.6), we decided to infuse Cortisol, in an attempt to
reach the plasma concentrations of Cortisol that we had observed after
»
central LHRH administration (see Section 6.3.1). Two regimes of Cortisol
administration were chosen for infusion, as described below. For the low
dose experiment, five ewes that had been ovariectomized 6-12 months
previously were used during March 1989. Eight ewes, ovariectomized at
least one month earlier, were used for the high dose experiment during
November 1988.
On the day before experimentation, bilateral jugular venous cannulae,
kept patent with heparinized saline, were inserted into each group of long-
term ovariectomized Scottish Blackface ewes. On the day of infusion, after
an initial 2-h sampling period starting at 08.00 h, the animals were infused
3ne jugular vein for 10 h at a rate of 2 ml/h with either saline or one
wo doses of hydrocortisone sodium hemisuccinate dissolved in
irinized saline. The low-dose group of animals (n = 5) received an i.v.
:tion of 1 mg Cortisol, immediately followed by infusion of Cortisol at 5
h for 10 h. The other, high-dose group (n = 8), received a 6-mg i.v.
:tion of Cortisol, immediately followed by a 10-h Cortisol infusion at 25
h. The animals in both groups also received an infusion of saline and
served as their own controls. After 9.5 h infusion, the animals were
n an intravenous injection of 500 ng LHRH in saline. Plasma Cortisol
measured in 20-min blood samples and plasma LH in 10-min samples
n from the contralateral vein.
tor the infusion experiments, precision syringe drivers (Infors HT
idor type 5003, Infors AG, Bottmingen, Switzerland) were used and
j adjusted to deliver 2.0 ml/h, when used with 20-ml syringes. Each
d control up to three such syringes, and two or three drivers were
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used in each experiment. The syringes were connected to the jugular
(infusion) cannulae by 210 cm of polyethylene manometer connecting
tubing (as described in Section 3.3.1), taking care to ensure there were no
kinks or air bubbles. Before the infusion started, the lines were filled with
infusate, so that infusion of the test solution started immediately when
the syringe driver was switched on. Injections were made into the
infusion cannula, by momentarily disconnecting the infusion line from
the cannula, immediately prior to the start of the infusion.
The mean plasma LH concentration during the first 9 h of the Cortisol
infusion was compared using Neuman-Keuls test with the mean LH level
during the first 9 h of infusion of saline in the same group of animals.
The mean area under the LH curve after intravenous LHRH injection
during infusion of each dose of Cortisol was also compared with the effect




Throughout the 12-h sampling period, all animals receiving saline
showed a pulsatile pattern of LH secretion typical of an ovariectomized
ewe and Cortisol levels did not depart significantly from a baseline of about
10-12 ng/ml.
;igures 6.1 and 6.2 show the plasma LH and Cortisol concentrations
r each i.e.v. injection for each treatment in two ovariectomized ewes
■ the 12-h sampling period. Injection of saline into the third ventricle
no effect on either LH secretion or on plasma Cortisol (Figures 6.1a and
). However, injection of 21 pmol LHRH resulted in a rapid rise in
ma Cortisol to approximately 4-5 times pre-injection levels, and after a
y, inhibited the secretion of LH (Figures 6.1b and 6.2b). When the
e dose of LHRH was injected into animals that had received a central
:tion of LHRH antagonist (69 pmol) 15 min earlier, the ability of third
:ricular LHRH to increase plasma Cortisol and to inhibit LH secretion
effectively abolished (Figures 6.Id and 6.2d). This dose of antagonist,
n injected i.e.v. alone, had no effect on either plasma Cortisol or LH
ures 6.1c and 6.2c). The effects of each treatment on mean plasma
Is of Cortisol are shown in Figure 6.3 for all five animals. Figure 6.3a
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Figure 6.1i Concentrations of LH in 10-min plasma samples
and of Cortisol in 30-min samples obtained over a 12-h
sampling period in an individual ewe (No. 6E94), showing
the marked rise in plasma Cortisol after i.c.v. LHRH and the
delayed inhibition of LH secretion, (a) effect of i.c.v. saline (50
pi), (b) effect of i.c.v. LHRH (21 pmol). Pretreatment with
LHRH antagonist (injected i.c.v. 15 min before LHRH, twice)
prevented both the rise in Cortisol and the inhibition of LH.
(c) effect of i.c.v. LHRH antagonist (69 pmol) alone, (d) effect
of i.c.v. LHRH (21 pmol) in the presence of i.c.v. LHRH
antagonist (69 pmol). Injections were made into the third
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Figure 6.2. Concentrations of LH in 10-min plasma samples
and of Cortisol in 30-min samples obtained over a 12-h
sampling period in another ewe (No. 115). (a) effect of i.e.v.
saline (50 (il). (b) effect of i.c.v. LHRH (21 pmol). (c) effect of
i.c.v. LHRH antagonist (69 pmol) alone, (d) effect of i.c.v.
LHRH (21 pmol) in the presence of i.c.v. LHRH antagonist (69
pmol). See legend of Figure 6.1 for further details, but note
that scales of axes differ. (Three of this animal's LH profiles
have already been shown in Figure 4.6, but are presented
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Figure 6.3. Effects of four treatments on mean half-hourly
plasma levels of Cortisol, showing the stimulatory effect of
central LHRH on plasma Cortisol and the ability of an LHRH
antagonist to block this, (a) effects of i.c.v. saline (50 pi) and
of i.c.v. LHRH (21 pmol). (b) effects of LHRH antagonist (69
pmol) and of LHRH (21 pmol) in the presence of antagonist
(69 pmol). Times of injection are indicated by arrows. Values
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shows the effect of central injection of 21 pmol LHRH on mean plasma
Cortisol concentrations, compared with the control response to saline. In
Figure 6.3b, the ability of the antagonist to block the stimulatory effect of
LHRH on Cortisol secretion is shown, as is the lack of effect of LHRH
antagonist alone. For clarity, the effect of the lower (2.1 pmol) dose of
LHRH on Cortisol and LH secretion has been omitted from these first three
figures.
The effects of each of the treatments on plasma Cortisol secretion,
expressed as the area under the Cortisol curve, are shown in Figure 6.4 for
all five animals. Analysis of variance, followed by Neuman-Keuls test,
showed there to be no significant difference between the areas under the
Cortisol curves in the 3.5-h pre-injection sampling period (Figure 6.4a). In
addition, there was no significant difference between the rises in plasma
Cortisol seen aftei* 21 pmol LHRH in the two 3.5-h post-injection sampling
periods. These data are therefore presented together (Figure 6.4b).
Intracerebroventricular injection of 21 pmol LFIRH significantly increased
the area under the Cortisol curve in the 7-h post-injection period
compared with saline (p < 0.01) and with LHRH antagonist (p < 0.01). The
LHRH antagonist was able to block the ability of central LFIRH to increase
Cortisol: when 21 pmol LHRH was injected i.c.v. 15 min after 69 pmol
LHRH antagonist, also administered i.c.v., the area under the Cortisol
curve was similar to that after saline and significantly different from that
after 21 pmol LFFRH (p < 0.05). The increase in Cortisol secretion by central
TTTir,H was dose-related in that a 10-fold lower dose (2.1 pmol) only
:ased the area under the Cortisol curve significantly in the first 3.5-h
•injection sampling period whereas the increase in the area under the
sol curve did not reach significance in the second (data not shown),
hapter 4, it was shown that LH secretion was not reduced until the
. 3.5-h time period (see Figure 4.4). If the increase in Cortisol secretion
mpared with the decrease in LH secretion during this time, there is a
degree of correlation. This is shown in Figure 6.5 where the change
ea under the LH curve is plotted against the change in area under the
sol curve at this time for both doses of LHRH. The correlation
icient, r, was -0.902, indicating that the higher the increase in plasma
sol, the greater the reduction in LH.
Cortisol injections
venous injection of 10 mg of Cortisol at half-hourly intervals resulted
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Figure 6.4. Grouped data showing the effects of each
treatment on the mean area under the Cortisol curve (±
s.e.m.). Doses of LHRH and LHRH antagonist as shown.
Where animals were treated with both LHRH and LHRH
antagonist, the dose of LHRH used was 21 pmol. (a) area
under Cortisol curve in the 3.5-h time period prior to the first
i.c.v. injection for each treatment, (b) area under the Cortisol
curve in the 7 h after the first injection (data pooled from the
two post-injection 3.5-h time periods). Note changed scale of
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Figure 6.5. Relationship between change in area under
Cortisol curve (x-axis) and change in area under LH curve (y-
axis) for each individual animal comparing the third 3.5-h
sampling period with the 3.5-h pre-injection control period.
O = i.c.v. LHRH-treated animals
(both doses shown) (n = 5 for each treatment).
ACortisol (ng.h/ml)
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in sharp peaks of Cortisol in plasma, reaching up to -300 ng/ml and
declining rapidly to -100 ng/ml within 0.5 h. Figure 6.6b shows the mean
plasma Cortisol concentrations in samples taken every 10 min for three
ewes as a result of half-hourly Cortisol injection. When Cortisol was
measured only in 20-min samples, half of the Cortisol peaks were missed
(Figure 6.6a). This highlights the fact that there is no Cortisol binding
globulin in the sheep and shows the importance of careful interpretation
of results. The plasma Cortisol profile created by the intravenous injection
of Cortisol was thus not of the same pattern or level as we had measured
after i.e.v. injection of LHRH. There was no effect on plasma
concentrations of LH (Figure 6.6c).
6.3.3. Cortisol infusions
»
Intravenous injection of 1 mg Cortisol followed by infusion of Cortisol at 5
mg/h for 10 h achieved plasma Cortisol levels of 40-50 ng/ml (Figure 6.7a),
i.e., comparable to the raised levels of Cortisol that we observed after
central LHRH administration (see Figures 6.1b and 6.2b). This dose
reduced LH levels significantly (p < 0.05) when compared with the effect of
the control infusion of saline (Figure 6.8). Intravenous injection of 6 mg
Cortisol followed by infusion at 25 mg/h for 10 h had a greater effect on LH
levels. This dose achieved a plasma Cortisol level of 300-400 ng/ml
(Figure 6.7b), i.e., -8-fold higher than we saw after central LHRH
administration and 20- to 30-fold higher than physiological levels. Mean
levels were reduced significantly compared with both saline control (p
)1) and the lower dose of Cortisol (p < 0.01) (Figure 6.8). This reduction
H secretion was more gradual than after central LHRH administration,
i doses significantly reduced the LH response of the pituitary gland to
ntravenous bolus dose of 500 ng LHRH given 0.5 h before the end of
nfusion (p < 0.05) (Figure 6.9).
Discussion
:tion of LHRH into the third cerebral ventricle of the ovariectomized
caused a significant and rapid rise in plasma Cortisol concentration
:h was prevented by prior treatment with an LHRH antagonist. The
ulatory effect of i.e.v. LHRH was dose-related in that the lower dose
Based Cortisol secretion initially post-injection whereas the effect of the
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Figure 6.6.» Effects of intravenous injection of 10 mg Cortisol
at half-hourly intervals for 4 h on plasma Cortisol and LH
levels. Injections commenced at t = 4 h as described in the
text, (a) measurement of Cortisol concentrations in 20-min
samples misses half the peaks. Data shown as mean ± s.e.m.
(n = 6). (b) Cortisol levels re-assayed in 10-min samples for
three of the ewes. The half-life of Cortisol in sheep plasma is
very brief, and injections cannot sustain a plateau, (c) effect
of Cortisol injections on mean area under LH curve (± s.e.m.)
comparing 4 h before with 4 h during injections (n = 6). Effect
of control injections of saline also shown. Intravenous
injection of Cortisol did not affect LH secretion.
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Figure 6.7. Effects of 10 h intravenous infusion of hydro¬
cortisone sodium hemisuccinate or saline on mean plasma
Cortisol concentrations. The period of infusion is represented
by the stippled bar and starts at t = 2 h. (a) injection of 1 mg
Cortisol i.v. at arrow (t = 2 h), followed by 10 h infusion at 5
mg/h (n = 5). (b) injection of 6 mg Cortisol i.v. at arrow (t = 2
h), followed by 10 h infusion at 25 mg/h (n = 8) (note change
of scale). Values are expressed as the mean ± s.e.m. The
plasma Cortisol levels during control infusion of saline in
each group are shown for comparison (note that normal
secretion of Cortisol is pulsatile).
(b) E
O Saline (n = 8)
TIME (h)
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Figure 6.8. Effect of Cortisol or saline infusion on mean area
under LH curve (± s.e.m.) for first 9 h of infusion. Left;
injection of 1 mg Cortisol i.v. followed by infusion at 5 mg/h
(n = 5). Right; injection of 6 mg Cortisol i.v. followed by
infusion at 25 mg/h (n = 8). Effects of control infusion of
saline in each group are also included. Levels of significance
are shown.
□ Saline
E3 Low Cortisol (n = 5)
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Addendum: Figure 6.8.1. Effect of Cortisol or saline infusion on (a) LH
pulse frequency (± s.e.m.) and (b) LH pulse amplitude (± s.e.m.) for first 9
h after infusion. See Figure 6.8 for further details.
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Figure 6.9. Effect of infusion of Cortisol on ability of LHRH
to release LH from the pituitary gland. 500 ng LHRH given
i.v. 0.5 h before end of infusion, i.e., at t = 11.5 h. (a) effect of
i.v. injection of 500 ng LHRH (at arrow) on LH release during
(left) infusion of Cortisol at 5 mg/h (n = 5) and (right)
infusion of Cortisol at 25 mg/h (n = 8). Plasma concentrations
of LH expressed as mean ± s.e.m. (b) both doses significantly
reduced the mean area under the LH curve, after correction
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higher dose was more sustained. The rise in plasma Cortisol was followed
by a reduction in plasma LH secretion as described in Chapter 4. The
degree of suppression of LH secretion correlated highly with the increase
in Cortisol. Whilst intravenous injection was without effect, intravenous
infusion of Cortisol to reach the same levels as observed after central
LHRH administration also significantly reduced LH secretion, but not to
the extent achieved after central LHRH. Furthermore, during the infusion
of Cortisol, the response of the pituitary gland to an intravenous bolus
injection of LHRH was reduced, suggesting that the inhibitory effect of
Cortisol infusion on LH secretion is due, at least in part, to a reduced
pituitary responsiveness to LHRH.
Pituitary responsiveness to i.v. LHRH was not, however, compromised
by the central LHRH treatment (Chapter 4). It could be argued that as we
observed an apparent reduction in pituitary LHRH-responsiveness with
infusion of Cortisol, even at the lower dose, then this suggests that Cortisol
is not a causative factor in the LHRH-induced inhibition of LH secretion.
Indeed, this may be the case, but it should be pointed out that although the
aim of the infusion experiments was to try to re-create the plasma levels of
Cortisol observed after central LHRH administration, the actual pattern
achieved was different in several ways. The infusion experiments created
a much more rapid rise in plasma Cortisol concentration which then
remained at a uniformly high level throughout the following 10 h. The
rise in Cortisol after central LHRH was not sustained at such a constant
1 —1 and was beginning to tail off towards the end of the sampling period,
h later. Thus the test of pituitary LHRH responsiveness during the
;ion was performed after almost 9.5 h of sustained increase in Cortisol,
:eas after the i.c.v. experiments, pituitary responsiveness was tested
i after the first i.c.v. injection, i.e. perhaps 6-7 h after the initial
;vement of the high concentrations. These observations, of course, do
preclude a contributory role for Cortisol as it is quite conceivable that
sol may have profound and rapid effects at the level of the
(thalamus and either delayed effects on the pituitary gland, or effects
are dependent on a more sustained rise. In this regard, it is
esting to note that when we gave half-hourly injections of Cortisol to
iectomized ewes in the preliminary experiment, these had no effect
lasma LH concentrations.
.lthough the stimulation of Cortisol release by third ventricular LHRH
cts the activation of the hypothalamo-pituitary-adrenal axis, it does
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not represent a non-specific 'stress' response as neither saline nor the
antagonist when injected alone affected Cortisol secretion. In addition, the
failure of the LHRH antagonist to affect the secretion of Cortisol, at the
dose tested, suggests that the hypothalamo-pituitary-adrenal axis is not
under tonic control by LHRH.
The aim of the experiments described in this chapter was to try to
investigate the delayed and sustained nature of the LHRH-induced
inhibition of LH secretion. Although it is possible that this delay could be
due, for example, to the time taken for the LHRH to diffuse from the third
ventricle to its site of action this is unlikely as presumably the LHRH
would be subject to degradation by proteases in the CSF and extracellular
spaces of the brain. The sustained nature of the inhibition could be due to
LHRH acting on a central receptor with a greater affinity for LHRH than
has the classical' pituitary receptor. Although we have no evidence to
support or refute this possibility, it seems unlikely as the inhibitory effect
of LHRH on LH secretion was readily blocked by the prior administration
of an LHRH antagonist. One more interesting possibility which would
account for these findings is that the hypothalamo-pituitary-adrenal axis is
acting to affect the reproductive axis. The high degree of correlation
between the increase in plasma Cortisol and the reduction in LH secretion
suggests that the two responses are related. As the reduction in LH
secretion took longer to become evident than the increased Cortisol
concentration, it is tempting to postulate a causative link; i.e., that the
—xiation of the hypothalamic-adrenal axis by central LHRH results in a
:tion in the activity of the LHRH/LH system.
lthough achieving similar plasma levels does not necessarily reflect
ing relevant concentrations at the active site(s) of a drug, intravenous
ion of Cortisol to reach the plasma concentrations seen after third
icular LHRH administration reduced plasma LH levels significantly,
ever, as we did not achieve a reduction to levels of LH obtained after
ventricular LHRH administration and as the reduction in LH
tion that we did observe during the infusion was not so abrupt, it
ars that the action of Cortisol alone may not account for the whole
omenon. Although, as we were unable to measure ACTH, we
at discount the intriguing possibility that we have activated a direct
il input to the adrenal cortex, the LHRH-induced stimulation of
;ol secretion presumably reflects an increase in activity of the
thalamo-pituitary-adrenal axis. Therefore, in addition to the
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increased levels of Cortisol reported in this chapter, endogenous CRH,
AVP and ACTH levels are all likely to be raised during this time and may
contribute to the large decrease in LH. It may be, for example, that
centrally-administered LHRH stimulates CRH release and that CRH itself
acts to suppress the hypothalamo-pituitary-gonadal axis. There is much
evidence to support this hypothesis for the rat. For instance, i.c.v. CRH
inhibits plasma LH secretion in the rat (Rivier & Vale, 1984), presumably
by inhibiting LHRH release from the mediobasal hypothalamus and the
median eminence. The latter mechanism, which is CRH-receptor-
mediated, has been demonstrated for the male rat in vitro (Gambacciani,
Yen & Rasmussen, 1986). In addition, LHRH release into the hypothal-
amo-pituitary portal system decreases after i.c.v. administration of CRH in
female rats (Petraglia, Sutton, Vale & Plotsky, 1987). There is also recent
immunocytochertucal evidence in the rat for direct synaptic contacts
between CRH- and LHRH-containing neurones in the medial preoptic
area (MacLusky, Naftolin & Leranth, 1988). These lines of evidence
suggest that, at least in the ovariectomized rat, CRH can act centrally to
inhibit gonadotrophin release. However, i.c.v. injection of CRH in the
ovariectomized ewe results in either no effect (Horton, Francis & Clarke,
1988) or a stimulation of LH secretion (Naylor, Porter & Lincoln, 1990) as
described in the following chapter. Therefore, an increase in CRH is
unlikely to account for these results in the sheep. This could, however, be
investigated further by pretreatment with aCRH(9_4i) antagonist or by
've immunization against CRH peripherally or centrally,
ne other attractive possibility is that the centrally injected LHRH is
g as a neurotransmitter with regard to the hypothalamic-ovarian and
ypothalamic-adrenal axes. In other words, this LHRH may be acting
imic the influence of LHRH neurones from higher centres both to
alate the hypothalamo-pituitary-adrenal axis and to inhibit the
iductive axis. It may be therefore that the increase in Cortisol is just a
:idental phenomenon and not causally related to the suppression of
ecretion. However, there is much evidence that increased activity of
ypothalamo-pituitary-adrenal axis in general, e.g. under conditions of
ical and environmental stress, and that increased plasma levels of
>corticoids in particular will adversely affect reproduction. Firstly,
is a clear correlation between plasma Cortisol levels and suppression
madotrophin secretion in patients with Cushing's disease (White,
erson, Mashiter & Joplin, 1981). Secondly, physical stress, such as
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unaccustomed strenuous exercise can result in menstrual disorders
(Bullen, Skrinar, Beitins et al. 1985): female runners, who often have
amenorrhoea, have increased plasma Cortisol levels (Villanueva,
Schlosser, Hopper et al. 1986), as do women with anorexia nervosa (Gold,
Gwirtsman, Avgerinos et al. 1986) and patients with functional
hypothalamic amenorrhoea (Suh, Liu, Berga et al. 1988). Thirdly,
administration of glucocorticoids in large doses, as in the treatment of
asthma or of chronic inflammatory disorders, may interrupt normal
menstrual cyclicity and render patients subfertile (Cunningham, Caperton,
Goldzieher, 1975; Sakakura, Takebe, Nakagawa, 1975).
In the sheep, Cortisol and/or ACTH has been reported to influence LH
secretion in a number of situations. The LHRH- and oestradiol benzoate-
induced release of LH is suppressed in the ewe by intravenous ACTH
(Dobson, Essawy & Alam, 1988). This is in contrast to the effects of i.v.
ACTH infusion in the ovariectomized monkey (Xiao & Ferin, 1988): in
this experimental model the secretion of LH and FSH is unaffected.
Although intravenous infusion of Cortisol has been shown to have no
effect on the oestradiol-induced LH surge in ewes (Moberg, Watson,
Stoebel & Cook, 1981) the animals investigated were intact anoestrous
ewes unlike the ovariectomized animals used in the current study. These
workers have also shown that in the ram, ACTH (but not short-term
Cortisol) suppresses the LH response to i.v. LHRH (Fuquay & Moberg, 1983;
Matteri, Watson & Moberg, 1984). It would appear, however, that the
ts of ACTH may, at least in the rat, be mediated via adrenal factors and
ria ACTH itself, since adrenalectomy abolishes the ability of ACTH to
ce plasma LH levels and i.c.v. ACTH has no effect on LH secretion
in, Evans, Edoimioya et al. 1985). There is evidence, also, that in
ans the ability of ACTH to lower basal LH levels is mediated through
cute rise in plasma Cortisol (Vierhapper, Waldhausl & Nowotny,
). Both ACTH and Cortisol therefore seem able to act on the
ithalamus and/or the anterior pituitary to interfere with
dotrophin release. Whilst we cannot make any definitive statements,
a possibility that in the present study we have observed a biphasic
n of Cortisol; i.e., a rapid hypothalamic effect followed by an effect on
ituitary gland that is observed after a sustained rise in plasma Cortisol,
i conclusion, central administration of LHRH caused a significant and
1 dose-related rise in plasma Cortisol concentration in the
.ectomized ewe. This was associated with a delayed but sustained
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reduction in LH secretion, the degree of reduction in LH correlating highly
with the increase in Cortisol. Intravenous infusion of Cortisol, to reach
plasma levels which were seen after central LHRH, significantly reduced
LH secretion due in part to a reduction in LHRH-responsiveness at the
pituitary gland. However, the pulsatile secretion of LH was not reduced to
that observed following central LHRH administration. These experiments
suggest that LHRH acts as a central neurotransmitter to activate the
hypothalamo-pituitary-adrenal axis and that Cortisol, alone or in
conjunction with another component(s) of the hypothalamo-pituitary-
adrenal axis, may play a role in the LHRH-induced inhibition of
LHRH/LH secretion (LHRH autoregulation) in the sheep.
7. Effects of central administration of cortico-
trophin-releasing hormone on the secretion
of gonadotropins, prolactin and Cortisol
7.1. Introduction
The experiments reported in this chapter develop further the theme of the
interaction between the hypothalamic-adrenal and hypothalamic-ovarian
axes. In the previous chapter, it was demonstrated that LHRH acts as a
neurotransmitter to stimulate the hypothalamo-pituitary-adrenal axis. In
addition, while we could not conclusively show it to be responsible for the
LHRH-induced suppression of LH, there is a profound effect of the
hypothalamo-pituitary-adrenal axis on the reproductive axis.
There is much evidence, especially in the rat, but also in other species
including the human, that stress of various types disrupts the normal
secretion of reproductive hormones and therefore exerts a deleterious
effect on reproductive function (Gray, Smith, Damassa et al. 1978; Du
Ruisseau, Tache, Brazeau & Collu, 1978; Tache, Du Ruisseau, Ducharme &
Collu, 1978; Rasmussen & Malven, 1983; Bullen, Skrinar, Beitins et al.
Gold, Gwirtsman, Avgerinos et al. 1986; Rivier, Rivier & Vale, 1986).
stress increases the plasma concentration of adrenocorticotrophic
one and of glucocorticoids, it is often suggested that activation of the
thalamo-pituitary-adrenal axis is responsible for stress-induced
ility. As discussed in the previous chapter, there is well-documented
nee for a role of each of the components of this axis in the
ession of LHRH and LH secretion. For example, administration of
I and Cortisol delays puberty and inhibits ovulation in rats (Smith,
on, Weick et al. 1971; Baldwin & Sawyer, 1974; MacFarland & Mann,
Baldwin, 1979), interrupts normal menstrual cyclicity in humans
\ingham, Caperton, Goldzieher, 1975; Sakakura, Takebe, Nakagawa,
and interferes with gonadotrophin release through an action on the
halamus and/or the anterior pituitary gland (Moberg 1976; Moberg,
>n, Stoebel & Cook, 1981; Fuquay & Moberg, 1983; Matteri, Watson &
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Moberg, 1984; Dubey & Plant, 1985; Dobson, Essawy & Alam, 1988).
In addition to the actions of ACTH and Cortisol, corticotrophin-
releasing hormone can act at the level of the central nervous system to
inhibit LH release in ovariectomized, adrenalectomized rats (Rivier &
Vale, 1984) and ovariectomized monkeys (Olster & Ferin, 1987; Gindoff &
Ferin, 1987). The inhibitory effect of central administration of CRH on
gonadotrophin release is due to inhibition of LHRH release into the
hypophysial portal circulation (Petraglia, Sutton, Vale & Plotsky, 1987),
and is mediated by endogenous opioid peptides (Gindoff & Ferin, 1987;
Almeida, Nikolarakis & Herz, 1988; Nikolarakis, Almeida & Herz, 1988;
Nikolarakis, Almeida, Sirinathsinghji & Herz, 1988).
Since the central injection of a CRH antagonist such as ocCRH(9-4i)
(Rivier, Rivier & Vale, 1984) can reverse the stress-induced suppression of
LH secretion in the rat (Rivier, Rivier & Vale, 1986), it has been proposed
that endogenous central CRH may mediate the deleterious effects of stress
on LHRH/LH release by an effect distinct from its activation of the
pituitary-adrenal axis. The hypothesis that endogenous CRH may
participate as a neurotransmitter in the brain and be responsible for
mediating responses to stress is strengthened further by the following
observations. Firstly, intracerebroventricular administration of the
hormone elicits prolonged increases in plasma concentrations of
noradrenaline and adrenaline (Brown, Fisher, Rivier et al. 1982; Brown,
Fisher, Webb et al. 1985; Brown, Gray & Fisher, 1986) similar to those
■ved during stress. Secondly, there is evidence that exogenous and
genous CRH may be involved in enhancing stress-induced
viours in the rat (Britton, Koob, Rivier & Vale, 1982; Krahn, Gosnell,
2 & Levine, 1986; Kalin, Sherman & Takahashi, 1988).
he following studies were therefore undertaken in ovariectomized
to investigate further the hypothesis that central CRH acts as a
^transmitter mediating stress responses in the brain. The effect of
al administration of CRH on pulsatile LH and FSH secretion was
tigated. In addition, the influence of CRH on the release of two stress
tones which are under different regulatory control mechanisms,
?ly prolactin and Cortisol, was studied. The potential involvement of
genous opioid peptides in the actions of centrally administered CRH
investigated using the opioid antagonist naloxone.
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7.2. Experimental design
Five Scottish Blackface ewes were housed in individual pens in the
University of Edinburgh Marshall Building, near Edinburgh, under
artificial lighting conditions corresponding to natural daylength from
February-May 1988 and from August-October 1988. Sheep were fed
concentrated pellets once a day and hay and water were available ad
libitum.
At least three to four weeks before experimentation, the animals were
ovariectomized and implanted with a stainless steel cannula directed
towards the third ventricle as described previously.
In the initial group of experiments (February-May), animals received
»
single central injections of ovine CRH (see Section 3.4) at two doses, 0.12
nmol (0.5 (ig) and 1.2 nmol (5 jig), and of 50 pi saline as control. In
addition, each animal received i.v. naloxone (4 x 25 mg) concomitantly
with 1.2 nmol CRH and also control injections of i.v. naloxone alone.
Two further treatments were given in a second group of experiments
(August-October). Firstly, animals were treated with a single, higher, dose
of CRH (5.2 nmol). Secondly, each animal received repeated (three) i.c.v.
injections of 1.2 nmol CRH and also (three) control injections of saline.
On the day before each sampling period, a jugular venous cannula was
inserted into each ewe and kept patent with heparinized saline. Blood
>les (3 ml) were collected at 10-min intervals for 10-12 h from 08.00 h
ie day of each experiment. After an initial 4-h control period a single
injection was made. The order of the various injections was based
cross-over design with each ewe serving as her own control and
ving each treatment. When multiple i.c.v. injections of saline or
were required, they were delivered at 3.5, 4.5, and 5.5 h into the
>ling period. Naloxone (4 x 25 mg) was injected intravenously at 4,
and 8.5 h into the sampling period.
hsma concentrations of LH were measured in samples taken every 10
FSH, prolactin and Cortisol levels were determined in 20-min
iles. For the analysis of the LH data, the sampling period was divided
three equal 3.5-h windows representing time periods before (pre),
tg (post 1) and after (post 2) the central injections. In the case of FSH,
.ctin and Cortisol, the mean areas under the curves were calculated
ig each treatment (3 h after injection).
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7.3. Results
Over the 12-h sampling period, control animals receiving saline showed
the characteristic pulsatile LH secretion pattern of an ovariectomized ewe.
During this period, the LH pulse frequency and mean LH concentration
did not change significantly with time.
Figure 7.1 shows the plasma LH concentrations over the 12-h sampling
period after injection of saline or three concentrations of CRH into the
third ventricle of an individual ewe. Injection of 50 |il saline into the
ventricular system did not alter the pulsatile secretion of LH (Figure 7.1a).
Similarly, injection of the lowest concentration of CRH appeared to be
without effect (Figure 7.1b). However, the administration of either 1.2 or
5.2 nmol CRH resulted in a stimulation of LH release (Figure 7.1c and d).
Figure 7.2 shows the grouped effects of three of these treatments on LH
pulse frequency (Figure 7.2a-c) and mean LH concentration (Figure 7.2d-f)
for all five animals. Central injection of 50 |il saline did not affect either
LH pulse frequency (Figure 7.2a) or mean LH levels (Figure 7.2d).
Following injection of 1.2 nmol CRH, however, there was a significant (p
< 0.01) increase in the mean LH concentration (Figure 7.2f) as a
consequence of a significant (p < 0.01) increase in LH pulse frequency
(Figure 7.2c). This stimulation of LH secretion appears to be dose-related,
as administration of a 10-fold lower dose (0.12 nmol) of CRH caused a
t increase in mean LH levels (Figure 7.2e), although this did not reach
tical significance. LH pulse amplitude following i.c.v. injection of
was not significantly different from the saline controls (Figure
-c), owing to large individual variation. In contrast to the effects on
ecretion, plasma levels of FSH were unaffected by central injection of
(Figure 7.3).
terestingly, in the individual animal's data shown in Figure 7.1 it
ars that the period of stimulation of LH secretion elicited by CRH is
ved by an inhibitory phase. However, such a response was not
nonly observed: in the post 2 time period, the LH pulse frequency and
i LH concentrations returned to levels observed prior to CRH
nistration (Figure 7.2). Furthermore, repeated (three) injections of 1.2
CRH did not result in any suppression of LH secretion (Figure 7.4).
;timulatory effect of central administration of CRH on LH secretion
not altered by naloxone (Figure 7.2.1d-f) even though intravenous
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Figure 7.1. Concentrations of LH in 10-min plasma samples
obtained over a 12-h sampling period in an individual ewe
(No. A124) showing the dose-related stimulation of LH
secretion by centrally-injected CRH. (a) effect of i.e.v.
injection with 50 |il saline, (b) effect of 0.12 nmol CRH i.c.v.
(c) effect of 1.2 nmol CRH i.c.v. (d) effect of 5.2 nmol CRH
i.c.v. Time of injection (t = 4 h) is indicated by the arrow.
Note difference in scales of the y-axes.
o>
0 i 1 1 1 1 1 1 1 1 1 1 1 1
0123456789 10 11 12
Time (h)
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Figure 7.2. Grouped data showing the effects of treatment
with saline (50 jj.1) or 0.12 or 1.2 nmol CRH on (a-c) LH pulse
frequency and (d-f) mean LH levels, before, during and after
i.c.v. treatment. Values expressed as mean ± s.e.m. (n = 5).
Levels of significance are shown. Note increase in mean LH
levels as a result of an increase in pulse frequency, and that
LH levels return to pre-injection levels in the post 2 time
period. The increase in mean LH after 0.12 nmol CRH did
not reach significance due to wide individual variation.
LH PULSE FREQUENCY MEAN LH CONCENTRATION
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LH pulse amplitude Effect of naloxone (4 x 25 mg, i.v.) on
release of LH by CRH (1.2 nmol, i.c.v.)





























































Pre Post 1 Post 2 Pre Post 1 Post 2
Addendum: Figure 7.2.1. (a-c) Effects of i.c.v. CRH on LH pulse amplitude. Note effect
of CRH on pulse amplitude is not significant, due to large individual variation, (d-f)
Effects of naloxone on CRH-induced increase in LH secretion. Note naloxone does not
alter the ability of CRH to stimulate LH secretion. See Figure 7.2 for further details.
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Figure 7.3. Effects of central injection of 50 pi saline or 1.2
nmol CRH on mean 20-min plasma concentrations of FSH.
Time of injection (t = 4 h) shown by arrow. Values are
expressed as the mean ± s.e.m. (n = 5). Central injection of 1.2
nmol CRH had no effect on plasma FSH levels.
° 50 (il saline
Time (h)
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Figure 7.4. Concentrations of LH in 10-min plasma samples
taken for 11 h in an individual ewe (No. R115), showing the
effect of multiple injections of CRH on plasma LH. (a) three
central injections of saline (50 |il) did not affect LH secretion,
(b) triple injections of CRH (1.2 nmol) at t = 3.5, 4.5 and 5.5 h
increased LH secretion. Arrows indicate times of injection.
LH(ng/ml)
LH(ng/ml)
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injection of this opioid antagonist significantly increased mean LH levels,
thus confirming our previous findings (Chapter 5).
The effects on mean plasma prolactin levels of i.e.v. injection of 1.2
nmol CRH and of 50 pi saline are shown in Figure 7.5a. Injection of saline
into the third ventricle did not alter the normal pattern of prolactin
secretion. In contrast, central administration of CRH evoked a marked
stimulation of prolactin release from the pituitary gland which was
evident within 20 min of the time of injection. This reached a maximum
of approximately 3-4 times pre-injection levels after 80 min and had
returned to baseline by 180 min. Figure 7.5b shows the effect of
intravenous administration of naloxone on this stimulatory action of
central CRH. In the presence of the opioid antagonist, CRH no longer
evoked a large rise in plasma prolactin whilst naloxone alone did not alter
basal prolactin Release. The CRH-induced increase in plasma prolactin
secretion seems to be dose-related, as shown in Figure 7.7a. The injection
of a ten-fold lower dose of CRH (0.12 nmol) appeared to increase plasma
prolactin levels compared with the control responses to saline, although
this did not reach statistical significance. The higher dose of CRH
increased prolactin secretion significantly, compared with both saline (p <
0.01) and the lower dose of CRH (p < 0.05). Figure 7.7a also demonstrates
the effect of naloxone on the stimulation of prolactin by CRH. Naloxone
reduced the CRH-induced stimulation, compared with CRH treatment
alone (p < 0.05), whilst intravenous injection of naloxone alone was
without effect.
tracerebroventricular injection of 1.2 nmol CRH also evoked a large
-apid increase in the plasma levels of Cortisol (Figure 7.6a) which
1 for longer than the effect on prolactin. In contrast to the prolactin
nse, the central stimulatory effect of CRH on Cortisol secretion was
ected by the opioid antagonist naloxone (Figure 7.6b). Intravenous
ion of naloxone alone did not alter basal Cortisol release, compared
the response to i.c.v. saline. The dose-related nature of the increase
rtisol secretion is shown in Figure 7.7b: injection of both 0.12 nmol
0.05) and 1.2 nmol CRH (p < 0.01) increased plasma Cortisol levels
:icantly. Concomitant treatment with naloxone did not affect this
.lation (p < 0.05 compared with saline).
lere was no significant difference between either the pre-injection
ol values or the pre-injection prolactin values before each treatment
not shown).
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Figure 7.5f Effects of intracerebroventricular injection of
CRH on mean plasma prolactin levels in samples taken
every 20 min over the 12-h sampling period, showing that
stimulation of prolactin by central CRH is opioid-mediated.
(a) central injection of 1.2 nmol CRH causes a large and rapid
rise in prolactin levels, whereas i.c.v. saline has no effect.
O = saline, • = CRH. (b) concomitant intravenous injection
of naloxone (4 x 25 mg) abolishes the CRH-induced stim¬
ulation of prolactin, whereas i.v. naloxone alone is without
effect. O = naloxone, • = CRH + naloxone. Single arrows
indicate times of central injection (t = 4 h), multiple arrows
show times of i.v. naloxone injection (t = 4, 5.5, 7 and 8 h).
Values are means ± s.e.m. (n = 5 for each treatment).
° 4 x 25 mg naloxone i.v.
• 1.2 nmol CRH + naloxone
Time (h)
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Figure 7.6. Effects of central injection of CRH on mean
plasma Cortisol levels in samples taken every 20 min over
the 12-h sampling period, showing that the stimulation of
Cortisol secretion by central CRH is not mediated by opioids,
(a) central injection of 1.2 nmol CRH causes a large and rapid
rise in Cortisol secretion, which lasts for longer than the rise
in prolactin, whereas i.c.v. saline has no effect. O = saline,
• = CRH. (b) concomitant intravenous injection of naloxone
(4 x 25 mg) does not diminish the increase in Cortisol
secretion caused by central CRH injection. Intravenous
injection of naloxone alone has little effect on basal Cortisol
levels. O = naloxone, • = CRH + naloxone. Single arrows
indicate times of central injection (t = 4 h), multiple arrows
show times of i.v. naloxone injection (t = 4, 5.5, 7 and 8 h).










° 4 x 25 mg naloxone i.v.
• 1.2 nmol CRH + naloxone
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Figure 7.7. Grouped effects of central administration of
CRH on secretion of prolactin and Cortisol and the effects of
opioid antagonism on these responses, (a) shows the dose-
related increase in prolactin secretion after central CRH and
its abolition by naloxone, (b) shows Cortisol secretion is also
increased in a dose-related manner, but naloxone does not
block this effect of CRH. Values are expressed as the mean
area under the curve (± s.e.m.) in the 3 h following
treatment, (n = 5 for each treatment). Plasma concentrations
of prolactin and Cortisol were not significantly different
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7.4. Discussion
Injection of CRH into the third cerebral ventricle of the ovariectomized
ewe stimulated the release of LH and prolactin from the anterior pituitary-
gland, but had no effect on plasma concentrations of FSH. This lack of
effect on FSH is an expected finding in view of the long half-life of FSH in
ovariectomized ewes (Fry, Cahill, Cummins et al. 1987) and the fact that
FSH secretion is normally unaffected by short-term alterations in the
supply of LFIRH to the pituitary gland (Fraser & McNeilly, 1983). The
stimulatory effect of i.e.v. administration of CRH was dose-related in that
the lower dose occasionally stimulated LH and prolactin release whereas
the higher concentration consistently evoked the release of both
hormones, that of prolactin by an opioid-dependent mechanism. The
increase in mean LH concentration was due to a significant increase in LH
pulse frequency, suggesting a hypothalamic site of action for CRH.
Although pulse amplitude was often increased, there was too much
individual variation for this to be statistically significant. Central
administration of CRH also resulted in a significant increase in the plasma
concentration of Cortisol. Despite a postulated involvement of opioid
peptides in regulating the hypothalamo-pituitary-adrenal axis
(Monteleone, Maj, Iovino & Steardo, 1988), no evidence was obtained in
these experiments to suggest that endogenous opioids are involved in
iting the axis under either basal or stimulated conditions. In
ist, naloxone stimulated LH release, thus confirming the findings
:ed in Chapter 5 that LFIRH/LH secretion is under tonic inhibitory
1 tone in long-term ovariectomized ewes.
e effect of central CRH on LHRH/LH secretion demonstrated by
experiments in the sheep is the opposite to that described for the rat
r & Vale, 1984; Petraglia et al. 1987; Almeida et al. 1988) and monkey
r & Ferin, 1987; Gindoff & Ferin, 1987). In addition to the evidence
o of an inhibitory effect of CRH on LH secretion, it has been well
nented that CRH suppresses the release of LHRH from rat
halamic slices in vitro (Gambacciani, Yen & Rasmussen, 1986;
arakis, Almeida & Herz, 1986a). Moreover, there is evidence that
hibitory effect of CRH in the rat is mediated through an activation of
;enous opioid pathways within the hypothalamus (Nikolarakis,
da & Herz, 1986b; Almeida et al. 1988; Nikolarakis et al. 1988).
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It could be argued that the absence of an inhibitory effect of CRH in the
sheep may be because an insufficient concentration of the peptide was
injected into the brain. Although this possibility cannot be excluded
completely, it is unlikely for the following reasons. Firstly, equimolar to
higher than equimolar concentrations of CRH were used compared with
those reported to be effective in the rat, and multiple injections of the
peptide also did not suppress LH release. Secondly, the higher dose of
CRH (1.2 nmol) was sufficient to stimulate prolactin and Cortisol release.
Alternatively, the presence of gonadal steroids such as oestrogen and
progesterone may be required for central CRH to be able to inhibit LH
secretion. However, this is unlikely as previous investigators have
demonstrated that CRH inhibits LH release in ovariectomized rats and
monkeys (Rivier & Vale, 1984; Gindoff & Ferin, 1987), as well as in intact
female rats (Petraglia et al. 1987). An explanation of this discrepancy,
therefore, may be that a species difference exists between sheep on the one
hand and rats and monkeys on the other. In support of this view, the
absence of an inhibitory effect of CRH on gonadotrophin secretion has
been reported recently in the sheep following administration by two
different routes. Using equimolar amounts of CRH to those used in the
experiments described in this chapter, neither i.v. (Parrott, Robinson &
Thornton, 1988) nor i.e.v. (Horton, Francis & Clarke, 1988) injection of
CRH altered any characteristic of LH secretion. The reasons for the
difference between this study and that of Horton et al. (1988) are unclear at
nt but seasonal factors governing the reproductive cycle of sheep may
mce the response to centrally injected neuropeptides and
transmitters.
different explanation for the stimulatory effect of central CRH
ibed here is that the peptide preparation was contaminated and
ined some factor with LH-releasing properties. An obvious
date for this would be LHRH or its analogues. However, since
al administration of LHRH inhibits LH secretion in sheep (see
ter 4) this possibility is unlikely. In addition, the bioactivity (ACTH-
ing property) of the batch of CRH used in this study was verified by
igel Brooks using in-vivo and in-vitro models.
jection of CRH into the ventricular system of the sheep also evoked a
release of prolactin into the peripheral circulation. This stimulatory
t was dose-related and could be prevented by the opioid antagonist
one, suggesting that endogenous opioid peptides mediate the effect
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of central CRH on prolactin secretion. An opioid-mediated stimulatory
effect of intravenous CRH on prolactin secretion has recently been
described in the monkey (Van Vugt, Webb & Reid, 1989). In addition,
there is considerable evidence that opioid peptides themselves are
involved in the stimulatory control of prolactin secretion (Dupont, Cusan,
Labrie et al. 1977; Rivier, Vale, Ling et al. 1977; Gold, Redmond &
Donabedian, 1979). Indeed, there is evidence that central opioid peptides
are responsible for the increase in plasma prolactin observed in response
to a number of stressful stimuli (Ferland, Kledzik, Cusan & Labrie, 1978;
Van Vugt, Bruni & Meites, 1978). Since CRH stimulates prolactin release
via opioid peptides, and as endogenous opioids have been implicated in
the mediation of stress-induced prolactin secretion, it seems likely that the
increase in plasma prolactin described here is a consequence of CRH acting
as a neurotransmitter in a 'stress-responsive' pathway. In other words,
CRH may serve as a central neurotransmitter (i.e., distinct from its ACTH-
stimulating effect on the pituitary gland) involved in the integration of
neuroendocrine responses to stressful stimuli. Although the experiments
described in this chapter provide no direct evidence to support such a
hypothesis, there is considerable evidence from other sources that CRH
may mediate responses to stress by actions at the level of the CNS (Brown
et al. 1982, 1985, 1986; Britton et al. 1982; Krahn et al. 1986; Kalin et al. 1988).
The absence of a tonic opioidergic control of prolactin secretion is
consistent with previous findings in non-lactating ewes (Horton,
^ nins & Clarke, 1987).
though it seems probable that CRH-induced prolactin release is
ited through a central action, this does not appear to be the case for
ffect of central CRH on Cortisol secretion. The most likely
nation for the stimulatory effect of i.c.v. administration of CRH on
nl secretion is that when injected into the ventricular system, leakage
H to the anterior pituitary gland occurred via the portal vessels and
oy evoked the release of ACTH and Cortisol. An alternative
:>ility is that injection of CRH into the third ventricle augmented
;enous CRH release through the ultrashort-loop positive feedback
n for CRH described by Ono, Bedran de Castro & McCann (1985).
ver, such a hypothesis would require further testing using the direct
irement of endogenous CRH in the portal plasma of conscious
. In contrast to their role in the action of central CRH on prolactin
ion, endogenous opioids sensitive to blockade by naloxone are not
Chapter 7 Central CRH and pituitary hormone release 114
involved in the stimulatory effect of i.e.v. injection of CRH on Cortisol
secretion. Furthermore, in the ovariectomized sheep, like the rat
(Buckingham & Cooper, 1986), opioid peptides do not exert a tonic
influence (whether inhibitory or stimulatory) on the basal activity of the
CRH-pituitary-adrenal axis as they do in humans (Monteleone et al. 1988).
If CRH does act as a neurotransmitter in a central 'stress-responsive'
pathway then it may be possible to provide a further explanation as to why
i.c.v. administration of CRH stimulated LH release in the sheep. Plasma
concentrations of LH appear to be affected differently by acute as opposed
to chronic stress. While chronic stress inhibits LH in intact and
adrenalectomized rats (Gray et al. 1978; Tache et al. 1978), acute stress has
been reported to stimulate LH release in both rats (Krulich, Hefco, Illner &
Read, 1974; Euker, Meites & Riegle, 1975; Armario, Restrepo, Hidalgo &
Lopez-Calderon,'1987; Briski & Sylvester, 1988) and monkeys (Hayashi &
Moberg, 1987), suggesting, perhaps, that the physiological response to stress
is dependent upon the novelty, duration and intensity of the stimulus. In
sheep, it has been reported that ovulation may be induced in anoestrus by
the stress of shipping, a response that has been attributed to an increased
output of gonadotrophins (Braden & Moule, 1964). In addition, the
increase in LH secretion in the ovariectomized ewe caused by the
presence of a ram is blocked by the CRH antagonist aCRH(9_4i) (Dr Alasdair
M. Naylor, unpublished observations). Furthermore, there is evidence in
a recent report (Lopez-Calderon, Gonzalez-Quijano, Tresguerres &
*--•
avarreta, 1990) that the increase in plasma LH in response to acute
is due to an increase in hypothalamic LHRH secretion. It seems
, therefore, that the central injection of CRH activated a 'stress-
nsive' neural pathway(s) which manifested itself as an increase in
cretion of both LH and prolactin.
conclusion, the experiments described in this chapter demonstrate
n the sheep, central administration of CRH causes a dose-related
lation of LH, prolactin and Cortisol release, that of prolactin by a
ss involving endogenous opioid peptides. These findings provide
iv evidence that CRH acts as a central transmitter in a neural
ray(s) integrating endocrine responses to stress.
8. Neuroendocrine actions of centrally
administered neuropeptide Y
8.1. Introduction
In the preceding chapters, interactions between several neuroendocrine
control mechanisms were described and the hypothesis was developed
that the hypothalamic releasing hormones could also act as central
neurotransmitters. In addition to the releasing hormones, other
hormonal peptides are known to modulate the primary neuroendocrine
mechanisms regulating the secretion of hormones from the anterior
pituitary gland.
One such factor is neuropeptide Y. This recently discovered peptide
amide has been measured in very high concentrations in the
hypothalamus (Allen, Adrian, Allen et al. 1983; Chronwall, DiMaggio,
Massari et al. 1985). Neurones immunoreactive for NPY are abundant in
the hypophysiotrophic areas of the brain (Everitt, Hokfelt, Terenius et al.
1984), NPY nerve terminals having been observed in close proximity to
LHRH and CRH cell bodies in the OVLT and PVN, respectively (Bai,
no, Shiotani et al. 1985; Wahlestedt, Skagerberg, Ekman et al. 1987;
Li & Pelletier, 1988).
'Y has been shown in vivo and in vitro to modulate the activity of
productive axis at the hypothalamic and pituitary levels. Depending
3 ovarian steroid environment, NPY can either stimulate or inhibit
icretion of LHRH and therefore of LH (Kalra & Crowley, 1984;
ley, Tessel, O'Donohue et al. 1985; Kerkerian, Guy, Lefevre &
ier, 1985; McDonald, Lumpkin, Samson & McCann, 1985; Crowley &
1987; Khorram, Pau & Spies, 1987; Khorram, Pau & Spies, 1988;
nald, Lumpkin & DePaolo, 1989).
>Y appears also to have a stimulatory role on the hypothalamo-
ary-adrenal axis, acting at the level of the hypothalamus,
iments in vivo and in vitro have suggested that NPY can stimulate
a ACTH levels, and that this is mediated by CRH in the PVN (Haas
>rge, 1987; Tsaragarakis, Rees, Besser & Grossman, 1989; Wahlestedt,
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Skagerberg, Ekman et al. 1987; Harfstrand, Eneroth, Agnati & Fuxe, 1987;
Inoue, Inui, Okita et al. 1989).
The studies in this chapter were therefore designed to examine the
central actions of NPY on the hypothalamo-pituitary-ovarian and
hypothalamo-pituitary-adrenal axes in the ewe and to investigate further
the potential involvement of ovarian steroids in the modulation of these
axes by NPY. Specifically, the effect of intracerebroventricular admin¬
istration of NPY on LH and Cortisol secretion was investigated in ovari-
ectomized ewes, with or without oestradiol-containing implants, and in
intact ewes in the follicular and luteal phases of the oestrous cycle.
8.2 Experimental design
»
For the experiments described in this chapter, three different groups of
animals were used; i.e., ovariectomized (OVX) ewes, ovariectomized ewes
implanted with oestradiol (OVX/E2), and intact cycling ewes.
8.2.1. Ovariectomized ewes
During August-September 1988, six Scottish Blackface ewes were
ovariectomized and implanted with a stainless steel cannula directed
towards the third ventricle as described previously.
Two to three months later, the animals were housed for experiment in
: 31 idual pens in the University of Edinburgh Marshall Building, near
)urgh, from October-November 1988, under artificial lighting
tions corresponding to natural daylength. They were fed concen-
[ pellets once a day and hay and water were available ad libitum.
Ovariectomized ewes implanted with oestradiol
1 Scottish Blackface ewes were ovariectomized in October 1988 and
nted one month later with a stainless steel cannula directed towards
Lird cerebral ventricle.
: least one week prior to experimentation, the animals were
.nted subcutaneously with oestradiol in silastic tubing according to
lethod of Karsch, Dierschke, Weick et al. (1973), modified only to the
t of using smaller tubing. Briefly, 1.5-cm lengths of silastic medical-
s tubing (outside diameter 3.5 mm, inside diameter 2 mm, Dow-
ng Medical, Midland, MI, USA), were packed with crystalline 17P*
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oestradiol (Sigma, Poole, Dorset) and sealed with silastic elastomer (Dow-
Corning). This was done away from the laboratory and sheep-facility
premises to prevent possible contamination of other studies. In order to
avoid an initial transient burst of oestradiol release from the capsule after
placement, the implants were soaked overnight in water and then stored
in 70% ethanol for approximately 30 min before insertion. Two capsules
were implanted via a 1-2 cm incision, made under lignocaine local
anaesthesia, in the shaved axillary skin of each ewe. They were inserted
subcutaneously and pushed 5-6 cm away from the incision site. The
wound was then sutured. Since assays sufficiently sensitive to estimate
peripheral levels of oestradiol in ewes were not available, it was not
possible to measure the plasma concentrations achieved. However, these
or similar implants have been shown previously to produce physiological
levels of oestradiol in the circulation (Dr Jon D. Curlewis, personal comm¬
unication; see also Goodman, Bittman, Foster & Karsch, 1981; Moenter,
Caraty & Karsch, 1990).
For the experiment, the animals were housed and fed as described
above (Section 8.2.1) from December 1988-January 1989.
8.2.3. Blood sampling and data analysis in OVX and OVX/E2 ewes
On the day before each sampling period, a jugular venous cannula was
inserted into each ewe and kept patent with heparinized saline. Blood
samples (3 ml) were collected at 10-min intervals for 10-11 h from 08.00 h
e day of each experiment. After an initial 4-h control period, the
lis received a single central injection of human NPY (see Section 3.4)
2 of two doses, 0.15 nmol (0.65 (ig) or 1.5 nmol (6.5 |ig), or of 50 pi
!. Each ewe received each treatment and thus served as her own
ol.
isma concentrations of LH were measured in samples taken every 10
nd Cortisol levels in half-hourly samples. For the analysis of the LH
the sampling period was divided into three 3-h windows
senting time periods before (pre), during (post 1) and after (post 2) the
il injections. Mean Cortisol concentrations in the 3 h after injection
compared with those in the preceding 3 h.
Intact ewes
"inn x Dorset ewes (37-46.5 kg) were implanted with a stainless steel
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guide cannula directed towards the third ventricle in July 1989. Four
months later, during the breeding season (November 1989), the animals'
oestrous cycles were synchronized prior to the start of experiments in
December.
The initial cycle synchrony was achieved by withdrawal of progestagen-
impregnated intravaginal sponges (Veramix, 600 mg medroxyprogest¬
erone acetate, Upjohn Animal Health, Crawley, Sussex) 12 days after their
insertion. All ewes displayed behavioural oestrus within 48 h as detected
by a vasectomized ram wearing a coloured wax marker crayon strapped to
his chest (oestrus = day 0).
On day 6 of the cycle, i.e. during the luteal phase, blood samples (1.5 ml)
were taken every 10 min from each animal for 10 h from 09.00 h to 19.00 h,
via a jugular venous cannula inserted the previous day. After a 3-h
control period, all animals received an injection of 50 pi saline into the
third ventricle. At the end of the 10-h sampling period, the cannulae were
removed and the animals allowed to recover. The ewes were re-
cannulated on the afternoon of day 9 of the same oestrous cycle.
Luteolysis was then induced at 23.00 h with an intramuscular injection of
100 |ig cloprostenol, a potent analogue of prostaglandin F2a (0.4 ml
Estrumate, Coopers Animal Health Care, Crewe, Cheshire). The next day,
the sheep were sampled every 10 min for 10 h from 09.00 h, i.e. starting at
10 h after prostaglandin administration, during the follicular phase of the
second cycle. Blood samples were then taken hourly for a further 60 h,
17.00 h on the fourth day of sampling. After the first 3 h of blood
ing, each animal again received an injection of 50 pi saline,
ree days later, the animals were cannulated again for a 10-h period of
sampling every 10 min on the following day (day 6). Sampling
started at 09.00 h and after a 3-h control period, the animals received
riol NPY, injected into the third ventricle. As before, at the end of
)-h sampling period, the cannulae were removed and the animals
id to recover. The ewes were then re-cannulated on the afternoon of
luteolysis was induced at 23.00 h with prostaglandin F2« analogue as
and, the next day, the sheep were sampled every 10 min for 10 h
39.00 h. Blood samples were taken hourly for a further 60 h, until
h on the fourth day of sampling. After the first 3 h of blood
ing, each animal received an injection of 1.5 nmol NPY.
;ure 8.1 shows the progesterone levels measured in samples taken
y the experiments on the intact cycling ewes to illustrate the design
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Figure 8.1. Progesterone concentrations in intact cycling
ewes, illustrating the timing of i.c.v. saline/NPY injections
(closed arrows) relative to the oestrous cycle(s). • = mean
plasma levels of progesterone in Finn x Dorset ewes during
the experiment ± s.e.m. (n = 5). Shaded line is diagrammatic
representation of progesterone concentration throughout the
cycle (after Wallace, Martin & McNeilly, 1988). Injections of
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in relation to stage of the cycle(s). Details of the progesterone assay are
given below.
Plasma concentrations of LH were measured in samples taken every 10
min for the first 10 h of sampling, and then in samples taken every hour
for the remainder of the sampling period. Changes in LH secretion were
analysed as for the OVX and OVX/E2 ewes (Section 8.2.3). The onset of the
LH surge was defined as the time after cloprostenol when LH levels were
first raised above 10.0 ng NIH-LH-S23 equiv/ml as part of a sustained rise
in LH concentration. Cortisol was measured in half-hourly samples for
the first 10 h. As there was large inter-animal variation in the pre-
injection levels of Cortisol, baseline secretion was calculated as the mean of
the concentrations measured in the 3 h preceding central injection. The
secretion of Cortisol in the remaining 6 h was then expressed as a
I
percentage of this. For analysis, the datawere condensed by calculating the
mean Cortisol levels in each hour after i.c.v. injection.
8.2.5. Progesterone assay
Plasma progesterone was measured by non-extraction radioimmunoassay
as follows. Briefly, samples were assayed in duplicate in a volume of 50 jllI.
Pooled plasma (50 pi) from ovariectomized sheep was added to 100 pi of
each standard (5.0-1 000 pg/100 pi, Sigma) and 50 pi sample was added to
100 pi buffer (phosphate citrate buffer containing 0.1% gelatin; pH 6.0).
The anti-progesterone antibody (S361) used in the assay was raised in a
1 by Dr R.J. Scaramuzzi (Prospect, NSW, Australia) against progest-
-lla-hemisuccinate conjugated to BSA. It was added at a dilution of
)00 in a volume of 100 pi. Radiolabeled progesterone was prepared
1 Swanston from a progesterone-lla-glucuronide-tyramine conjugate
the chloramine-T technique. 100 pi 125I-progesterone (15 000 cpm)
dded to each tube and the assay incubated overnight at 4 °C for 24 h.
r was diluted in phosphate citrate buffer without gelatin, but with
8-anilino-l-naphthalene-sulphonic acid/ml buffer. 1 ml 25% poly-
?ne glycol (PEG) was added and tubes were then centrifuged at 3 000
'2 110 g) for 30 min at 4 °C. The centrifuge buckets were then placed
3 and the supernatant aspirated, leaving a white precipitate which
hen counted as previously. All samples were included in the same
and intra-assay variation was less than 8%.
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8.3 Results
We were unable to demonstrate any effect on LH secretion of the
administration of exogenous NPY into the third cerebral ventricle, in any
of the three groups of animals. Mean LH levels, LH pulse amplitude and
LH pulse frequency were unchanged.
Figure 8.2a-c shows the lack of effect on LH secretion of centrally
injected saline and of two doses of NPY (0.15 and 1.5 nmol) in
representative ovariectomized ewes. Similarly, injection of NPY at these
doses was without effect in ovariectomized ewes implanted with
oestradiol, as shown in Figure 8.2d-f. The lack of effect of NPY treatment
on mean LH levels before, during and after injection in both OVX ewes
and OVX/E2 ewes is shown in Figure 8.3 for each group of animals.
A cursory glance at Figure 8.3b suggests that the lower dose of NPY, and
also the control treatment with saline, may possibly have had an effect on
the secretion of LH in these OVX/E2 animals. Taking the group as a
whole, this was not the case. However, in several OVX/E2 animals treated
with either saline or the lower dose (0.15 nmol) of NPY we observed a
gradual suppression of LH secretion starting at the time of injection. In
these animals, there was also a slow increase in plasma Cortisol
concentrations. This was surprising, as in our other studies we found
littio effect of i.c.v. saline on Cortisol secretion and no effect on LH (see
ters 6 and 7). A possible explanation for these observations is the
ring. These animals had not been used for experiment for some
as and it may be that, on introducing the needle to administer the
[tents, we may have caused tissue damage around the end of the
cannula. If this were the case, it could have resulted in the
lation of prostaglandin (Rudy, Williams & Yaksh, 1977) and/or
eukin-1 production (Rivier, Chizzonite & Vale, 1989), with
quent activation of the hypothalamo-pituitary-adrenal (HPA) axis,
could be reflected in the increased secretion of Cortisol and,
mably, of ACTH. Based on the results of Chapter 6, this may have
ed in a suppression of LH secretion to account for our observations,
te this, the animals have been included in the analysis, as we have
rect proof that the i.c.v. injections were in fact compromised in such
*ure 8.4 illustrates that i.c.v. injection of 1.5 nmol NPY also had no
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Figure 8.2. Concentrations of LH in 10-min blood samples
over an 11-h sampling period in (a-c) ovariectomized ewes
and (d-f) ovariectomized ewes implanted with oestradiol,
showing lack of effect of centrally-administered NPY at two
doses on LH secretion. LH profiles are from several
representative ewes treated i.e.v. with (a, d) 50 (il saline, (b, e)
0.15 nmol and (c, f) 1.5 nmol NPY. Time of injection is
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Figure 8.3. Grouped data showing the effects of i.e.v.
treatment with 50 (il saline or 0.15 or 1.5 nmol NPY on mean
LH levels in 3-h time periods before (Pre), during (Post 1) and
after (Post 2) central injection in (a) ovariectomized ewes
(n = 6) and (b) ovariectomized ewes implanted with
oestradiol (n = 7). Values expressed as mean + s.e.m. There
was no effect of NPY at either dose on LH secretion. LH
concentrations in terms of NIH-LH-S23.
(a) Ovariectomized ewes
15 i
□ 50 ^1 saline (n=6)
El 0.15 nmol NPY (n=6)
0 1.5 nmol NPY (n=6)
□ 50 jil saline (n=7)
□ 0.15 nmol NPY (n=7)
□ 1.5 nmol NPY (n=7)
(b) Oestradiol-implanted OVX ewes
15 i
Pre Post 1 Post 2
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Figure 8.4. Injection of 1.5 nmol NPY into the third cerebral
ventricle has no effect on LH secretion in the intact ewe,
whether given in (a) the follicular phase, or (b) the luteal
phase. Concentrations of LH are shown in 10-min samples
over a 10-h sampling period for two ewes. Control and
treated data from the same animal. Time of injection (t = 3 h)
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effect on LH secretion in the intact ewe, whether injected in the follicular
(Figure 8.4a) or the luteal (Figure 8.4b) phase of the oestrous cycle. There
was no effect of NPY on mean LH levels before, during or after NPY
injection in either phase of the cycle (Figure 8.5). In addition, NPY
treatment in the follicular phase had no effect on the timing (time to peak;
NPY, 51.8 ± 2.22 h vs. saline, 53.8 ± 1.78 h; n = 5 in each group) or
characteristics (peak height; NPY, 104.4 ± 18.58 ng/ml vs. saline, 141.7 ±
20.77 ng/ml; n = 5 per group) of the pre-ovulatory LH surge.
The effects of central injection of NPY on plasma Cortisol concen¬
trations in ewes of the various groups are shown in Figures 8.6-8.9.
Central administration of 1.5 nmol NPY resulted in increased secretion of
Cortisol in both OVX/E2 ewes (Figure 8.6f) and, though less consistently,
OVX ewes (Figure 8.6c). Injection of 0.15 nmol NPY produced variable
responses in the' two groups. There was little or no effect on Cortisol
secretion in most OVX ewes (Figure 8.6b), though several animals
responded with a large stimulation of Cortisol secretion. The majority of
OVX/E2 ewes responded to the lower dose with an increased secretion of
Cortisol (Figure 8.6e).
The effects of central administration of saline or NPY on mean Cortisol
levels in the 3 h after injection in OVX and OVX/E2 ewes are shown in
Figures 8.7a and 8.7b for each dose. Central injection of 1.5 nmol NPY
appeared to result in a modest increase in Cortisol secretion in OVX ewes
(Figure 8.7a), as did the injection of 0.15 nmol NPY. However, the
ise to tke iower dose was equivocal as indicated by the large standard
shown in the figure. There was no effect of NPY in the majority of
mimals, but several responded with a large increase in activity of the
al axis. In OVX/E2 ewes the responses to NPY were more consistent
e 8.7b). Although the effect of the lower dose was very variable,
animals responded with a large increase in Cortisol secretion. The
ase to the 1.5 nmol dose of NPY in OVX/E2 ewes was much more
tent and indeed reached statistical significance (p < 0.05). Figure 8.7c
ates the change in mean Cortisol secretion effected by 1.5 nmol NPY
s group of animals during the 11-h sampling period. The mean
a levels of Cortisol in half-hourly samples are shown,
e effects of saline and central NPY injection on Cortisol secretion in
dual intact ewes in the follicular and luteal phases of the cycle are
1 in Figures 8.8a-c and 8.8d-f respectively. NPY administration
g the follicular phase stimulated the secretion of Cortisol
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Figure 8.5. Grouped effects of NPY treatment on mean LH
levels before, during and after injection in (a) the follicular
(n = 5) and (b) the luteal phase (n = 5) of the oestrous cycle.
Central injection of 50 pi saline or of 1.5 nmol NPY had no
effect on mean LH concentrations. Bars represent the mean
concentrations of LH (± s.e.m.) in the 3-h time periods before
(Pre), during (Post 1) and after (Post 2) i.c.v. injection. LH
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Figure 8.6. Plasma levels of Cortisol in half-hourly samples
taken over the 11-h period, showing the effects of i.e.v.
injection of saline or NPY (0.15 or 1.5 nmol) on Cortisol
secretion in (a-c) representative ovariectomized ewes (n = 6)
and (d-f) ovariectomized ewes implanted with oestradiol.
Third ventricular injection of 1.5 nmol NPY (c, f) resulted in
increased secretion of Cortisol in both groups, (e) injection of
0.15 nmol NPY increased Cortisol secretion in the majority of
OVX/E2 ewes, but (b) had little effect in most OVX ewes.
Time of injection (t = 3 h) shown by arrows.
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Figure 8.7. Effects of the central injection of NPY on mean
plasma concentrations of Cortisol in (a) ovariectomized ewes
(n = 6) and (b, c) ovariectomized ewes implanted with oestra-
diol (n = 7). (a, b) effects of i.e.v. saline and two doses of NPY
(0.15 and 1.5 nmol) on mean Cortisol levels in the 3 h after
central injection, compared with the 3 h before. Data shown
are mean ± s.e.m. NPY stimulated Cortisol secretion in both
OVX and OVX/E2 ewes, though this only reached significance
at the higher dose in the OVX/E2 group (p < 0.05). (c) effect of
i.c.v. injection of 1.5 nmol NPY on mean half-hourly levels
of Cortisol in OVX/E2 ewes (n = 7). Time of injection (t = 4 h)
as shown by arrow.
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Figure 8.8 Effects of i.e.v. injection of 50 (il saline or 1.5
nmol NPY on plasma levels of Cortisol in half-hourly blood
samples over a 10-h period in individual ewes in (a-c) the
follicular phase and (d-f) the luteal phase of the oestrous
cycle. Note different scales of the y-axes. Injection of
1.5 nmol NPY in the follicular phase resulted in a variable
increase in Cortisol secretion. However, injection of this dose
in the luteal phase stimulated Cortisol secretion consistently
in all animals, (b, c) Cortisol profiles of two animals
responsive to NPY in the follicular phase, (e, f) represent¬
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considerably in some animals though only modestly in others. The effects
of 1.5 nmol NPY injected i.e.v. on plasma concentrations of Cortisol in two
of the animals that showed responses during the follicular phase are
shown Figures 8.8b and 8.8c. The response shown in Figure 8.8c was
unusually large, but short-lived. In contrast, NPY treatment at this dose in
the luteal phase stimulated Cortisol secretion consistently, as shown by the
representative responses in Figures 8.8e and 8.8f. Interestingly, two out of
five animals' responses were as in Figure 8.8e, whereas the other three
were as shown in Figure 8.8f.
The effects of i.e.v. NPY on mean Cortisol levels during the follicular
and luteal phases in the group of animals are shown in Figures 8.9a and
8.9b respectively. As the baseline levels of Cortisol were very variable
between animals, the results after injection were first expressed in terms of
the percentage of each animal's baseline in the 3 h prior to injection. The
means of these normalized results are presented in the figure. Central
injection of 1.5 nmol NPY stimulated significantly the secretion of Cortisol
relative to baseline in both the follicular (Figure 8.9.a) and the luteal
(Figure 8.9b) phases of the oestrous cycle, the response to NPY being
particularly robust in the luteal phase.
8.4 Discussion
Administration of neuropeptide Y into the third ventricle of the ewe had
?ct on any aspect of LH secretion at the doses tested, whether in the
ctomized ewe, the ovariectomized ewe implanted with oestradiol,
he intact ewe in the follicular or the luteal phase,
contrast, NPY administration stimulated the HPA axis in the intact
)VX/E2 animal, though only inconsistently in the OVX ewe. The
ation of Cortisol secretion was modest, though significant, in the
E2 ewe and in the follicular phase, but profound in the luteal phase
oestrous cycle.
; lack of effect of NPY on LH secretion in the studies reported in this
r is in marked contrast to data obtained in other species, where
i administration of NPY showed clear stimulatory and inhibitory
(Kalra & Crowley, 1984; Kerkerian, Guy, Lefevre & Pelletier, 1985;
laid, Lumpkin, Samson & McCann, 1985; Khorram, Pau & Spies,
There are several possible explanations for this, most of which can
rounted. It is unlikely that the doses of NPY used were too low for
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Figure 8.9. Grouped mean Cortisol concentrations in the 6 h
after i.e.v. injection of 1.5 nmol NPY in (a) the follicular
phase (n = 5) and (b) the luteal phase (n = 5), expressed
relative to the baseline secretion of Cortisol in the 3 h
preceding injection. Note different scales of y-axes. Central
injection of NPY stimulated Cortisol secretion relative to
baseline in both the follicular and luteal phases. However,
the stimulatory effect was much greater in the luteal phase.
Data shownaremean ± s.e.m. * p < 0.05, ** p < 0.01, compared
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several reasons. Firstly, the doses employed resulted not only in a robust
stimulation of the adrenal axis in the OVX/E2 ewe and in the luteal phase,
but also caused a noticeable, but unquantifiable, increase in feeding
behaviour. This effect on appetite was not such a remarkable phen¬
omenon as that reported for the rat, however, where NPY injected into
the third ventricle (Clark, Kalra, Crowley & Kalra, 1984) or the PVN
(Stanley & Leibowitz, 1984; 1985) evoked a potent feeding response.
Secondly, the central administration of NPY to sheep at doses 10- to 100-
fold greater than those used in this study have been shown by Clarke's
group to be without effect on LH secretion (Dr Iain J. Clarke, personal
communication). It is also unlikely that the lack of effect on LH secretion
is due to an insufficient quantity of the peptide reaching the active sites
relevant to an effect on the reproductive axis. The hypophysiotrophic
areas of the sheep hypothalamus are located immediately adjacent to the
third ventricle, and there is direct access to some of these, such as the
OVLT (McKinley, Denton, Leventer et al. 1983). It remains a possibility,
however, that centrally administered NPY acts on LHRH secretion in
opposite directions via different pathways, resulting in no net observable
effect when measured in terms of LH secretion.
Another plausible explanation for the inability of NPY to affect the
LHRH/LH axis is that the structure of the exogenous, human, NPY used
in the study compromised its physiological capacity to influence LHRH
secretion. At the time the experiments were performed, the structure of
NPY was not known. However, it has since been characterized and
to differ from human NPY by only two amino acids, at positions 10
7, and from porcine NPY by only one amino acid, at position 10
d, Agerberth, Mutt & Jornvall, 1989). These substitutions are
rvative (aspartate for glutamate at position 10, and leucine for
onine at position 17) and it seems highly unlikely that these minor
es are capable of altering the tertiary structure of the molecule in
i way as to alter dramatically its biological activity. In any case, the
lat central administration of human NPY has such a profound effect
i adrenal axis illustrates that it does possess biological activity with
I to the sheep.
e most likely explanation for the lack of effect of NPY on LHRH and
cretion, therefore, is that a true species difference exists between the
d the rabbit on one hand, and the sheep, and also the cow, on the
In addition to our results in vivo, and those of Clarke's group,
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there is evidence from experiments in vitro that NPY is without effect on
pituitary LH secretion in these species. In contrast to data obtained
primarily in the rat, NPY has no modulatory influence on either basal or
LHRH-stimulated LH release from cultured ovine pituitary cells (Brooks,
Graham & Naylor, 1990) and nor does it modulate the release of LH from
bovine pituitary cells in culture (Chao, Scribner, Dixon & Malven, 1987).
Although the results of the experiments reported in this chapter show
that exogenous NPY does not affect the reproductive axis of the sheep at
the level of the hypothalamus, and those of Brooks et al. (1990) show no
effect at the level of the pituitary, it is clear that exogenous NPY acts to
stimulate the activity of the HPA axis in this species. We observed a clear
stimulatory effect of i.e.v. NPY on this axis, assessed in terms of the
secretion of Cortisol, that was particularly effective in the luteal phase of
the intact ewe arid in the OVX/E2 animal, but also to a lesser extent in the
follicular phase. It seems likely, therefore, that the ability of NPY to affect
this axis in the sheep is dependent upon the ovarian steroid environment,
and in particular upon the presence of physiological levels of
progesterone, for an optimal action. These results confirm and extend
previous studies in the rat (Harfstrand et al. 1987) and dog (Inoue et al.
1989) that NPY has corticotrophin-releasing properties.
It seems most likely that the action of NPY in this regard is to stimulate
the secretion of CRH within the hypothalamus (Haas & George, 1987;
Tsaragarakis et al. 1989). The precise nature of the effect of NPY on the
neurone is not known, but the two types of Cortisol secretion
yed after NPY administration in the luteal phase in the current
ment (Figure 8.8e-f) suggest two hypothetical possibilities. Firstly, it
be that NPY acts to cause the CRH neurone to depolarize completely
elease a large proportion of the contents of the nerve terminal
e 8.8e?). Secondly, NPY may act to modulate the electrical activity of
RH neurone in such a way, perhaps by depolarizing the membrane
tial only slightly, or by altering the threshold for release, that it
res 'hyperexcitable' and fires more rapidly and with greater
tude than normal (Figure 8.8f?). These possibilities can only remain
lative until the neurotransmitter actions of NPY within the PVN are
igated electrophysiologically. However, it is of interest in this regard
I.e.v. NPY potentiates the effectiveness of central CRH as a
agogue for ACTH, acting at sub-threshold doses in synergism with
(Inoue et al. 1989). Whether NPY acts directly, or in synergy with
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CRH, to release ACTH from the pituitary corticotrophs is unclear at
present, although Inoue et al. (1989) found it to be only a weak ACTH-
secretagogue when injected intravenously. These potential actions were
not addressed in the present experiments, but could be investigated using,
for instance, cultured pituitary cells.
In conclusion, the experiments described in this chapter demonstrate
that, in contrast to data obtained primarily in the rat, LHRH/LH secretion
is not under the regulatory control of NPY in the sheep. However, the
results show quite clearly that NPY is involved in the multi-factorial
regulation of ACTH and Cortisol release in this species. In this chapter, the
experiments reported addressed the effects of exogenous NPY. The next
chapter describes experiments to investigate the role of endogenous NPY
in the control of LH secretion, and in particular the role this neuropeptide
may play with respect to the LH surge.
9. Role of endogenous neuropeptide Y in the
secretion of LH during the oestrous cycle
9.1. Introduction
In the previous chapter, the actions of exogenous NPY on the
hypothalamic-ovarian and -adrenal axes were reported. Whilst central
NPY stimulated the HPA axis, the acute administration of NPY into the
third ventricle was without effect on LH secretion at the doses tested.
However, there is preliminary evidence in the rat that NPY may play a
part in the initiation of the LH surge.
The concentration of NPY in the pituitary portal plasma of the rat is
considerably higher than that in the peripheral plasma (McDonald,
Koenig, Gibbs et al. 1987). Moreover, pituitary portal NPY levels change
throughout the oestrous cycle in the rat (Sutton, Toyama, Otto & Plotsky,
1988), being particularly high on the afternoon of pro-oestrus. Passive
systemic (Sutton et al. 1988) or central (Wehrenberg, Corder & Gaillard,
1989) immunization with antibodies to NPY inhibits the oestradiol- and
progesterone-induced LH surge in the ovariectomized rat. In addition, it
en shown that hypothalamic ir-NPY increases during prepubertal
pment and that an increase in pituitary portal NPY levels precedes
;t oestrous cycle of puberty in rats (Sutton, Mitsugi, Plotsky & Sarkar,
A recent study by this group demonstrated that immunization with
um against NPY suppresses the preovulatory surge of LH on the
>on of first pro-oestrus and that a central, rather than peripheral,
of administration of antibody was more effective (Minami,
chy, Plotsky et al. 1990). These findings suggest that endogenous
lay play a physiologically important role in the initiation of the pre-
3ry LH surge.
; experiments reported in this chapter were designed to investigate
sr endogenous NPY is important in the control of LH secretion in
eep oestrous cycle. We raised antibodies to NPY in sheep and
lined the effects of the peripheral and central (i.c.v.) administration
i-NPY antibodies on the timing and/or characteristics of the
135
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oestradiol-induced surge in anoestrous ewes and of the pre-ovulatory LH
surge in cycling ewes. In addition, we looked for evidence of the presence
of NPY in the hypothalamus and attempted to measure the secretion of
NPY throughout the cycle.
9.2 Experimental design and methods
The experiments described in this chapter involved four groups of intact
ewes. Three groups of Scottish Blackface ewes were used (a) for measure¬
ment of NPY throughout the oestrous cycle; (b) to investigate the effect of
peripheral administration of anti-NPY antibodies on the oestradiol-
induced LH surge or (c) the pre-ovulatory LH surge. A group of Finn x
Dorset ewes was also used in which the effect of i.c.v. administration of
anti-NPY antibodies on the pre-ovulatory LH surge was measured.
In addition, four Scottish Blackface ewes were immunized against NPY
to raise antibodies for the immunoneutralization studies.
9.2.1. Tissue extraction for measurement of neuropeptide Y content
Hypothalamic tissue was obtained from an intact control Scottish
Blackface ewe (No. G253) in the early luteal phase. The animal was killed
with an overdose of sodium pentobarbitone (Euthasate, Willows Francis,
Crawley, West Sussex), the skull opened and the intact brain carefully
removed leaving the pituitary gland in situ. The median eminence and
tediobasal hypothalamus (MBH) were removed quickly from the
frozen rapidly on dry ice and stored at -70 °C. The MBH extended
the base of the brain to approximately 4-5 mm from the floor of the
ventricle dorsally, to the optic chiasm anteriorly, the mamillary
5 posteriorly and to the optic tracts laterally. The median eminence
;asily identified as a highly vascular ovoid structure, 2-3 mm in
(ter, on the ventral surface of the hypothalamus.
Dzen mediobasal hypothalamus or median eminence tissue was
I for 5 min in a mixture (1:1) of acetic acid (1 M) and HC1 (0.1 M)
l/g tissue). After cooling on ice, the tissues were homogenized
ron, Kinematica, Luzern, Switzerland), taking care to avoid cross-
nination, and an aliquot removed for protein determination using a
ercially available kit (BioRad, Munich, FRG) based on the method of
3rd (1976). The homogenate was centrifuged at 3 000 rpm (2 110 g) for
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60 min at 4 °C and the supernatant decanted and neutralized with 1 M
NaHCC>3. The neutralized supernatant was then centrifuged at 3 000 rpm
for 30 min and the resulting supernatant decanted and lyophilized under
vacuum overnight. Freeze-dried tissue was reconstituted in assay buffer
for determination of NPY content as below. I am grateful to Dr Fiona
Gibson for help and advice with the tissue extractions, and for performing
the protein assay.
9.2.2. Measurement of NPY during the oestrous cycle
During January 1989, the oestrous cycles of 10 Scottish Blackface ewes were
synchronized prior to blood sampling in February. Initial cycle synchrony
was by withdrawal of progestagen-impregnated intra-vaginal sponges 12
days after their insertion as described in the previous chapter (Section
I
8.2.4). All ewes displayed behavioural oestrus. On day 10 of the
subsequent cycle, luteolysis was induced at 23.00 h with an i.m. injection of
cloprostenol as previously. The animals were sampled every 10 min for
10 h from 09.00 h (10 h after cloprostenol) and subsequently every hour for
a further 60 h until 07.00 h on the fourth day of sampling. Samples were
collected on ice and the plasma separated and stored immediately at -20 °C
until extracted for NPY assay.
Plasma samples (750 jil) were extracted with 3 ml HCl-ethanol (1.5 mM
HC1 in ethanol) in polystyrene tubes. Samples were vortexed for 30 sec
and centrifuged at 3 200 rpm (2 400 g) for 15 min at 4 °C. The supernatant
ecanted and dried down overnight in a water-cooled centrifugal
rator (GyroVap, Howe, London) and reconstituted in 250 pi buffer
ay of NPY as below. Extraction efficiency, as determined by recovery
thetic NPY added to a freeze-thawed plasma pool was -100% (range
)%).
Radioimmunoassay of neuropeptide Y
nination of NPY content in tissue and in plasma samples was by a
ed form of the methodology reported by McDonald and colleagues
>nald, Dees, Ahmed et al. 1987; McDonald, Koenig, Gibbs et al. 1987;
no, Collins & McDonald, 1989). Briefly, the assay used a rabbit
■um raised against synthetic porcine NPY conjugated to BSA with
aldehyde. This antiserum—NPY-3 from rabbit #3, April (4)/1985
-was a generous gift from Dr John K. McDonald, Emory University
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School of Medicine, Atlanta, GA, USA, to whom we are grateful.
The assay was carried out in polystyrene tubes using 0.05 M phosphate
buffer containing 0.3% BSA, 0.01 M EDTA and 0.2% sodium azide at
pH 7.4. Human NPY (Cambridge Research Biochemicals, Harston,
Cambridge) for use as standard was stored at -40 °C at a concentration of
200 ng/ml and diluted appropriately on the day of assay in RIA buffer.
Mono-iodinated [125I] synthetic porcine NPY, labelled with Bolton-Hunter
reagent, was purchased from Amersham and stored in aliquots of 10 (il
(1 jiCi) at -20 °C until required for assay.
100 (il of standard (0.1-25 ng/ml) or extracted tissue/plasma sample
(see above) was incubated with 100 )il anti-NPY antiserum (1: 9 000) and
100 pi [125I]-pNPY (~7 000 cpm/100 pi) for 24 h at 4 °C. The bound fraction
was then separated by incubating overnight at 4 °C with 100 pi donkey
anti-rabbit serum? (1:16) and 100 pi normal rabbit serum (1: 800). 1 ml 0.9%
saline/0.02% Triton X-100 was then added and the tubes centrifuged. The
supernatant was decanted and the remaining pellet counted as described
previously (Chapter 3). Binding in the presence of unlabelled NPY was
typically 25-30% and the non-specific binding was 2%. The sensitivity of
the assay was 20 pg/tube and, after the concentration step in the plasma
extraction, the detection limit was 67 pg/ml. (Representative standard
curve shown in Figure 9.3).
9.2.4. Generation of anti-NPY antibodies
e primary immunization and the first boost, NPY was conjugated to
y-globulin (ryG). However, ryG is not to be recommended as a
i. The in-house ovine gonadotrophs assays (and many others) use
ry antisera raised in rabbits, and so the anti-rabbit antibodies raised
^y-product' of conjugation to ryG will cause the assay to produce
us high concentrations when none exist. The anti-rabbit antibodies
)re had to be removed from the anti-NPY antiserum before use (see
I. Other haptens such as bovine or porcine thyroglobulin or keyhole
: haemocyanin would avoid this problem and indeed porcine
jlobulin (pTG) was used for subsequent boosts. The method
3ed below was that for conjugation to pTG, but the same principle
llowed for ryG.
man NPY was conjugated to porcine thyroglobulin (Sigma) in a
ratio of 5: 1 with l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
zhloride (carbodiimide; Sigma). 400 |ig hNPY and 12.5 mg pTG were
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dissolved in 1 ml sterile saline (pH 5.5-6.0). 30 mg fresh carbodiimide was
dissolved in 400 pi distilled water and added to the proteins. The mixture
was then agitated at room temperature for 4 h, before dialysis against 5 1
0.9% saline for 24 h, replenishing the saline at least three times. For
immunization and subsequent boosts, the NPY conjugate was made up to
4 ml with saline and and emulsified with 6 ml Freund's complete
adjuvant (GIBCO Laboratories, Grand Island, NY, USA). The emulsi-
fication and injections were made using a 5.0-ml Eppendorf Multipipette
combitip (Eppendorf-Netheler-Hinz GmbH, Hamburg, FRG) trimmed to a
fine aperture for the emulsification and cut down to accept a 19-gauge
needle for the injections.
Four Scottish Blackface ewes were injected intradermally in the axillary
skin at multiple sites with 100 pg NPY conjugate emulsified with Freund's
(total volume 2.3 ml). The sheep were boosted at 10, 15, 20 and 30 weeks
after the initial immunization, again with 100 pg NPY conjugate
emulsified with complete Freund's. 12 days after each boost, 400 ml blood
was collected from each sheep and the plasma stored at -20 °C. The
antibody titres were determined by incubating dilutions of these samples
with 125I-NPY. Bound tracer was separated from free with polyethylene
glycol (PEG). 1 mg ryG in 100 pi buffer and 1 ml 20% PEG/0.02% Tween in
buffer was added to each tube and, after vortexing thoroughly, the tubes
were centrifuged at 3 000 rpm for 30 min at 4 °C. The supernatant was
aspirated and the remaining white pellet counted. As shown in Figure 9.1,
he third boost (07.06.89 bleed), one sheep (No. A137) had a titre of
000 (defined as the final dilution of antiserum required to bind 30%
-labelled NPY trace). The titre of this animal after the fourth boost
89 bleed) was similar, and antibodies from both these bleeds were
n the immunoneutralization studies described in this chapter.
Removal of anti-ryG antibodies from anti-NPY antiserum
to use, the antiserum was cleaned of anti-rabbit antibodies (see
1 by passing it through an agarose gel column containing ryG (Sigma)
;d to the gel by the following method. 15 g CnBr-activated Sepharose
(Pharmacia AB, Uppsala, Sweden) was swollen for 15 min in 1 mM
nd then washed and reswollen with 1 mM HC1 on a sintered glass
The gel was then washed with 75 ml coupling buffer (0.1 M
:O3/0.5 M NaCl; pH 8.3) and immediately transferred to a solution of
g rabbit y-globulin in coupling buffer. The protein solution was
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Figure 9.1. Titres of anti-NPY antibodies measured in four
immunized sheep after the first three boosts with conjugated
NPY and Freund's complete adjuvant (see text). After the
third boost, sheep A137 had a titre of 1:112 000.
Anti-NPY antibody titres (dilution for 30% binding)
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mixed gently with the gel suspension for 2 h at room temperature and the
remaining active groups blocked with 0.2 M glycine (pH 8.0). Excess
adsorbed protein was washed away by washing alternately 4-5 times with
high-pH coupling buffer and low-pH acetate buffer (0.1 M sodium
acetate/0.5 M NaCl; pH 4.0). The coupled gel was stored in 0.075 M
phosphate buffer until required.
To remove the anti-ryG antibodies from the anti-NPY antiserum, it
was passed through the column very slowly 2-3 times. The anti-rgG
antibodies were eluted from the column with 0.1 M glycine/HCl (0.1 M
glycine adjusted to pH 2.5 with 0.2 M HC1) and, after washing the column
with phosphate buffer, the antiserum was passed through again. This
treatment was successful in removing ryG-binding activity from the
antiserum. Titres of anti-NPY antibodies were unaffected.
»
9.2.6. Systemic immunization against NPY during the oestradiol-induced
LH surge in anoestrous Scottish Blackface ewes
During June 1989, twelve Scottish Blackface ewes were housed for
experiment in approved restraint crates in the University of Edinburgh
Marshall Building. Two days before, and on the day before experiment,
the animals received either 10 ml anti-NPY plasma (A137; 07.06.89 bleed)
(n = 6) or 10 ml non-immune plasma (n = 6) at 12.00 h by slow intra¬
venous injection. On the day prior to experiment, a jugular venous
cannula was inserted into each ewe and kept patent with heparinized
. At 00.00 h on the day of experiment, each animal received an i.m.
on of 50 jig oestradiol benzoate (E2B; Sigma) and a blood sample (2.5
as taken. 6 h later, at 06.00 h, the sheep received a third i.v. injection
:ibodies (or non-immune plasma) as previously and hourly blood
ing (2.5 ml) for 24 h was commenced. Plasma was separated and
at -20 °C until assayed for LH. The time after E2B to the onset of the
rge was defined as in Section 8.2.4.
Systemic immunization against NPY during the pre-ovulatory LH
in cycling Scottish Blackface ewes
g October-November 1989, the oestrous cycles of 20 Scottish
ace ewes (47-75 kg) were synchronized prior to experimentation in
nber. Initial cycle synchrony was by withdrawal of progestagen-
gnated intra-vaginal sponges 12 days after their insertion as
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described previously (Section 8.2.4). All ewes displayed behavioural
oestrus. On day 10 of the subsequent cycle, a jugular venous cannula was
inserted into each ewe and kept patent with heparinized saline. The
animals were placed in approved restraint crates for experiment and
luteolysis was induced at 23.00 h with an i.m. injection of cloprostenol.
10 h after cloprostenol, i.e. at 09.00 h, the animals received either 8 ml anti-
NPY antiserum (A137; 21.08.89 bleed) (n = 10) or non-immune plasma
(n = 10) by slow intravenous injection. These injections were repeated at
09.00 h on the following two days. Blood samples (2 ml) were taken every
10 min for 10 h from 09.00 h (10 h after cloprostenol) and subsequently
every hour for a further 60 h until 07.00 h on the fourth day of sampling.
Plasma was separated and stored at -20 °C until assayed for LH. The time
to the onset of the pre-ovulatory LH surge was defined as in Section 8.2.4.
I
9.2.8. Central (i.e.v.) immunization against NPY during the pre-ovulatory
LH surge in cycling Finn x Dorset ewes
Four of the Finn x Dorset ewes described in Section 8.2.4 were used for this
part of the study during January-February 1990. After the experiments on
these animals reported in the previous chapter, all ewes showed
behavioural oestrus. At 21.00 h on day 9 of the following cycle, each
animal received an injection of 50 (il non-immune plasma into the third
cerebral ventricle. The next day (day 10), a jugular venous cannula for
blood sampling was inserted into each sheep and each received a further
injection of control plasma. Luteolysis was induced with i.m.
stenol at 23.00 h. At 09.00 and 21.00 h on each of the three following
the animals received an i.c.v. injection of 50 jil non-immune
a. Starting 10 h after cloprostenol (09.00 h), blood samples (0.8-1.0
are taken every 10 min for 10 h and subsequently every hour for the
0 h. All animals showed behavioural oestrus. Due to the small
a volume collected, blood was centrifuged in small heparinized
vithout beads and the plasma decanted by pipette,
a animals were allowed two complete oestrous cycles for recovery,
; which they did not receive any treatment. They were then given
v. injection of 50 |il anti-NPY antiserum (A137; 07.06.89 bleed) at
\ on day 9 of the subsequent cycle. The i.c.v. injection of anti-NPY
urn was repeated at 21.00 h the next day and at 09.00 and 21.00 h on
lowing three days, as above for control plasma. On the afternoon of
), a jugular venous cannula was inserted into each animal and
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luteolysis induced at 23.00 h with i.m. cloprostenol. Blood samples (0.8-
1.0 ml) were taken every 10 min for 10 h from 09.00 h (10 h after
cloprostenol) and subsequently every hour for the next 60 h. Figure 9.2
shows the times of injection of antibody in relation to the stage of the
oestrous cycle as illustrated by progesterone levels measured in plasma.
9.3. Results
9.3.1. Hypothalamic NPY content
Serial dilutions of extracts of mediobasal hypothalamus and median
eminence exhibited close parallelism with synthetic human NPY
standards in the radioimmunoassay (see Figure 9.3), demonstrating NPY-
immunoreactivity in the hypothalamus of the sheep.
The content of NPY in the MBH was 489 ng/g tissue and, in the ME,
336 ng/g tissue. As the MBH and ME contained 63.7 and 23.4 mg protein/g
tissue respectively, these values correspond to concentrations of NPY of
3.68 pg/g protein in the MBH and 14.3 |ig/g protein in the ME, or 0.86 and
3.36 pmol NPY/mg protein respectively.
9.3.2. Plasma concentrations of NPY during the oestrous cycle
After several abortive attempts to extract and measure NPY in plasma
samples taken prior to and during the expected time of the pre-ovulatory
rge, we obtained the profile shown in Figure 9.4. With the caveat
is is only one profile from a single animal, this appears to show that
a. concentrations of NPY increase around the time that the pre-
ory surge of LH might be expected to occur and also that NPY
□n earlier in the cycle may be pulsatile.
fortunately, it is not known when the LH surge occurred in this
ilar ewe, as the whole sample was required for extraction due to the
>w concentration of NPY in the peripheral plasma. In addition, this
eant that the NPY assay could not be performed in duplicate. It is
>re impossible to draw any conclusions from this part of the study.
Effects of systemic passive immunization against NPY
mous administration of anti-NPY antibodies in anoestrous Scottish
ice ewes had no effect on the E2B-induced LH surge. The time from
istration of E2B to the onset of the LH surge was not altered (14.2 ±
Chapter 9 Role of endogenous NPY 144
Figure 9.2. Progesterone concentrations in intact cycling
ewes, showing the timing of i.c.v. administration (see text) of
control plasma (open bar) or anti-NPY antibodies (shaded bar)
relative to the oestrous cycle(s). • = mean plasma progest¬
erone levels in Finn x Dorset ewes during the experiment ±
s.e.m. (n = 4). Injections of cloprostenol shown by open
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Figure 9.3. Content of immunoreactive NPY in (□) medio-
basal hypothalamus and (■) median eminence. Dilutions of
tissue extracts show parallelism with hNPY standard
curve (•). Tissue obtained from a control ewe during the
early luteal phase.
ir-NPY in sheep extracts
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Figure 9.4. Measurement of NPY in extracted peripheral
plasma before and during the expected time of the pre¬
ovulatory LH surge. Note split and change of scale of x-axis
after t = 20 h. Time measured from induction of luteolysis
with cloprostenol (see text).
Timerelativetocloprost nol(h)
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0.44 h in antibody-treated animals, compared with 15.2 ± 1.11 h in ewes
treated with non-immune plasma; n = 6 in each group). Other character¬
istics of the surge, such as the peak height (Ab-treated, 144.1 ± 26.1 ng/ml
vs. control, 106.2 ± 17.3 ng/ml), were also not altered (Figure 9.5a).
Passive intravenous immunization against NPY during the pre¬
ovulatory LH surge in Scottish Blackface ewes, though, did reduce the
time to the onset of the surge in cycling animals (Ab-treated, 48.8 ± 2.69 h
vs. control, 58.5 ± 2.24 h; n = 10 in each group; p < 0.05, Neuman-Keuls
test). Other characteristics of the surge, however, including peak height
(Ab-treated, 95.8 ± 13.4 ng/ml vs. control, 81.1 ± 11.0 ng/ml), were
unaltered (Figure 9.5b).
Although there was no difference in the mean weights of the two
groups of animals (Ab-treated, 56.7 ± 2.1 kg vs. control, 61.2 ± 2.0 kg), it
seems likely that the reduction in time to onset of the surge seen with
immunization against NPY may be due to a confounding effect of the
nutritional state of the animal (see Section 9.4 below).
9.3.4. Effects of central (i.e.v.) immunization against NPY
In contrast to the effects of peripheral NPY-Ab treatment, i.e.v.
administration of anti-NPY antibodies prior to and during the expected
time of the pre-ovulatory surge in Finn x Dorset ewes delayed or
apparently abolished the LH surge in all three ewes for which we were able
to obtain both control and treated data. Figure 9.6 shows the LH profiles of
three ewes treated with anti-NPY antibodies i.e.v. and also the
;s of the same animals treated with non-immune plasma i.e.v. for
irison. Interestingly, three out of the four ewes did not show
ioural oestrus during the NPY-Ab treatment, and the fourth (No.
)) did not allow the ram's attempted mounts to succeed.
ie to the nature of the data, and as we were only able to obtain a
ete set from three animals, it was not possible to perform a statistical
;is. We were, however, able to obtain a complete data set from the
0 h of sampling (i.e., from 10-20 h after cloprostenol) and found
to be no effect of NPY immunization on mean basal Cortisol
atration over this time period (Ab-treated, 24.6 ± 3.68 ng/ml vs.
1, 28.1 ± 3.64 ng/ml; n = 4 in each group).
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Figure 9.5f Passive systemic immunization with anti-NPY
antiserum had no effect on the characteristics of (a) the
oestradiol-induced surge of LH in anoestrous Scottish
Blackface ewes or (b) the pre-ovulatory LH surge in cycling
Scottish Blackface ewes. The means (± s.e.m.) of the LH
profiles relative to the peak concentration of LH are shown
for each treatment, (a) effect of i.v. administration of (O)
non-immune plasma (n = 6) and of (•) anti-NPY antibodies
(n = 6) on the oestradiol-induced LH surge in anoestrus. (b)
effect of i.v. treatment with (O) control plasma (n = 10) and
(•) anti-NPY antibodies (n = 10) on the pre-ovulatory surge
in cycling ewes. LH concentration expressed in terms of NIH-
LH-S23.
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Figure 9.6. Effect of i.e.v. administration of anti-NPY
antibodies (see text) on the timing of the pre-ovulatory LH
surge in three cycling Finn x Dorset ewes. The effects of (O)
control treatment with non-immune plasma and (•) admin¬
istration of anti-NPY antiserum are shown. Central
administration of anti-NPY antibodies delayed the LH surge
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9.4. Discussion
We have clearly shown that ovine hypothalamic and median eminence
tissues contain high concentrations of neuropeptide Y. While in the
present study tissue from only one animal was used, the content of NPY
in these tissues was within an order of magnitude of the concentrations
shown in the rat brain (Chronwall et al. 1985). These authors applied a
rigorous and detailed quantitative analysis to micro-dissected brain
regions in a large group of rats. The present study did not set out to be
rigorous, and nor could the brain areas be described as micro-dissected.
However, within the aim of the study, we have demonstrated the
presence of ir-NPY in these hypothalamic areas and that this
immunoreactivity dilutes in parallel with human NPY standards. These
results are suggestive that hypothalamic NPY could have a role in brain
function in the sheep.
Our attempts at measuring NPY in peripheral plasma unfortunately
did not reveal any conclusive data. To get the extremely low peripheral
concentrations of NPY to read on the standard curve of the RIA, large
volumes had to extracted and concentrated up. This had the disadvantage
that samples could not be assayed in duplicate and nor was there enough
sample to assay for LH. This is unsatisfactory from the point of view of
relating NPY levels to the stageof the oestrous cycle. From the one profile
/e were able to obtain, it appears that NPY concentrations may
ly rise around the expected time of the surge and that NPY secretion
have a pulsatile component. These conclusions are entirely
ative until a better method of assessing endogenous NPY secretion
found.
'eral ways of overcoming these problems could be suggested. In the
PY levels have generally been reported in pooled plasma samples
Sutton et al. 1988; McDonald et al. 1987) which gets round the
:m with, however, considerable loss of resolution. An immuno-
aetric assay (IRMA) would better overcome the problems of low
itrations, as in general IRMAs are much more sensitive. An NPY
has been reported by Corder & Lowry (1985) and, if combined with
rlonal antibody technology, such an assay would have distinct
tages over RIA.
s approach that would reveal the greatest amount of physiologically
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interesting information regarding the secretion of NPY would be to
measure NPY in serial samples of portal blood using an IRMA.
Techniques for the acute collection of portal plasma in the sheep have
been developed by Clarke & Cummins (1982) and further refined by Caraty
& Locatelli (1988). These would be ideally suited to investigation of NPY
secretion from the hypothalamus without interference from NPY from
peripheral sources such as the ovary, adrenals, or the blood vessel smooth
musculature.
A much less traumatic or invasive technique with significant
advantages over the surgical trans-nasal/-sphenoidal approaches has been
developed for use in the horse (Irvine & Alexander, 1987). This takes
advantage of the unique venous drainage pathway of the pituitary gland
in this species and allows for collection of essentially portal blood samples
of large volume (up to 4 ml) at frequent intervals (e.g. every 2 min) for up
to several days. There are, however, some disadvantages to this model.
Firstly, the blood collected is venous effluent—i.e., after it has passed
through the pituitary gland—and presumably a proportion of the
hypothalamic hormones will be internalized by the cells of the anterior
pituitary. Secondly, due to the unique anatomy of the venous pathway
used, it is only possible in the horse, which is a species not widely used as a
neuroendocrine model. Nevertheless, this would be an ideal model in
which to investigate the hypothalamic secretion of NPY through the
oestrous cycle.
T~ order to investigate the possible role of endogenous NPY in the
A of LH secretion at the pituitary and hypothalamic levels, we raised
dies to NPY and administered them both peripherally and centrally
y either the E2B-induced LH surge in anoestrous ewes (peripheral
or the pre-ovulatory surge in cycling ewes. Systemic treatment with
PY antibodies had no effect on the induction of a surge of LH by i.m.
This is in contrast to data obtained in the ovariectomized rat (Sutton
1988), where i.v. treatment with anti-NPY antibody inhibited the
diol- and progesterone-induced surge of LH. However, it is not
sing as NPY has no effect at the level of the pituitary gland in the
(Brooks et al. 1990). It appears also that the peripheral admin-
on of antibody in this pharmacological model does not affect the
ile modulation by NPY of LHRH release from circumventricular
; outside the blood-brain barrier, such as the median eminence and
VLT.
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Systemic immunization against NPY during the pre-ovulatory LH
surge appeared to reduce the time to surge onset without, however,
altering the characteristics of the surge. It seems that this may be due to a
confounding effect of the nutritional state of the animals. Whilst the
weights of the two groups were not different, the antibody-treated group
was composed, in the main, from animals recently brought in from
pasture, whereas the majority of the control animals had been housed
indoors in the sheep facility for several months on a diet of hay,
supplemented with concentrated feed. A lower body condition (degree of
fatness) in hill and upland sheep, such as the Scottish Blackface, has been
shown to be associated with reduced numbers of large follicles, with a
lower proportion of oestrogenic, potentially ovulatory, follicles among
this reduced population (McNeilly, Jonassen & Rhind, 1987). If the body
condition of the outdoor sheep was significantly higher for the same
weight, with a consequentially increased follicular development, then this
provides the only plausible explanation for the difference in the time to
onset of the LH surge.
In contrast to the effects of systemic (peripheral) immunization against
NPY, i.c.v. administration of anti-NPY antibodies resulted in a delay in the
onset of the LH surge in all animals for which we were able to obtain
control and treated data. This is in agreement with the findings of
Minami et al. (1990) with regard to the onset of the first LH surge of
puberty in the rat. These authors observed two populations of effect of
■" " NPY-Ab on the surge; in some animals the surge was abolished
the observation period, whereas in others it was only delayed. As
ion occurred in all the treated rats, except for one, on the next
ag, they concluded that a surge of LH had perhaps occurred after the
: the sampling period. It is possible that this was the case in our
^.b-treated sheep. However, the absence of behavioural oestrus and
le presence of apparently anoestrous ovaries in one of the ewes on
ctomy shortly after the completion of the experiment (Dr Alan S.
illy, personal communication) suggests either that an LH surge did
cur, or if it did, it was not sufficient to produce ovulation. The breed
ep used for the central experiment—the Finn x Dorset—does not
y enter anoestrus until later in the year, as it has been specifically
Dr, amongst other attributes, a longer breeding season. The delay in
of the pre-ovulatory LH surge, or its abolition, caused by i.c.v.
lization against NPY suggests that endogenous NPY plays a part in
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the modulation of the timing of the LH surge in the sheep, and that this
occurs at the level of the hypothalamus. It may be that NPY acts to
synchronize or optimize the firing of LHRH neurones in such a way that
this contributes to the creation of the LH surge. Alternatively, NPY
neurones could act in an interneurone capacity to regulate the response of
the LHRH neurones to circulating levels of oestradiol; i.e., they may
influence the 'set-point' of oestradiol positive feedback. Either or both of
these explanations could account for our findings.
Although the experiments of the previous chapter and those of Inoue
et al. (1989) in the dog show that NPY is involved in the multi-factorial
regulation of ACTH release, Cortisol levels were found to be unchanged
during the central immunization against NPY. This suggests that NPY is
not important for basal Cortisol release. It would be of interest, however,
to determine the' effects of anti-NPY immunization on stimulated Cortisol
release as, for instance, in hypoglycaemic stress or in response to an audio¬
visual stimulus such as a barking dog. This would address the
physiological significance of endogenous NPY in the activation of the
HPA axis.
In conclusion, we have shown that endogenous NPY is involved in
the modulation of the timing of the LH surge in the sheep, and that in
contrast to the role of NPY in this regard in the rat, this only occurs at the
level of the hypothalamus. It is not possible from the current experiments
to determine whether this role of NPY is an obligatory part of the surge-
ting mechanism. However, the effects of central NPY immun-
l in the rat suggest that, at least in this species, NPY plays a
lory role in the generation of the LHRH surge. It may be, therefore,
e function of NPY in the regulation of reproduction in the sheep is
vide a means whereby the efficient generation of a pre-ovulatory
/LH surge is ensured.
10. General discussion
The primary control of reproduction is through the action of the
hypothalamic releasing hormone LHRH, released in a pulsatile fashion
into the pituitary portal system. The generation of LHRH pulses is clearly
an intrinsic property of the LHRH neuronal system as LHRH pulses
continue at a physiological frequency if the human MBH is placed in an
in-vitro perifusion system (Rasmussen, Gambacciani & Swartz et al. 1989).
However, afferent pathways that project to LHRH cells are important for
the modulation of LHRH pulses. The experiments reported in this thesis
have shown that other neuropeptides have the ability to regulate this
primary drive and that the intra-hypothalamic interactions between
neuropeptides involved in the control of the reproductive axis are diverse
and complex.
The findings of Chapter 4 (see also Naylor, Porter & Lincoln, 1989)
indicate that an inhibitory autoregulatory mechanism exists in the control
of LHRH within the hypothalamus, and confirm and extend the results of
experiments in the rat. The functional significance may be to provide a
mechanism to switch off each pulse of LHRH. Experiments by Stephen
Kuffler and colleagues have identified LHRH as a peptide neuro-
litter in the sympathetic ganglion cell of the bullfrog. Stimulation
afferent nerves to this preparation results in two excitatory post-
:ic potentials, a fast synaptic potential mediated by acetylcholine and
• much slower potential that lasts for several minutes (see Kuffler,
lis & Martin, 1984). LHRH-ir was found to increase after electrical
ation of the pre-ganglionic fibres and exogenously applied LHRH
ked the effects of nerve stimulation (Jan, Jan & Kuffler, 1979; 1980;
Jan, 1982). Moreover, application of an LHRH antagonist blocked
he late slow potential and the LHRH-induced potential (Jan et al.
Jan & Jan, 1982). Furthermore, Kuffler & Sejnowski (1983)
tstrated that the amplitude and duration of conductance changes
ced by the neurally released transmitter and by LHRH on the
naptic cell were indistinguishable. These experiments provide clear
tee that LHRH acts as a neurotransmitter in this preparation,
ting late and long lasting excitatory actions on the postsynaptic cell
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membrane. If the effect of LHRH upon LHRH neurones is characterized
by such a slow onset, long-lasting action on ion channels, but to
hyper-polarize the cell membrane, then—as suggested by Dyer & Robinson
(1989)—this could provide a mechanism for timing the release of LHRH
pulses. The experiments reported here are unable to answer this specific
question. Detailed electrophysiological studies of hypothalamic POA
slices, or of cultured neurones are now required to determine the
autoregulatory effects of LHRH at the neuronal level.
In a very recent paper, Caraty, Locatelli, Delaleu et al. (1990) have
suggested that an autoregulatory mechanism in the control of LHRH
secretion does not exist. Their conclusions were based on the measure¬
ment of endogenous LHRH in the portal blood of short-term castrated
rams: during the peripheral (intramuscular) administration of an LHRH
agonist and an LHRH antagonist, LHRH secretion continued, whilst LH
secretion was interrupted. However, it is erroneous to infer from these
particular findings that an intra-hypothalamic 'ultra-short' loop feedback
mechanism does not exist for LHRH. As peptides do not cross the blood-
brain barrier to any great extent, due to the non-fenestrated nature and the
tight endothelial junctions of the brain capillaries (see Dunn & Berridge,
1987), this approach only addresses the effects of the LHRH analogues on
the pituitary gland. Evidence for LHRH autoregulation within the hypo¬
thalamus is much more convincing (see Chapter 4).
Caraty et al. (1990) also raised the question of dose, implying that the
ity of LHRH required to produce an inhibitory effect when injected
lly was very high when compared with levels of LHRH in the CSF.
ppropriate dose of a neuropeptide is indeed problematic, yet it is
known what the physiologically effective concentration of a
peptide is, nor is it known what concentration of the administered
le reaches the active site(s). Interestingly, at the neuromuscular
3n, it has been estimated that the concentration of acetylcholine
me released quantum is 0.3 mM (Kuffler & Yoshikami, 1975); which
ibove the Kd for the muscle acetylcholine receptor. Even if the Kd of
ceptor were taken as an estimate, then the effective concentration
[ correspond to 10~12 to 10-9 M, depending on the affinity of the
or, or a dose of 1 pmol to 1 nmol distributed over the entire rat brain
. & Berridge, 1987). For a decapeptide such as LHRH, this would
e a dose of between 1 ng and 1 (lg in the rat. The doses used in the
t studies are thus well within the active range.
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The temporal characteristics of the inhibition of LH secretion induced
by central administration of LHRH suggested the possible involvement of
another neural or endocrine system. Although the potential roles of the
endogenous opioid peptides and the hypothalamo-pituitary-adrenal axis
were investigated, the work reported here is not conclusive regarding the
direct or indirect nature of LHRH autoregulation. The results presented in
Chapter 5 indicate that the EOPs do not mediate the inhibition, and those
in Chapter 6 suggest that Cortisol, if it is implicated, is unlikely to be the
sole factor involved in the suppression. The stimulatory effects of CRH
on LHRH, and therefore on LH secretion, reported in Chapter 7 indicate
that CRH is unlikely to suppress LHRH secretion centrally in the sheep.
However, it is possible that CRH and/or AVP may be involved in some
other pathway to inhibit LHRH secretion, not mimicked by i.c.v. admin¬
istration of CRH. One way to determine this in vivo could be to
administer anti-CRH or anti-AVP antibodies, or antagonists of either
hormone centrally, prior to the ventricular injection of LHRH. In
addition, the potential role of ACTH could be investigated further in vivo,
by immunization against this hormone.
Another neuroendocrine mechanism not investigated in the current
studies, but of interest as a potential mediator of the LHRH-induced
suppression of LHRH/LH secretion, is the endogenous GABAergic system.
Many of the LHRH neurones in the anterior hypothalamus have been
shown to receive a GABAergic input (Leranth, MacLusky, Sakamoto et al.
1 notr\ jhere is also much evidence in the rat for an action of GABA on
secretion which is dependent both on the site of action within the
lalamus (Nikolarakis, Loeffler, Almeida & Herz, 1988) and on the
[ environment (Jarry, Perschl & Wuttke, 1988). Moreover, GABA
a reduction in plasma LH levels when injected into the third
:le of the rat (Fuchs, Mansky, Stock et al. 1984). Therefore, this is a
. that warrants further investigation in vivo and in vitro.
\ results of the experiments described in Chapter 7 indicate that in
e, the central application of CRH causes an increase in the pulsatile
m of LHRH. As discussed in that chapter, this is in contrast to the
utained in the rat. However, this does not discount the theory that
nay also act to inhibit LHRH secretion in the sheep under some
stances. The dominant pathway mimicked by the central admin-
>n of CRH appears to be a neural circuit(s) involved in the
ition of neuroendocrine responses to stress. The physiological
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significance may be that such a mechanism underlies the LH responses to
shipping/handling stress. An interesting area of further study in this
respect would be to investigate whether the activation of such CRH
pathways is involved in the so-called 'ram effect'. During anoestrus, if
ewes previously isolated from the presence of rams are exposed to a ram,
this results in the stimulation of the frequency of LH pulses (e.g., see
Martin & Scaramuzzi, 1983; Martin, Scaramuzzi & Lindsay, 1983). This
seems to be mediated via pheromones, but could also provide a
physiological role for CRH to stimulate LHRH/LH secretion.
We also found differences between the responses to NPY in the sheep
and those reported in the rat. Neither the experiments described in this
thesis, nor the results of Brooks et al. (1990), indicate any pituitary locus of
action for NPY in the regulation of reproduction in the sheep. This
I
questions the suitability of the rat as a model for the ewe, or indeed for
other species including man. Much care is required in the interpretation
of results across species, particularly with respect to the hypothalamo-
pituitary-adrenal axis (see Chapter 7). This was highlighted in a recent
article by Funder (1990), in which the commonality and differences
between animal models used in endocrinological studies was discussed
and the 'normative' physiology of the rat brought into question.
The precise physiological roles of the mechanisms demonstrated by the
current investigations remain somewhat speculative. However, it is
possible to propose a hierarchy of neural circuitry involved in the
ation of LHRH, CRH and NPY pathways with respect to the
luctive and hypothalamo-pituitary-adrenal axes. The secretion of
Ld ACTH is clearly under the control of LHRH, and CRH and/or
respectively, from the hypothalamus. Superimposed upon these
*y controls is the influence of LHRH on its own secretion, the action
T from higher centres on LHRH, and the modulation by NPY from
ainstem and the arcuate nucleus on LHRH and CRH secretion (see
10.1).
? in-vivo approach used in the studies has many advantages and
tended our knowledge of the action of hypothalamic neuropeptides,
yer, it can only demonstrate the net, pituitary effect of all the
ls affected by the treatment applied. Even if we were able to sample
blood, in this respect the hypothalamo-pituitary unit would still
>le a 'black box'. A specific localization of effect could be achieved by
of the microinjection of the peptide/antagonist into particular
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Figure 10.1. Schematic diagram showing some of the
interactions of LHRH, CRH and NPY in the regulation of the
reproductive axis and of the hypothalamo-pituitary-adrenal
axis. Primary control mechanisms are shown in bold.
Hypothetical excitatory and inhibitory pathways are indicated.
LHRH: luteinizing hormone-releasing hormone; CRH:
corticotrophin-releasing hormone; NPY: neuropeptide Y;
AVP: arginine vasopressin; EOP: endogenous opioid peptide;
PIF: prolactin-inhibiting factor; ACTH: adrenocorticotrophic
hormone, corticotrophin; LH: luteinizing hormone; FSH:
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nuclei or terminal fields, or by push-pull perfusion of individual brain
areas. The latter technique has the disadvantage that less control is
possible over the precise dose delivered. Tissue damage at the site of
interest is also a major problem. In addition, the push-pull perfusion
technique is more reliable with some neuropeptides than others (e.g., see
Rondeel, de Greef, van der Waart et al. 1989). These approaches are more
effective in species such as the rat, where the stereotaxic co-ordinates of
specific nuclei are constant and predictable. However, the inter-animal
variation is notably very wide in sheep, even within breeds, and this can
cause considerable complications with the identification of intra-
hypothalamic structures.
The experiments in this thesis have addressed only some of the
neuropeptides potentially involved in the hypothalamic control of the
secretion of hormones from the anterior pituitary gland. Other examples
for investigation include CCK, which is a potent inhibitor of LH secretion
in the OVX rat, and VIP which stimulates LH secretion both in vivo and
in vitro. These and other candidates for the integrative control of the
hypothalamo-pituitary unit have been discussed further by McCann,
Samson, Aguila et al. (1986). In addition, two recently discovered neuro¬
peptides worthy of further investigation in this regard are the hypo¬
thalamic peptide amides, galanin and PACAP (pituitary adenylate cyclase-
activating polypeptide).
Galanin is a 29-amino acid peptide amide originally isolated from
e intestine by Tatemoto, Rokaeus, Jornvall et al. (1983). In the rat,
ghest brain concentrations are found in the hypothalamus and ME
strom, Melander, Hokfelt et al. 1987). Moreover, co-existence of
n-ir with many of the classical neurotransmitters suggests that it
:unction as a modulator of neuroendocrine function (Melander,
s, Hokfelt et al. 1985; Melander, Hokfelt, Rokaeus et al. 1986; Levin,
.enko, Howe et al. 1987). Although a physiological role for galanin
Dt been defined, it has been shown to influence the secretion of
a hormone, prolactin and dopamine in man and rat, probably acting
level of the hypothalamus (Bauer, Ginsberg, Venetikou et al. 1986;
z, Samson & McCann, 1986; Melander, Fuxe, Harfstrand et al. 1987;
trom, Melander, Hokfelt et al. 1987). In addition, hypothalamic
^ for galanin has been shown to increase after oestrogen treatment
rat (Kaplan, Gabriel, Koenig et al. 1988). However, in another study,
t\alamic levels of the peptide were unaltered by ovariectomy or
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oestrogen treatment, though ovariectomy reduced pituitary galanin
content considerably and oestrogen produced a significant increase in
pituitary galanin and galanin mRNA content (O'Halloran, Jones, Steel et
al. 1990). A role for galanin in the regulation of the reproductive axis is
still speculative, and it is possible that it may have a hypothalamic
function in addition to an autocrine or paracrine role at the pituitary level.
PACAP is a bioactive peptide isolated very recently from ovine
hypothalamic tissue by Miyata, Arimura, Dahl et al. (1989). It was so-
named because of its ability to stimulate the accumulation of intra- and
extracellular cAMP in cultures of rat anterior pituitary cells. Elucidation of
the primary structure of PACAP revealed it to be a 38-amino acid peptide
amide of the VIP family (PACAP38). PACAP(i_28) shows 68% homology
with porcine VIP; however, the PACAP(29_38) C-terminal region appears to
be unique. PACAP was shown to contain an amidation site at amino acid
positions 29-30, which suggested the presence of a shorter amidated
peptide of 27 amino acid residues, PACAP27. This has also been isolated
from ovine hypothalamus (Miyata, Katsuura, Gottschall et al. 1989).
Dense immunoreactive fibre networks of both PACAP27 and PACAP38
have been demonstrated throughout the hypothalamus and septum of the
sheep, and particularly in the ME; immunoreactive cell bodies were also
demonstrated in the PVN and the supraoptic nucleus (Koves, Arimura,
Somogyvari-Vigh et al. 1990). In addition, these authors demonstrated the
presence of PACAP-ir fibres clinging to unstained cell bodies and their
ites in the lateral hypothalamus and lateral septum, and also
nding blood vessels in the latter area. Thus it appears that PACAP
>lay a multifunctional role including that of a hypophysiotrophic
>ne, neurotransmitter, neuromodulator, and vasoregulator.
j current studies have shown clearly that neuropeptides have a
functional role within the hypothalamus, acting as releasing factors,
:ransmitters and neuromodulators. Further research, outlined
needs to be done to explore the specific actions of LHRH, CRH and
t particular intra-hypothalamic loci. This could include, in the first
:e, the electrophysiological analysis of neuropeptide action both in
nd in vitro, using isolated brain slice preparations (see Ferguson &
d, 1987; Pittman, MacVicar & Colmers, 1987). This would allow the
of hypothalamic function in more detail in the context of a specific
rnal circuit and at the membrane level. A first step could be to
gate the concept of LHRH autoregulation or alternatively, the
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hypothesis that NPY acts as a neurotransmitter within the PVN. Such an
approach, either in vivo in the rat, or in vitro, would complement the
findings of the current neuropharmacological studies.*
*
Plans have been made to move to the Neuroscience Research Group at the University of
Calgary, under the auspices of Dr. Quentin J. Pittman, where electrophysiological invest¬
igation of the role of NPY as a neurotransmitter in the rat PVN will be carried out in vivo
and in vitro.
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